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ABSTRACT
The proto-oncogene tyrosine kinase Src is a ubiquitously expressed non-receptor
tyrosine kinase involved in critical cellular functions including wound healing, migration,
survival, and proliferation. Accordingly, aberrant Src signaling is also significantly involved in
many diseases. Src is most well known as an oncogenic protein, however, there are emerging
roles for Src signaling in various tissues involved in inflammatory diseases. One such tissue is the
respiratory epithelium, which comprises the first line of defense against inhaled microbial,
particulate, and chemical insults and is a critical nexus of innate immune signaling. Recent work
has detailed the involvement of Src in many innate injury and wound healing responses within the
airway epithelium, specifically with respect to its simultaneous Cys oxidation and activation by
the NADPH oxidase family member dual oxidase 1 (DUOX1). To date, however, there has been
little investigation into the specifics of this Cys oxidation, the structural alterations that promote
oxidative Src activation, or the exact role of Src with respect to the secretion of innate immune
cytokines following airway epithelial insult.
Src is classically known to be regulated by conformational changes depending on the
phosphorylation of its critical regulatory tyrosine residues. However, Src activation is also known
to be regulated by reactive oxidation species (ROS)-mediated Cys oxidation. While redox
regulation of Src has been observed for some time, no Cys residues have been directly implicated
outside of mutational studies with no exploration of Src conformational changes. Utilizing
quantitative mass spectrometry, we identified two Cys residues, C185 and C277, that were
predominantly oxidized in Src when compared to the other Cys. Additionally, we confirmed their
importance for Src activity using both kinase assays with recombinant C to A mutants, as well as
cell lines expressing C to A mutant Src. Finally, utilizing molecular dynamics simulations, we
established a role for the oxidation of these two Cys residues in conformational changes
associated with promoting kinase activation, suggesting a possible mechanistic explanation for
Src activation by ROS.
DUOX1 has previously been identified as a critical mediator of innate epithelial
responses to allergens, inducing acute secretion of the epithelial cytokine interleukin-33 (IL-33)
and downstream type 2 responses involving the epidermal growth factor receptor (EGFR).
However, the importance of Src has not been evaluated in this pathway. Through pharmacologic
inhibition and genetic knockout/silencing strategies, we have determined that Src is involved in
epithelial IL-33 secretion and downstream type 2 responses following allergen challenge in vivo
and in vitro. Interestingly, we also observed that IL-33 was capable of inducing its own secretion
in an unexpected acute “autoamplification” pathway where blocking IL-33 signaling inhibited IL33 secretion following allergen challenge. Similarly, DUOX1 and Src signaling were involved in
downstream secretion of the type 2 cytokines IL-5 and IL-13 following direct IL-33 challenge.
Finally, following 4-day in vivo IL-33 treatment, we observed Src- and DUOX1-mediated IL-33
secretion, as well as IL-5 and IL-13 secretion, in mouse airways. The secretion of these cytokines
was accompanied by DUOX1-dependent alterations of mouse lung function.
In total, this dissertation provides further insight into the redox regulation of the Src
kinase and identifies a role for Src in innate epithelial IL-33 signaling and autoamplification.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
1.1 Protein Tyrosine Kinases
1.1.1. Protein Tyrosine Kinase Signaling
Cellular

signal

transduction

is

regulated

by

reversible

post-translational

modifications, allowing cells to respond to external stimuli thereby translating them into
intracellular biochemical responses. Reversible protein phosphorylation by protein
phosphotransferase enzymes, otherwise known as kinases, represents a major mechanism
by which cellular processes such as cell survival, proliferation, differentiation and
migration, are regulated. Accordingly, protein kinases have received much attention as
drug targets in the treatment of various diseases. The various types of protein kinases
found in eukaryotes are divided into ~428 serine/threonine kinases and ~90 tyrosine
kinases, based on their substrate target residues. The focus of this following section will
be the mammalian protein tyrosine kinases (PTKs).
All kinase enzymes catalyze the transfer of the γ-phosphate from ATP to the hydroxyl
group of a protein side chain (Fig. 1.1) (Endicott et al., 2012). The installation of a
phosphate comprises a mechanistic switch that serves to modulate target protein activity
and alters protein binding affinities by recognition and binding of specialized protein
domains (e.g. SH2 domains binding phosphotyrosine) (Pawson et al., 2001). Protein
kinases can be activated by diverse external stimuli, which commonly involves
phosphorylation modifications within the kinase enzyme, thus promoting signal
transduction in a phosphorylation cascade. Protein phosphorylation is reversed by the
action of phosphatase enzymes, which dephosphorylate proteins via phospho-amino acid
hydrolysis (Fig. 1.1) (Barford et al., 1998). Since phosphatases can in turn also be
1

regulated by phosphorylation, this overall signaling machinery can create a rich array of
regulatory processes with both negative and positive feedback mechanisms.
Among the protein kinase families, PTKs appear to be present primarily in
multicellular organisms, which evolved during episodes of increasing atmospheric
oxygen concentrations. As such, PTKs are particularly relevant in processes related to
cell differentiation and specialized cell functions, and have become recognized as
important clinically responsive targets for tyrosine kinase inhibitors (TKI) in treatment of
e.g. various cancers (Zhang et al., 2009). PTKS can generally fall into two distinct
categories: receptor tyrosine kinases (RTKs), which generally exist as transmembrane
receptors that activate their kinase domain upon ligand binding, and non-receptor tyrosine
kinases (NRTKs), which are not directly regulated by ligand binding and generally
require trans-phosphorylation by other kinases to regulate their activities. The catalytic
activity of protein tyrosine kinases (PTKs) is exquisitely controlled through protein
structural changes (Johnson et al., 1996). All tyrosine kinases contain a catalytic domain
that consists of two structured lobes comprising a catalytic cleft where ATP binds and is
hydrolyzed to ADP along with installation of phosphate on the protein target (Taylor et
al., 1994). Catalytic activity is critically dependent on structural changes of the N-lobe
αC-helix (red in Fig. 1.2) and C-lobe activation loop (A-loop, orange in Fig. 1.2). In the
inactive state, the A-loop is folded and prevents the binding of protein substrates,
stabilizing the αC-helix in the “outward” position (Taylor et al., 1994). Activation of
tyrosine kinases occurs by diverse actions, but generally involves “inward” rotation of the
αC-helix, enabling the engagement of a conserved glutamic acid within the ATP binding
site, as well as unfolding of the A-loop allowing for substrate access to the kinase active
2

site (Huse et al., 2002). Diverse cellular and biochemical mechanisms universally
influence these PTK structural elements to directly modulate the activity of PTKs, and
these often involve protein (auto)phosphorylation (e.g. within the A-loop) to promote or
sustain kinase activation. Interestingly, there is another aspect of PTK regulation exists
that works alongside phosphorylation, either promoting or antagonizing kinase activity,
related to the general levels of cellular oxidants produced by various factors.

Figure 1.1 Basic components of tyrosine kinase signaling. Tyrosine kinase signaling
involves the phosphorylation of a substrate protein via the addition of a phosphate to a
substrate Tyr residue, catalyzed by a kinase, leading to activation or inactivation of this
target protein. Phosphorylated Tyr residues can act as a recognition site for SH2 domaincontaining proteins that “read” and transmit the signal. Protein tyrosine phosphorylation
can be reversed through hydrolysis by a Tyr phosphatase. Adapted from Dustin et al.,
2019. Used with permission from Oxford University Press.
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Figure 1.2 The C-Src Kinase Domain and the Conservation of Cys residues in SFKs.
Architecture of the c-Src kinase domain with regulatory αC-helix (red cartoon) and Aloop (orange cartoon) (PDB: 2SRC). Main chain spheres represent the composite
locations of conserved cysteine residues across the kinome within the kinase domain
(blue), the activation loop (orange), and within a conserved cysteine cluster distant from
the ATP binding site (red). Adapted from Dustin et al., 2019. Used with permission from
Oxford University Press.

1.1.2. Tyrosine Kinase Signaling in the Airway Epithelium
Among the myriad cell types and tissues in which PTKs have a critical regulatory role,
they have a particularly critical role in both airway epithelial signaling and inflammatory
airway diseases. In fact, PTK inhibition has been suggested aa a treatment strategy for
various airway diseases, and have in some cases been adopted clinically. However,
despite their potential as treatment targets, these kinases still play critical roles in normal
cellular signaling in the airways. This section will review some of the critical kinases in
4

airway epithelial biology, with a focus on the epidermal growth factor receptor (EGFR)
and the Src kinase.

1.1.2.1 EGFR in the Airway Epithelium
Receptor tyrosine kinases (RTKs) comprise several families of high-affinity cell
surface receptors for various growth factors and hormones (Ullrich et al., 1990). Among
these, the epidermal growth factor receptor (EGFR), a member of the ErbB family, has
been extensively studied because of its broad roles in various cellular processes (e.g.
proliferation, migration, cell survival, immune signaling) and the prevalence of diverse
activating mutations within this protein in various cancers (Normanno et al., 2006).
Similar to other RTKs, EGFR is a transmembrane receptor expressed on the cell surface
that is activated by one of its seven cognate ligands (e.g. EGF) through homodimerization
or heterodimerization with other ErbB family members. Dimerization of the extracellular
ectodomain leads to kinase activation through the formation of an asymmetric kinase
dimer complex comprising an activator and receiver kinase pair (Fig. 1.3) followed by
EGFR tail (auto)phosphorylation on several tyrosine residues (Zhang et al., 2006). EGFR
can also be activated by transactivation processes, in which other kinases (such as SFKs)
phosphorylate unique tyrosines within the EGFR kinase domain to enhance kinase
function (Sham et al., 2013).
Ligand-mediated EGFR activation in the context of epithelial signaling generally
involves the initial liberation of ligands from the cell surface, where they exist in a
transmembrane “tethered” state, thus allowing their association with the receptor (Blobel,
2005). Ligand shedding is induced by the activity of proteins called sheddases, which
5

specifically cleave membrane-bound proteins and are involved in liberating many
membrane-bound ligands (Reiss et al., 2009). In the context of EGFR signaling, ligand
availability can be controlled by multiple sheddases, but one specific sheddase called a
disintegrin and metalloproteinase-17 (ADAM-17) generally cleaves the EGFR ligands
EGF, amphiregulin (AREG), and transforming growth factor α (TGF-α) in epithelial cells
by phosphorylation or redox changes modifying its conformational state (Gooz, 2010;
Lee et al., 2003; Sham et al., 2013; Sternlicht et al., 2008). This process can be controlled
by different factors and pathways, but one of the main signals involves damage
associated ATP release activating purinergic receptors to send signals downstream, e.g.
the P2Y2 receptor (Sham et al., 2013; Wesley et al., 2007). P2Y2 activation then leads to
the activation of phospholipase C and protein kinase C, as well as subsequent
mobilization of Ca2+ from both the endoplasmic reticulum and import via TRPV1
channels, followed by activation of the H2O2-generating NADPH oxidase DUOX1
(Schiffers et al., 2020). DUOX1-mediated H2O2 production can then cause downstream
activation of ADAM-17 by both oxidation and Src kinase-mediated phosphorylation,
inducing a more open and active conformation (Boots et al., 2009; Gooz, 2010; Wang et
al., 2009). In this way, EGFR can be activated and regulated through substrate
availability, in addition to its post-activation-associated regulation by clathrin-mediated
receptor internalization and degradation (Singh et al., 2005).
EGFR has been shown to play a role in multiple airway diseases. One of the most
well-studied of these diseases is lung cancer, which can originate in epithelial cells (e.g.
Non-Small Cell Lung Cancer, NSCLC) and metastasize through epithelial to
mesenchymal transition (EMT) (Xiao et al., 2010). Among the myriad causes of NSCLC,
6

EGFR comprises a major source of cancer development through either overexpression or
through various mutations (such as the L858R activating mutation (Ladanyi et al., 2008),
T790M gatekeeper mutation (Yun et al., 2008), or C797S covalent inhibitor resistance
mutation (Thress et al., 2015)) which lead to abnormal levels of EGFR signaling and
concurrent increases in cellular proliferation, migration, and survival (Bethune et al.,
2010). Interestingly, it has also been shown that EGFR can associate with transcription
factors and migrate to the nucleus to modulate cancer-associated gene transcription,
which has been linked to the oxidation status of EGFR in airway epithelial cells (Brand et
al., 2011; Little et al., 2019).

Figure 1.3. Active asymmetric EGFR kinase dimer model. Positions of the activator
αH helix, containing the conserved CXXXXXXXMXXCW motif (cysteines of this motif
shown as red spheres), and αC-helix (red) inward positioning in the active receiver kinase
are shown. αH and αC helix of the receiver and activator kinases, respectively, are
labeled for clarity. Adapted from Dustin et al., 2019. Used with permission from Oxford
University Press.
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EGFR is also known to be critical in the development of inflammatory airway
diseases. It has been reported that EGFR expression is increased in the bronchial
epithelium of asthmatic individuals, and that EGFR signaling contributes heavily to
airway repair, remodeling, inflammation, and hyperreactivity in severe asthmatics
(Hamilton et al., 2005; Le Cras et al., 2011; Puddicombe et al., 2000). It has also been
observed that epithelial heparin-binding EGF (HB-EGF) can induce significant levels of
goblet cell hyperplasia, as well as remodeling in airway smooth muscle (Tamaoka et al.,
2008). EGFR is similarly critical in epithelial cell differentiation in response to various
stimuli. For example, TGF-α, an EGFR ligand, can specifically induce differentiation of
epithelial cells to mucus-producing goblet cells depending on cellular density (Kim et al.,
2005). The impact of EGFR on epithelial differentiation is consistent in already
differentiated epithelia as well, where EGFR is enriched in epithelial basal cells, and its
activation by EGF and/or amphiregulin control differentiation to a more squamous and/or
mesenchymal phenotype. This then weakens epithelial barrier integrity and is associated
with mucus cell hyperplasia, a phenotype commonly seen in smoking-related injury and
COPD (O'Donnell et al., 2004; Shaykhiev et al., 2013; Zuo et al., 2017). EGFR is also
involved in inflammatory responses (e.g. IL-8 secretion) to pollutants, which are capable
of inducing downstream growth factor mobilization (Parnia et al., 2014). Similarly,
EGFR has a large role in innate immune responses (Burgel et al., 2008). For example, it
has been shown that toll-like receptor signaling can activate EGFR through TGF-α
liberation in a DUOX1-dependent manner (Koff et al., 2008), and EGFR can be involved
in many of the later responses inducing mucin production in response to various stimuli
(Burgel et al., 2001), similar to its role in cigarette smoke responses. Work from our lab
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has also demonstrated that epithelial EGFR signaling has a strong redox component
linked to its activation through DUOX1 (Hristova et al., 2016), which was similarly
required for chronic asthma phenotypes in mice (Habibovic et al., 2016). With respect to
further chronic and progressive diseases, EGFR and its ligands have been shown to be
involved in the characteristic pleural thickening and submucosal inflammation of fibrosis,
which can be attenuated through EGFR inhibition (Ishii et al., 2006) or induced by
overexpression of EGFR ligands such as TGF-α (Hardie et al., 2004).

1.1.2.2 Src Family Kinases in the Airway Epithelium
The Src family kinases (SFK) represent one of the most widely studied families of
non-receptor tyrosine kinases (Parsons et al., 2004). Structurally, SFKs consist of an Nterminal Src homology (SH) 4 domain that contains lipid modification sites, a poorly
conserved “unique” domain, an SH3 domain that binds to specific proline-rich sequences,
an SH2 domain that can bind to specific tyrosine phosphorylated proteins, and a Cterminal tyrosine kinase domain followed by an unstructured negative regulatory Cterminal peptide tail. In their inactive state, SFKs are held in a “clamped” autoinhibited
state via intramolecular binding of a C-terminal phosphotyrosine (pY527; based on
chicken c-Src numbering) to their SH2 domains, as well as binding of their SH3 domains
to a polyproline sequence within the kinase linker domain (Xu et al., 1999). Activation of
SFKs occurs in a mechanism initiated by dephosphorylation of pY527 (or its homolog)
and results in detachment of the SH2/SH3 domains from the back of the kinase domain,
thereby inducing “unclamping” and allowing for recognition of these SH2/SH3 domains
by target proteins (Xu et al., 1999). In a concerted fashion, SH2/SH3 domain detachment
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“unclamps” the kinase domain in an allosteric mechanism leading to unfolding of the
activation loop, exposing a conserved A-loop tyrosine (Y416 in Src) for phosphorylation,
and inward rotation of the αC-helix. Protein tyrosine phosphatase (PTP)-dependent
dephosphorylation of Y416 and phosphorylation of Y527 by C-terminal Src kinase
(CSK) can reverse this activation and restore the inactive state (Roskoski, 2005).
The SFKs consist of nine distinct kinases that share similar activation
mechanisms and activities, but differ in their cellular expression and target specificity:
Src, Yes, Fyn, Fgr, Lyn, Lck, Hck, Blk, and Frk (Parsons et al., 2004). Of these kinases,
there are three that are known to be ubiquitously expressed in all cell types: Src, Yes, and
Fyn. The others are variably expressed in various hematopoietic cell types (Parsons et al.,
2004). Within this family of kinases, the prototypical and most well-studied member is
Src, which was first discovered as the protein responsible for carcinogenesis associated
with the Rous Sarcoma Virus, and was later discovered to be a cellular protein critical for
many normal processes (Roskoski, 2015). As mentioned earlier, Src is a non-receptor
tyrosine kinase, meaning it is not capable of activation by ligand binding and must be
activated by another upstream kinase, often thought to be an intermolecular (or trans-)
autophosphorylation (Roskoski, 2005). Generally, Src activation follows ligand mediated
RTK or G-protein coupled receptor activation, inducing the (auto)phosphorylation of
unclamped Src at its regulatory tyrosine Y416, but Src can also play a role in integrin
mediated signaling and is activated based on cell adhesion via focal adhesion kinase
(Bromann et al., 2004; Luttrell et al., 2004; Playford et al., 2004). Classically, following
its activation by upstream phosphorylation, Src can then feed into multiple downstream
pathways critical for cell function. For example, Src is well known to feed into
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FAK/ERK/STAT3 pathways involved in migration and angiogenesis, NF-kB pathways
involved in cell survival, and MAPK pathways involved in proliferation and survival,
among others (Playford et al., 2004; Roskoski, 2015; Wheeler et al., 2009).
Src, like EGFR, is involved in many critical processes that have important roles in
epithelial signaling such as migration and cell survival. Specifically, in the case of
epithelial insult responses, it has been demonstrated that Src activation is enhanced by
DUOX1 activation following its association with Src. This then leads to enhanced
activity and activation of ADAM-17 and EGFR, as previously discussed (Heppner et al.,
2016; Sham et al., 2013). Interestingly, Src has also been shown to transactivate EGFR
via phosphorylation at its Y845 residue, which is generally ligand independent (Biscardi
et al., 1999; Sato, 2013). Src and EGFR can then feed into downstream activation of
various MAPK molecules, which can induce the transcription and secretion of critical
innate response mediators (Burgel et al., 2008; Sham et al., 2013). Src has also been
shown to play a key role in the preservation of epithelial barrier integrity, with aberrant
Src activation leading to increases in epithelial permeability, barrier destruction, and
inflammatory signaling, which can be triggered by multiple epithelial insults and is
relevant for diseases such as asthma and COPD (Danyal et al., 2016; Geraghty et al.,
2014; Hardyman et al., 2013). Additionally, it has been hypothesized that epithelial Src
and Fyn could be playing a role in the remodeling of the airways. This is due to their
important roles in cellular migration (El-Hashim et al., 2017) and epithelial-tomesenchymal transition (Avizienyte et al., 2005; Kim et al., 2011; Zhang et al., 2012),
both of which are processes critical in cancer progression and

potentially in the

development of idiopathic pulmonary fibrosis (Bartis et al., 2014). Src can also contribute
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to high levels of inflammatory mediator secretion (Okutani et al., 2006), as well as
elevated mucus production, which is critical in diseases such as asthma and cystic fibrosis
(Li et al., 1998). Additionally, many SFKs are important in immune cell functions which
could be relevant to lung disease. For example, the SFKs Lck and Fyn are known to be
critical proteins in T cell development and differentiation, with additional functions in T
cell receptor signal transduction (Salmond et al., 2009). Lyn and Hck are also generally
involved in B-cells and myeloid cell signal transduction (Parsons et al., 2004). SFKs
additionally have a potential role in fibrotic remodeling, as it has been seen that
Saracatinib (AZD0530), a Src inhibitor, can attenuate the expression of fibrotic genes
(such as α-smooth muscle actin) and inhibit transforming growth factor β (TGFβ)/bleomycin-induced fibrosis (Hu et al., 2014). Similarly, another non-receptor tyrosine
kinase inhibitor that targets SFKs, Nintedanib (Wollin et al., 2015), has been used
clinically for the treatment of pulmonary fibrosis, however this is a much less selective
inhibitor. Finally, similar to EGFR, Src is likely most well-known as a major oncogene
involved in NSCLC (Mazurenko et al., 1992; Zhang et al., 2007) alongside recent data
similarly showing a role for the SFK Yes (Garmendia et al., 2019; Ichihara et al., 2017).
This is likely due to the involvement of Src in epithelial pathways known to be involved
in migration, which are important processes for normal wound healing responses (Sham
et al., 2013), as well as metastatic and survival responses in cancer (Giaccone et al.,
2008). Multiple SFKs are also known to be involved in phosphorylation and translocation
of EGFR to the nucleus, which is potentially involved in NSCLC (Iida et al., 2013).
Similarly, it was very recently shown that Src is redox regulated through the interaction

12

of NOX5 and another tyrosine kinase Pyk in NSCLC, all of which can be reciprocally
regulated through phosphorylation and intramolecular interactions.(Chen et al., 2020).

1.1.2.3 Other PTKs
Src and EGFR are not the only PTKs involved in epithelial signaling, either in
normal signaling or in the case of abnormal disease signaling. Table 1.1 outlines some of
the other examples of PTK signaling in the airway epithelium. However, kinase signaling
is not the only means that cells have of modulating signaling, and often these responses
(as well as PTKs) are often regulated by another less-apparent means of signal
modulation: redox signaling.
Table 1.1 – Other PTKs in the airway epithelium.

Kinase
Syk
Kinase
Syk

Pyk2
Pyk2

JAK

VEGFR
JAK

VEGFR

Airway epithelial activity
Inflammatory
Responses
Airway epithelial
activity

Reference
(MócsaiReference
et al., 2010)
(Ulanova et al., 2005)
Inflammatory Responses
(Mócsai
et al.,
2010)
(Wang et al.,
2006)
(Ulanova
et
al.,
2005)
Integrin Signaling
(Ulanova et al., 2005)
Viral Responses
(Wang
et et
al.,al.,
2006)
(Wang
2006)
Allergic Inflammation/responses
(Penton et al.,
Integrin Signaling
(Ulanova
et 2013)
al., 2005)
Activation
(Wex et al., 2011)
Viral
Responses
(Wang et al., 2006)
Wound
Healing/EGFR
Activation
(Block et al., 2010)
Allergic
Inflammation/responses
(Penton
et al., 2013)
(Keely et al., 2000)
Activation
(Wexetet
2011)
CFTR Regulation
(Cook
al.,al.,
2017)
Wound Healing/EGFR Activation
(Liang
et
al.,
2011)
(Block et al., 2010)
Allergic Inflammation
(Duan
et al.,
2010)
(Keely
et al.,
2000)
Nox5 and Src
activation
in
NSCLC
(Chen
et
al.,
2020)
CFTR Regulation
(Cook et al., 2017)
NF-kB signaling
(Kao et al., 2004)
(Liang et al., 2011)
Asthma
(Pernis et al., 2002)
Allergic Inflammation
(Duan etetal.,
al.,2015)
2010)
Th1 Responsese
(Fenwick
Nox5 and Src activation in NSCLC
(Chenetetal.,al.,
2020)
Epithelial Development
(Brown
2001)
NF-kB signaling
(Zhao
2005)
(Kaoetetal.,al.,
2004)
Mucus Asthma
Secretion
(Kim et al.,
(Pernis
et 2019)
al., 2002)
Remodeling/Angiogenesis
(Kranenburg et al., 2005)
Th1 Responsese
(Fenwick et al., 2015)
Epithelial Development
Mucus Secretion
Remodeling/Angiogenesis
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(Brown et al., 2001)
(Zhao et al., 2005)
(Kim et al., 2019)
(Kranenburg et al.,
2005)

Table 2.1 – Other PTKs in the airway epithelium.

1.2 Redox Regulation of Proteins
The evolution of multicellular organisms has largely relied on the use of oxygen
in mitochondrial respiration, which results in generation of reactive metabolites from
molecular O2, termed reactive oxygen species (ROS). Multicellular organisms also
contain multiple isoforms of NADPH oxidases (NOX), which produce ROS in a
regulated fashion for specific purposes (Holmstrom et al., 2014). Primary ROS include
superoxide anion (O2-) or hydrogen peroxide (H2O2), but other ROS can be generated via
interactions with transition metal ions (e.g. hydroxyl radical, OH●) or nitric oxide (NO● ;
to form e.g. peroxynitrite, ONOO-) (Holmstrom et al., 2014). Although elevated ROS
production is often referred to as “oxidative stress” and associated with systemic cellular
distress (Schieber et al., 2014), emerging evidence has led to the widely embraced
concept of “redox-based signaling”, involving reversible oxidative post-translational
modifications (PTMs) as an important biological mechanism of protein regulation (Jones
et al., 2015). While biological protein oxidation is highly diverse and multifactorial, as
will be outlined below, the functional relevance of such oxidative modifications can be
categorized in two general classes: 1) enzymatic loss-of-function due to modifications of
catalytic amino acids (e.g. cysteines or selenocysteines) and 2) structural changes upon
modification of non-catalytic amino acids that affect enzyme activity indirectly or impact
on subcellular protein targeting, protein-protein interactions, or protein stability.
Especially in these latter cases, our understanding of how e.g. diverse cysteine
modifications control protein structure and/or function is still limited, and much remains
to be learned about the molecular mechanisms by which these specific oxidative
modifications affect protein function. For example, accumulating evidence has indicated
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that protein tyrosine kinase signaling is subject to regulation by oxidant-dependent
mechanisms in an orthogonal fashion, largely through reversible modification of redoxactive protein cysteine residues (Corcoran et al., 2013). Such redox-based mechanisms
regulate protein tyrosine phosphorylation at various levels, and have important
implications for ongoing approaches to therapeutically target this signaling pathway and
for our overall understanding of oxidant-driven processes in health and disease.

1.2.1 Redox Modification of Cysteine Residues
From a chemical perspective, protein redox regulation most commonly involves
oxidation of cysteine residues on their thiol side chains (Janssen-Heininger et al., 2008).
Cysteines are statistically under-utilized in the proteome, yet are often highly conserved
when present in primary gene sequences, illustrating their importance in protein structure
and function. Reaction of ROS (typically H2O2) with Cys generally proceeds through
reaction with its reactive thiol (P-SH), typically as a deprotonated thiolate (P-S-), and
initially forms a sulfenic acid (P-SOH), which usually possesses limited stability and
undergoes further reactions with other thiols or ROS (Janssen-Heininger et al., 2008).
Indeed, P-SOH is known to rapidly react with local reduced thiols to form intra- or
intermolecular disulfide bonds or alternative redox-based PTMs with glutathione or free
Cys, resulting in S-glutathionylation or S-cysteinylation, respectively (Janssen-Heininger
et al., 2008). In some cases, P-SOH reacts with the protein main chain amide to form an
intramolecular sulfenyl amide, which can induce structural alterations and thereby
modulate protein function (Janssen-Heininger et al., 2008). Each of these modifications
can be reversed by endogenous cellular reducing systems, such as thioredoxins and
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glutaredoxins (Janssen-Heininger et al., 2008). Additionally, overoxidation can occur
when P-SOH is further oxidized to corresponding sulfinic or sulfonic acids (P-SO2H and
P-SO3H, respectively), which are generally irreversible (Janssen-Heininger et al., 2008).
Protein cysteine thiols can also be modified by NO●-derived products resulting in
S-nitrosylated (P-SNO) proteins (Janssen-Heininger et al., 2008). Additionally, cysteine
thiols can be converted to persulfides or polysulfides (P-SnSH), through the action of
hydrogen sulfide or related reactive sulfur species, which forms an area of rapidly
growing interest (Filipovic et al., 2018). Since P-SnSH are typically more nucleophilic
than the corresponding P-SH, they are also subject to additional oxidative modifications
(Heppner et al., 2018). Protein Cys residues are subject to alternative biological
modifications as well, such as alkylation by electrophilic metabolites formed during lipid
oxidation (e.g. acrolein, 4-hydroxynonenal, nitro-lipids) (Cai et al., 2009; Schopfer et al.,
2011), or by acylation (e.g. palmitoylation) regulated by enzymatic actions of acyl
transferase enzymes and acyl-protein thioesterases (Jiang et al., 2018). Although these
latter modifications are technically not the result of ROS chemistry, they have the
potential to interfere with redox-based thiol modifications and can thereby impact on
redox signaling pathways. Moreover, each of these modifications can be reversed by
cellular reducing systems, although cysteine alkylation is generally thought to be
relatively irreversible.

1.2.2 Redox Modification of Other Amino Acids
With considerable emphasis on Cys residues as redox-sensitive protein targets, it
should be noted that other amino acids are also redox active and therefore subject to
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redox-based modifications. Selenocysteine (Sec), a rare amino acid in a limited number
of proteins, is highly susceptible to redox modification due to the similar electrochemical
properties of selenium and sulfur (Reich et al., 2016). Another sulfur-containing amino
acid, methionine (Met), is also susceptible to oxidation by ROS and can be oxidized to
methionine sulfoxide and/or sulfones, and the existence of methionine sulfoxide
reductase enzymes suggests the biological importance of Met oxidation in regulating
protein function (Hoshi et al., 2001). Indeed, emerging evidence from bioinformatics
studies suggests that methionine oxidation may also be important in controlling protein
phosphorylation (Rao et al., 2013). Finally, oxidation of other amino acids (histidine,
tyrosine, tryptophan) has been demonstrated in response to various ROS, although these
are generally considered irreversible modifications and their relevance for biological
protein regulation is unclear (van der Vliet et al., 2018).

1.3 Redox Regulation of Protein Tyrosine Kinases
While various post-translational modifications (including phosphorylation events)
can regulate PTK function, recent evidence indicates that redox-dependent cysteine
modifications can represent an important regulatory mechanism for PTK function. Over
80% of all protein tyrosine kinases contain highly conserved cysteine residues within a
CXXXXXXXMXXCW motif found in their C-lobe αH-helix (Figure 1.2 red spheres),
which is in a structured region and is speculated to be important for activity and/or
protein stability (Kato et al., 2000; Nakashima et al., 2005; Veillette et al., 1993). In
addition, tyrosine kinases, as well as other protein kinase families, frequently contain
cysteines within their ATP binding regions (Figure 1.2). The function of these cysteines
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is typically unknown, and they are often considered appealing targets for irreversible
covalent kinase inhibitors. Indeed, bioinformatics analysis has suggested that >150
protein kinases (among which are several PTKs) contain suitable cysteines for such
covalent targeting (Rao et al., 2019). However, a number of studies over the past decade
have indicated that several of these conserved cysteine residues in PTKs are susceptible
to redox-based modification, with variable impact on kinase function (Corcoran et al.,
2013; Truong et al., 2013). Table 1.1 summarizes the major studies to date that have
addressed the role(s) of specific cysteine modifications in regulating PTKs, but the
molecular basis is still only superficially understood. Intriguingly, in some cases such
redox-dependent activation of kinase function involves cysteines that are also targets for
irreversible inhibitors of these kinases (e.g., C797 in EGFR and C277 in Src) (Heppner et
al., 2018; Paulsen et al., 2011; Truong et al., 2016). In the following sections, we will
discuss recent advances with respect to the molecular mechanism by which reversible
cysteine oxidation regulates PTK function in some detail, focusing primarily on Src
family kinases and the epidermal growth factor receptor as prototypical examples of nonreceptor tyrosine kinases and receptor tyrosine kinases, respectively.
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Table 3.2 - Direct Regulation of PTKs by oxidant signaling.
Kinase

Involved
residue(s)

Modification

Functional
outcome

Reference

ND

ND

Activation

(Xi et al., 2012)

Glutathionylation

Activation

C185

Disulfide

C185, C277
C245, C487
C245, C277,
C487, C498
C277
C487
C498
C483, C487,
C496, C498
C491, C506
C488
C466
C479
C464, C475
ND
C866, C917
C1094, C1105
C122, C164
C206
C39

Sulfenic acid
Proposed Disulfide
ND

Cortactin
binding
Activation
Activation
Activation

(Heppner et al., 2016),
(Little et al., 2019)
(Evans et al., 2012)
(Heppner et al., 2018)
(Giannoni et al., 2005)
(Zhang et al., 2015)

Disulfide
ND
S-nitrosylation
ND

Inactivation
Activation
Activation
Activation

(Kemble et al., 2009)
(Block et al., 2008)
(Rahman et al., 2010)
(Oo et al., 2003)

ND
ND
ND
ND
ND
ND
Disulfide
ND
Disulfide
Inhibitor Adduction
Inhibitor Adduction

Activation
Activation
Activation
Activation
Activation
Activation
Inactivation
Inactivation
Inctivation
Inactivation
Inactivation

(Senga et al., 2008)
(Kim et al., 2016)
(Yoo et al., 2011)
(Senga et al., 2008)
(Veillette et al., 1993)
(Mallozzi et al., 2001)
(Smith et al., 2012)
(Smith et al., 2012)
(Mills et al., 2007)
(Visperas et al., 2015)
(Visperas et al., 2015)

Non-receptor PTKs
Src

Table 4.2 - Direct Regulation
of PTKs
by oxidant signaling.
ND
Sulfenylation

Yes
Fyn
Lyn
Lck
Hck
JAK2
CSK
SYK
ZAP-70
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Kinase

Involved
residue(s)

Modification

Functional
outcome

Reference

C488
ND

Disulfide
Sulfenylation

Inactivation
Activation

S-Glutathionylation

(Kemble et al., 2009)
(Heppner et al., 2016),
(Little et al., 2019)
(Little et al., 2019)

Receptor PTKs
FGFR
EGFR

C166, C305

S-Nitrosylation

Nuclear
trafficking
Inhibition

C797

Sulfenic acid

Activation

C797
C1025, C1122

Acrolein Adduction
Palmitoylation

IGF-1R
RET

ND
C376

Nitrosylation
Potential Disulfide

VEGFR

C1199, C1206

Disulfide

Inhibition
Receptor
trafficking
Inactivation
UV
Activation
Inhibition

(Murillo-Carretero et al.,
2009)
(Heppner et al., 2016),
Paulsen et al. (2011),
(Truong et al., 2016)
(Danyal et al., 2016)
(Runkle et al., 2016)
(Okada et al., 2017)
(Kato et al., 2000)
(Kang et al., 2011)

“ND” indicates that the published study did not specifically detect this property.
Underlined residues indicate Cys found in the CXXXXXXXMXXCW motif

1.3.1 Indirect Activation of PTKs by Redox-Dependent Inactivation of Protein
Tyrosine Phosphatases
The first reported examples of redox-based regulation of protein tyrosine
phosphorylation involved oxidant-mediated inactivation of a protein tyrosine phosphatase
(PTP), thereby indirectly prolonging PTK activation (Finkel, 1998). All PTPs contain an
active site Cys residue located in a (I/V)HCXAGXGR(S/T) active site motif that is
critical for catalytic function, as this cysteine is responsible for nucleophilic attack on the
phosphotyrosine substrate to generate an intermediate phospho-cysteine, after which the
phosphate group is eliminated by hydrolysis via a conserved Asp residue within its WDP
loop to reconstitute the native enzyme (Stone et al., 1994). Since this catalytic cysteine
typically has a low pKa to promote its function, it is also particularly susceptible to
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oxidation (Tonks, 2005). PTP oxidation can occur by elevated ROS concentrations in e.g.
cancer cells or during NOX activation, and allow for prolonged PTK activity (Holmstrom
et al., 2014; Tonks, 2005). The best studied PTP with respect to redox signaling is protein
tyrosine phosphatase 1B (PTP1B), and its inactivation by e.g. H2O2 proceeds through
oxidation of its active site Cys residue to a sulfenic acid (P-SOH) (Denu et al., 1998).
Structural elucidation by X-ray crystallography of oxidant-inactivated PTP1B revealed a
sulfenyl amide modification within the catalytic site (Salmeen et al., 2003), but in the
cellular context the main inactive form of PTP1B appears to exist as a S-glutathionylated
protein, due to reaction of P-SOH or the sulfenyl amide with GSH (Barrett et al., 1999).
PTP1B can also be reversibly inactivated by nitric oxide-derived oxidants via Snitrosylation (Chen et al., 2008). Other PTPs can be similarly inactivated, such as SHP1/2 (Src homology region 2 domain-containing phosphatase-1/2) (Weibrecht et al., 2007),
PTEN (phosphatase and tensin homolog) and KIM (kinase interaction motif) family PTPs
(Lee et al., 2002; Machado et al., 2017), and in the latter cases the active site cysteine
becomes engaged in intra- or intermolecular disulfide bonds with other protein cysteines.
The diverse nature of these various modifications is likely not relevant for enzymatic
loss-of-function, as each of these would inactivate the catalytic cysteine. Instead, the
various modes of cysteine modification in PTPs are likely more critical for regulating the
duration of inactivation, as distinct reduction mechanisms are involved in their reversal
(Frijhoff et al., 2014). In some instances, redox-dependent modification can also enhance
phosphatase function, as has been reported for some dual-specificity phosphatases in
which oxidation of Cys residues in Zn-binding domains enhances phosphatase activity
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through disulfide and associated structural changes (Bonham et al., 2009; Fox et al.,
2007).

1.3.2 Redox Regulation of the Src Family Kinases
In addition to classical SFK regulating mechanisms (discussed in Section 1.1.2.2),
recent discoveries highlight the impact of redox regulation on the inactive/active state
equilibrium of these kinases through direct Cys oxidation, although these mechanisms
vary between the different family members based on the evolutionary conservation of
Cys residues ((Oo et al., 2003); Fig. 1.4 A). The Src protein contains 9 Cys residues that
are distributed across its SH2 and kinase domains (Fig. 1.4 B). None of these cysteines
are involved in structural disulfide bonding, and several are contained within the
conserved CXXXXXXXMXXCW motif. The first indication that Src is redox regulated
came from studies showing that various Cys-SH targeting alkylating agents can abrogate
Src activity (Fukazawa et al., 1990). Later, it was observed that exposure of fibroblasts or
immunoprecipitated c-Src to NO-generating molecules could in fact promote Src
activation, independent of its Y527 phosphorylation status, and this was found to be
associated with redox-dependent formation of putative Src multimers through disulfide
formation, although no direct role for such disulfide formation was demonstrated
(Akhand et al., 1999). Follow up studies by the same group suggested a role for the four
clustered C-terminal Cys residues (including the CXXXXXXXMXXCW motif C487 and
498) in Src activation induced by HgCl2 or P-SNO (Oo et al., 2003; Rahman et al., 2010;
Senga et al., 2008). These and subsequent studies suggested that increased cellular NO●
production in e.g. breast cancers could promote cell invasion and oncogenesis by S22

nitrosylation of Src and/or associated disulfide formation (Rahman et al., 2010; Switzer et
al., 2012).

Figure 1.4 The nine Cys residues found in the c-Src kinase and their conservation
within the SFKs. The Cys residues contained within the CXXXXXXXMXXCW domain
conserved within Tyr kinases are indicated. B. Crystal structure of c-Src (PDB: 2SRC)
indicating the location of the nine Cys residues, as well as the regulatory Y416 and Y527
residues. CXXXXXXXMXXCW domain Cys residues are highlighted in red. Adapted
from Dustin et al., 2019. Used with permission from Oxford University Press.

Giannoni and co-workers highlighted an alternative mechanism of Src redox
regulation by cellular ROS in the context of anchorage-dependent growth. They found
that Src activation was associated with cysteine oxidation within the Src protein
following adhesion-induced activation of 5-lipoxygenase via integrin signaling, and
mutation studies implicated C245 within the SH2 domain and C487 within the
CXXXXXXXMXXCW motif in such oxidative regulation (Giannoni et al., 2005).
Subsequent studies by the same authors also implicated these Cys residues in redox23

dependent Src activation in increased anoikis resistance via EGFR-dependent
mechanisms (Giannoni et al., 2008; Giannoni et al., 2009). The authors postulated
formation of a putative intramolecular disulfide bond between these residues in such
oxidative Src activation (Giannoni et al., 2005), although this would seem unlikely from a
structural perspective since these Cys are quite distant from each other in the inactive Src
structure (e.g. Fig. 1.4 B). However, since Src activation was recently shown to involve
the formation of asymmetric dimers (Spassov et al., 2018), is it plausible that
intermolecular disulfide bonds between two Src monomers may be involved. Other
studies have highlighted a role C487 in redox-dependent Src activation in angiotensin IImediated cellular hypertrophy or in IFG-1 signaling during hyperglycemia, which was
linked to cellular H2O2 production by the NADPH oxidase isoform NOX4 (Block et al.,
2008; Xi et al., 2012). NOX activation was also associated with Src activation in the
context of TGF-β signaling, and mutagenesis studies suggested the involvement C245,
C277, C487 and C498 (Zhang et al., 2015). Although none of these studies actually
demonstrated the ability of H2O2 to directly enhance Src activity, this was demonstrated
more recently in studies with immunoprecipitated Src (Krasnowska et al., 2008).
Most of the Cys residues highlighted above are conserved among all SFKs, and
other SFKs have also been shown to be regulated by ROS. For example, Fyn and Yes
represent

ubiquitously

expressed

SFK

members

that

also

contain

a

CXXXXXXXMXXCW motif (Fig. 1.4), and activation of Fyn in keratinocytes in
response to solar UV-light exposure was found to involve oxidation of C488
(homologous to Src C487), which was thought to represent a potential redox sensing
mechanism to induce protective cellular apoptosis and prevent melanoma (Kim et al.,
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2016). In a model of zebrafish tail fin regeneration, hematopoietic cell-specific Lyn was
found to be a critical mediator of neutrophil recruitment to areas of high ROS production
at injury sites, which was dependent on oxidation of the kinase CXXXXXXXMXXCW
motif residue C466 (homologous to Src C487) (Yoo et al., 2011). Similar cysteine
residues were also implicated in HgCl2 -induced activation of Yes (C491/C506;
homologous to Src C483/C498) and Lyn (C479; homologous to Src C498) (Senga et al.,
2008) and in redox-dependent activation of the lymphocyte-specific SFK Lck (at residues
C464 and C475, homologous to Src C487 and C498 respectively) (Veillette et al., 1993).
Finally, Hck was also found to be activated by the oxidant peroxynitrite (ONOO-),
although no specific Cys residues were implicated (Mallozzi et al., 2001).
In aggregate, these various studies strongly implicate the importance of
CXXXXXXXMXXCW motif cysteines within αH-helix of SFK kinase domains, perhaps
in combination with other Cys residues, in redox-mediated activation of several SFKs.
However, the mechanisms by which modification of these cysteines control kinase
function are still not understood, largely because the relevant cysteine modifications have
not been identified. No structural studies exist, to our knowledge, to directly link
oxidation of CXXXXXXXMXXCW motif cysteines to SFK activation, and this region is
typically thought to be rather inconsequential for kinase activation based on structural
studies (Xu et al., 1999). Indeed, recent molecular dynamics (MD) simulations of Src
C498 oxidation (to its primary oxidation product P-SOH) did not reveal significant
structural alterations that would explain increase kinase function (Heppner et al., 2018).
We therefore speculate that redox-dependent modification of these cysteines may involve
altered interactions with other associated proteins (such as other SFK monomers),
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potentially via disulfide-mediated interactions, but this has to date not been addressed
directly.

1.3.3 Unique Cysteine Modifications in Redox-Dependent Activation of Src
Our research group recently demonstrated the importance of the NOX isozyme
DUOX1 in airway epithelial wound responses via ATP-dependent stimulation of
purinergic P2YR2 receptors and redox-dependent activation of Src (Sham et al., 2013).
Src activation by P2YR2 stimulation was found to involve recruitment of Src to the
P2YR2 via its PXXP domain, and also appears to involve recruitment of DUOX1. We
attempted to associate Src activation with specific redox-based modifications within the
Src protein (P-SOH and P-SSG), which suggested that Src activation corresponded most
closely with formation of P-SOH (Heppner et al., 2016). Studies with recombinant Src
protein indicated that H2O2 was capable of enhancing Src kinase activity, whereas
formation of P-SSG by addition of GSSG was ineffective (Heppner et al., 2016). Mass
spectrometry analysis using P-SOH-specific probes, to identify the main redox-sensitive
cysteines within recombinant Src protein, highlighted prominent sulfenylation of two
cysteines that are rather unique within Src compared to other SFK members, namely
C185 within the SH2 domain and C277 within the ATP binding region of kinase domain
(Fig. 1.2 and 1.4). Mutation of either cysteine significantly attenuated H2O2-dependent
Src activation, both in studies with recombinant proteins in vitro and in a cellular context
(Heppner et al., 2018). Moreover, MD simulations demonstrated that introduction of
sulfenylated forms (P-SOH) of either C185 or C277 within the autoinhibited Src crystal
structure (PDB 2SRC) promoted electronic and structural changes that are consistent with
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Src activation mechanisms (Heppner et al., 2018). Indeed, modeling of C277-SOH
indicated that this modification directly influences the A-loop, promoting energetically
favorable unfolding and solvent exposure of Y416. Inclusion of C185-SOH altered
interactions with the inhibitory pY527, destabilizing its binding affinity to the SH2
domain and enhancing its solvent accessibility and potential susceptibility to
dephosphorylation (Heppner et al., 2018). Since both cysteine residues appeared to
contribute to ROS-dependent Src activation in a cellular context, we proposed a stepwise
redox-based mechanism of SRC activation, involving the successive oxidation of both
C277 and C185 to P-SOH (Heppner et al., 2018). Subsequent S-glutathionylation of
either residue would be expected to lock the Src kinase into its active “unclamped” state
until these modifications are reversed by cellular reductases (Heppner et al., 2016).
The most intriguing aspect of our recent studies relates to the fact that it concerns
relatively unique cysteines that are not present in most other SFK members, although
similar cysteines are found in other PTKs. C277 is conserved in only 2 other SFK
members and its function is largely unknown, and has therefore been targeted by newly
developed covalent Src inhibitors (Rao et al., 2019). Studies with recombinant Src
proteins indicated that removal of DTT in the kinase buffer causes loss of kinase activity,
and this was attributed to formation of disulfide-linked homodimers via C277 (Kemble et
al., 2009), but the significance of such a disulfide-based mechanisms of Src inactivation
has to date not been demonstrated in a cellular context. The importance of C185 in the
SH2-domain of Src is also poorly understood, and all other SFKs contain a serine in the
corresponding position (Fig. 1.4 A), although similar cysteines can be found in other SH2
domains (Evans et al., 2012). Mutation studies with recombinant Src proteins suggested
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that the presence of a cysteine in this position may weaken binding affinity to
phosphotyrosine-containing peptides that mimic the autoinhibitory pY527-containing
domain, and may thus be more readily activated (Bradshaw et al., 1999). A more recent
study implicated C185 in Src in recognition of substrates through formation of an
intermolecular disulfide, as was demonstrated for the Src substrate cortactin (Evans et al.,
2012).
Overall, it follows that redox mechanisms of SFK regulation are exceedingly
complex and may involve intrinsic mechanisms that induce structural alterations that alter
enzyme function, but may also involve redox modifications that impact on interactions
with substrates (Evans et al., 2012) or potentially affect asymmetric Src dimerization as a
critical mechanism in promoting autophosphorylation and Src activation (Spassov et al.,
2018). Some SFKs, but not Src itself, also contain additional Cys residues within their Nterminal SH4 domains that are modified by S-acylation (palmitoylation) to regulate SFK
trafficking and membrane targeting (Sato et al., 2009). It is not known to date whether
these cysteines are also subject to redox regulation.

1.3.4 Redox Regulation of Other Non-Receptor Tyrosine Kinases
Redox-based mechanisms have also been implicated in regulation of other
NRTKs, such as the Janus Kinases (JAK), which are predominantly involved in cytokine
signaling and activation of STAT family of transcription factors (Yamaoka et al., 2004).
JAK proteins also contain a CXXXXXXXMXXCW motif (including C1094 and C1105)
but, in contrast to SFKs, are generally found to be inactivated by oxidative mechanisms
through oxidation of unique cysteines (Duhe, 2013). Four distinct Cys residues (C866,
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C917, C1094, and C1105) in JAK2 were found to be independently responsible for
redox-dependent suppression of kinase activity, with C866 and C917 postulated to form a
disulfide bond based on their spatial proximity (Smith et al., 2012). The PTK C-terminal
Src kinase (Csk), which negatively regulates Src by mediating Y527 phosphorylation
(Okada et al., 1991), is redox regulated by formation of an intramolecular disulfide bond
within its SH2 domain (between its C122 and C164 residues), and this inhibits kinase
activity compared to the fully reduced enzyme (Mills et al., 2007). Other uniquely
regulated non-receptor kinases include the spleen tyrosine kinase (SYK) and its related
family members, which are predominantly involved in T cell activation and adaptive
immune signaling (Mócsai et al., 2010). SYK, as well as its related family member ZAP70, were found to be susceptible to Cys-targeted covalent inhibitors as well as H2O2,
which target Cys residues within their dual SH2 domain motif and thereby prevent these
kinases from binding substrate peptides (Visperas et al., 2015). These examples indicate
that cysteine oxidation can regulate tyrosine kinase signaling by multiple distinct
processes, not only by directly affecting kinase activity but also by regulating kinase
signaling more indirectly, e.g. by interfering with phosphopeptide substrate binding.

1.3.5 Redox Regulation of the Epidermal Growth Factor Receptor
The full-length EGFR protein contains 60 Cys residues, most of which are present
in the extracellular domain and are involved in structurally important disulfide bonds
(Abe et al., 1998). However, the intracellular kinase domain contains an additional 6
cysteine residues (and some others are also present in the C-terminal phosphorylation
tail),

including

cysteines

contained
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within

the

previously

mentioned

CXXXXXXXMXXCW motif within the kinase αH-helix. Since this αH-helix plays a
critical role in the activation of EGFR through direct coil-coil interaction with the αChelix of the receiver kinase in the asymmetric dimer (Fig. 1.3), it is conceivable that
redox-modification of these cysteines could affect such dimer interactions. However, in
contrast to studies with SFKs discussed above, no studies to date have addressed the
specific function of these CXXXXXXXMXXCW motif cysteines within EGFR.
It has been recognized for over 20 years that EGFR activation can promote
production of cellular ROS (e.g. by NOX activation) and that this promotes EGFRdependent signaling (Gamou et al., 1995; Goldkorn et al., 1998). While this was largely
attributed to redox-dependent inactivation of PTPs (as described earlier), recent
pioneering studies by Kate Carroll and co-workers have highlighted the ability of ROS to
directly regulate EGFR. They illustrated that H2O2 can directly activate EGFR by
oxidation of a conserved cysteine (C797) within the ATP binding region (Paulsen et al.,
2011; Truong et al., 2016). Among the 6 cysteines with the EGFR kinase domain, C797
is the most solvent accessible and redox-sensitive, due to its relatively low pKa (Truong
et al., 2016). Indeed, studies with recombinant EGFR kinase domains showed that,
although C797 is not critical for intrinsic kinase activity, the ability of H2O2 to enhance
kinase activity relies fully on the presence of C797 (Paulsen et al., 2011; Truong et al.,
2016). Redox-dependent EGFR activation by ligand stimulation was found to involve
activation of the NOX isoform NOX2, which is recruited to the EGFR signaling complex
following EGF stimulation (Heppner et al., 2016; Paulsen et al., 2011). Our research
group recently highlighted activation of EGFR in airway epithelial cells in the context of
ATP-dependent wound signaling, and this was found to involve activation of a different
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NOX isoform, DUOX1, which promotes EGFR transactivation by initial redoxdependent activation of Src associated with cysteine oxidation within Src and EGFR
(Heppner et al., 2016; Sham et al., 2013). DUOX1-dependent EGFR activation was also
demonstrated to contribute to innate airway responses to allergens and to features of
allergic asthma (Habibovic et al., 2016; Hristova et al., 2016). Evaluation of distinct
cysteine modifications indicated that H2O2-induced EGFR activation is mediated
specifically by formation of P-SOH, whereas other modifications (P-SSG, P-SO2/3H) did
not appear to alter intrinsic kinase activity (Heppner et al., 2016; Schwartz et al., 2014).
MD simulations indicated that formation of C797-SOH can alter local electrostatic
interactions due to hydrogen bonding between C797-SOH and a critical R841 residue
within the ATP binding region, thereby potentially aiding in coordinating ATP binding
(Truong et al., 2016). Interestingly, C797 within the EGFR kinase domain is also the
target for covalent EGFR TKI inhibitors (Cross et al., 2014; Singh et al., 2011) and for
inhibition by other thiol-reactive electrophiles such as acrolein (Danyal et al., 2016).
Hence, oxidation of EGFR C797 would be expected to negatively impact on efficacy of
irreversible kinase inhibitors, as was indeed observed in several studies (Schwartz et al.,
2014; Truong et al., 2016).
The importance of cysteine oxidation in EGFR has been implicated in EGFRdependent functions in normal epithelial biology (e.g. (Heppner et al., 2016; Sham et al.,
2013)), but may be dysregulated in the context of lung cancer, especially those involving
oncogenic EGFR mutants. For example, the oncogenic L858R/T790M double mutant,
which inserts an Arg residue onto the A-loop opposite the active site in addition to the
Met gatekeeper mutation, was found to display increased sulfenylation over a higher
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range of EGF concentrations in comparison to other oncogenic cell lines (Truong et al.,
2016). Alternatively, redox events may also regulate subcellular EGFR trafficking as was
illustrated by increased caveolin-dependent perinuclear trafficking in cancer cells under
conditions of oxidative stress (Khan et al., 2006). More recent findings indicated that the
absence of DUOX1 in lung cancers can promote EGFR internalization and nuclear
localization, and this was associated with altered redox modification(s) within EGFR
(Little et al., 2019). In this regard, it is important to consider that EGFR is also regulated
by palmitoylation on several cysteine residues, including C797, with apparent
consequences for EGFR membrane interactions and dimerization, and such
palmitoylation has been implicated in development of tumor resistance against EGFR
kinase inhibitors (Thomas et al., 2019). In addition to C797, cysteines within the Cterminal tail of EGFR (C1025 and C1122), have also been identified as sites for
palmitoylation, regulating receptor turnover and recycling (Runkle et al., 2016).
Inhibition of EGFR palmitoylaton by inhibiting the palmitoyltransferase DHHC20 was
found to result in sustained EGFR activation, and to sensitize cancer cells to EGFR TKI
inhibitors (Runkle et al., 2016). Redox modification of C797 or these C-terminal
cysteines might therefore indirectly affect EGFR function by interfering with EGFR
palmitoylation. Intriguingly, recent studies highlighted development of tumor resistance
against covalent EGFR inhibitors that target C797, which was found to involve acquired
mutation of this Cys to a Ser (Thress et al., 2015), which would also suggest that EGFR
signaling is in these cases refractory to redox regulation or palmitoylation at this cysteine.
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1.3.6 Redox Regulation of other Receptor Tyrosine Kinases.
Other RTKs may be similarly redox regulated based on the presence of conserved
cysteines. For example, other ErbB family members such as ErbB2/HER2 or
ErbB4/HER4 contain homologous cysteines to C797 in EGFR (Nakashima et al., 2005;
Truong et al., 2013), as do some other RTKs (Truong et al., 2012), but the importance of
redox regulation of these cysteines has not yet been addressed. The insulin-like growth
factor 1 receptor (IGF-1R) is known to be regulated by S-nitrosylation, and was reasoned
to be disrupting intramolecular disulfide bonds, thereby inhibiting cell growth as well as
disulfide-mediated complex formation (Okada et al., 2017). Fibroblast growth factor
receptors (FGFR) contain a cysteine within their ATP binding regions that is homologous
to C277 in Src, and studies with recombinant FGFR1 protein showed loss of kinase
activity under oxidizing conditions (in the absence of DTT) corresponding to formation
of disulfide-based homodimers similar to Src (Kemble et al., 2009), although the
relevance for potential redox regulation in a cellular context is unclear. Similarly,
exposure of cells to high levels of H2O2 was found to be capable of promoting
intramolecular disulfide bonds within the VEGF receptor, between C1199 and C1206
within its cytoplasmic domain, which resulted in its activation (Kang et al., 2011).
Finally, disulfide-linked dimers were also implicated in the activation of the RET kinase
due to UV-mediated oxidation, which was observed to involve C376 within its kinase
domain (Kato et al., 2000).
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1.3.7 Alternative Redox-Dependent Regulation of PTK Signaling
In addition to the aforementioned redox regulation of EGFR kinase domains,
some studies have indicated that NO● is capable of inhibiting EGFR activation and tumor
cell proliferation, which was associated with S-nitrosylation of extracellular C166 and
C305 residues within EGFR (Murillo-Carretero et al., 2009). However, contrasting
reports demonstrated that NO donors can enhance increased tumor cell proliferation and
pointed to P-SNO associated EGFR activation involving Src and β-catenin (Switzer et al.,
2012), although specific cysteine residues were not identified in this case. Another
potential redox modification involves the rapidly emerging aspect of hydrogen sulfide
and related persulfides/polysulfides, which can modify various proteins by formation of
persulfides (P-SSH). Indeed, recent studies by our group indicated that persulfides exist
within EGFR as well as Src and may also be subject to oxidation, leading to
perthiosulfenylation (P-SSOH) (Heppner et al., 2018), but the functional importance of
these modifications is unknown.
In addition to redox regulation of PTPs and PTKs, cysteine oxidation within SH2
domains could also affect phosphotyrosine signaling more indirectly by impacting on
phospho-Tyr binding, as was shown recently with respect to C185 within the SH2
domain of Src and its involvement in intermolecular disulfide cross-linking with the Src
substrate protein cortactin (Evans et al., 2012). An estimated one quarter of all SH2
domains contain cysteine residues within a similar phosphotyrosine binding region
(Evans et al., 2012), and such redox-based regulation of SH2 domains and their
phosphoprotein substrates recognition might apply more broadly. Indeed, modification of
similar SH2 domain cysteines within zeta-chain associated protein of 70 kDa (ZAP-70)
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or SYK by thiol-reactive small molecules or by H2O2 has been found to inhibit
phosphopeptide binding (Visperas et al., 2015). As another example, formation of a
disulfide within the SH2 domain of the C-terminal Src kinase (Csk), a constitutively
active kinase that phosphorylates and inhibits Src, attenuates Csk function as an indirect
redox-based mechanism involved in Src activation (Mills et al., 2007).

1.4 NADPH Oxidases
NADPH oxidases (NOXes) are transmembrane proteins found in many
tissues/cell types and are one of the major sources of ROS within cells (Bedard et al.,
2007). The NOX family includes 5 NOX isoforms (NOX 1-5) and two Dual Oxidase
(DUOX) isoforms (DUOX1 and DUOX2). These proteins vary in complexity, with some
containing multiple functionally critical subunits, while others have relatively few (Geiszt
et al., 2004). However, a common feature between all NOX enzymes is an intracellular
NADPH binding domain that transfers electrons from NADPH molecules to O2 through
the transmembrane segment, generating oxidants (Bedard et al., 2007). Due to the
discovery of what would later be referred to as NOX2 in phagocytes, NOX enzymes were
initially postulated to be predominantly host defense enzymes, producing ROS to aid in
phagocytosis (Panday et al., 2015). However, in the years following, it was discovered
that that NOX enzymes have multiple other functions outside of phagocytes, chief among
them being their ability to produce H2O2 or O2- as second messenger molecules that can
participate in downstream redox signaling (Geiszt et al., 2004). In this context, activation
of NOXes can feed into multiple critical pathways, such as wound healing and
inflammation, with a multitude of downstream targets (Panday et al., 2015).
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Inflammatory diseases of the airways have long been associated with a marked
increase in oxidative stress, which is thought to proceed simultaneously with chronic
inflammation (Andreadis et al., 2003; Rahman et al., 2006; van der Vliet et al., 2018). In
general, oxidant stress is characterized as a notable increase in oxidants such as H2O2/O2-,
in addition to alterations in cellular antioxidant levels, such as the ratio of reduced to
oxidized glutathione (Fitzpatrick et al., 2012; van der Vliet et al., 2018). Interestingly,
however, large scale testing of antioxidant therapies conducted in an effort to study this
phenomenon have seen little success (Fitzpatrick et al., 2012; van der Vliet et al., 2018).
As mentioned earlier, higher levels of oxidant generation leads to increased Cys
modification, which is well known to alter protein function in a variety of ways including
activity increases/decreases and alterations in target binding (Paulsen et al., 2010; Poole,
2015). Sources of ROS within cells are fairly well known, with the majority of ROS
being the products of either NOX activation or mitochondrial respiration (Holmstrom et
al., 2014). It has been shown that proper mitochondrial ROS generation is critical in
normal airway signaling, and dysfunction of mitochondria leading to higher levels of
ROS can lead to various issues, including the development of asthma and other chronic
airway diseases (Aguilera-Aguirre et al., 2009; Kim et al., 2014; van der Vliet et al.,
2018). With respect to NOX-mediated ROS generation in the airways, there is particular
interest in DUOX1/2 and NOX2/4, as these tend to be the predominant isoforms in the
airway epithelium, as well as in the different phagocytic cells of the immune system (e.g.
neutrophils, etc.) (van der Vliet, 2008).
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1.4.1 NOXes and the Airways
1.4.1.2 NOX2
As previously mentioned, NOX2 was first discovered as the main phagocyte
oxidase and is present in myeloid cells such as macrophages, neutrophils, and eosinophils
(Lambeth, 2004). Given the role of these cells in asthma pathogenesis, it has been
hypothesized that NOX2 plays an important role in contributing to the ROS that are
found at higher levels in asthmatic individuals. This has led to interest in NOX2 as a
possible target for asthma treatment, however conflicting reports lean more towards
lower NOX2 levels inducing higher levels of inflammation and asthmatic phenotypes
following allergen treatment (Banerjee et al., 2012; Kwon et al., 2017; Sevin et al., 2013),
and the suggestion that mitochondrial ROS may be a more important signal than NOX2derived ROS (Kwon et al., 2017). It has also been demonstrated that macrophage NOX2
is a strong contributor to COPD development, particularly in terms of emphysema
development (Trocme et al., 2015). Aside from its function in myeloid cells, NOX2 is
also known to exist in other airway cells, notably the airway epithelial cells. For example,
it is known that NOX2 is one of the main NOX enzymes responsible for epithelial
signaling during wound responses, specifically through participating in the EGF signaling
pathway (Heppner et al., 2016; Paulsen et al., 2011). It has also been identified as a
possible oxygen sensor in epithelial cells, specifically within neuroepithelial bodies,
sensing alterations to oxygen levels and detecting hypoxia (Jones et al., 2000).
Additionally, NOX2 is known to be involved in innate responses to viral infection of
epithelial cells, often being utilized as a host defense mechanism that can activate
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downstream signaling (e.g. NF-kB pathways) (Fink et al., 2008; Soucy-Faulkner et al.,
2010).

1.4.1.2 NOX4
Among the NOX enzymes, NOX4 is somewhat of a special case, as it is thought
to be the only NOX enzyme that is constitutively activated and strongly controlled by
expression rather than activation by cellular mechanisms (Lambeth, 2004). However, this
is only partially the case as regulatory mechanisms have been identified that are
independent of NOX4 expression (Matsushima et al., 2016). NOX4 is expressed in
multiple airway cell types and plays a large role in TGF-β1-induced signaling. It has been
shown that TGF-β1 and/or the chemotherapeutic bleomycin can induce higher levels of
NOX4 signaling in epithelial cells, fibroblasts and smooth muscle cells, which lead to
higher levels of cell death and airway remodeling (Veith et al., 2019). These processes
are well known to eventually lead to airway fibrosis, causing an overall thickening of the
airway/alveolar tissue and impeding proper airflow (Amara et al., 2010; Carnesecchi et
al., 2011; Hecker et al., 2009). Additionally, NOX4 is known to be involved in asthma,
both in the airway smooth muscle cells where it is upregulated and plays a role in
increased contractility (Sutcliffe et al., 2012), as well in airway epithelial cells where
higher expression levels impede ciliary function (Wan et al., 2016). Finally, it was fairly
recently shown that NOX4 plays a role in the development of COPD, as it was seen that
NOX4 expression was correlated with higher levels of ROS in airway smooth muscle
cells leading to COPD development (Hollins et al., 2016; Liu et al., 2016).
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1.2.2.3 DUOX1 and DUOX2
The dual oxidase (DUOX) isoforms are thought to be among the most abundantly
expressed NOX enzymes in the airways. Of the two, the isoform thought to be dominant
with respect to airway epithelial injury and allergen signaling is DUOX1 (Hristova et al.,
2016; Wesley et al., 2007), and will therefore be more thoroughly discussed, whereas
DUOX2 is thought to be more involved in antimicrobial defenses (Gattas et al., 2009; Joo
et al., 2011). However, functionally and structurally, DUOX1 and DUOX2 are highly
homologous, therefore much of what applies to DUOX1 also applies to DUOX2 in that
regard (Donko et al., 2005). Interestingly, with respect to the difference between DUOX1
and DUOX2, evidence points towards different preferences of the two enzymes towards
either Th1 (DUXO2) and Th2 (DUOX1) immunity, complementary to their main
activating stimuli (Harper et al., 2005). However, both of these NOX enzymes are known
to be involved in asthma, as well as other diseases of the airways (Chang et al., 2013;
Voraphani et al., 2014).
DUOX1 was initially discovered in the thyroid gland as a protein critical in
iodine-mediated generation of thyroid hormone (Donko et al., 2005), which would later
expand into a host of roles in many different signaling contexts. DUOX1 is
predominantly localized to the apical plasma membrane of epithelial cells, such as those
in the bronchial epithelium or type 2 alveolar epithelial cells (Fischer et al., 2007), as well
as in endoplasmic reticulum membranes where it may have some functional role (Morand
et al., 2009). Unlike most other NOX enzymes, DUOX1 is a single subunit that only
requires the binding of its maturation factor DUOXA1 for proper cellular localization and
activity (Donko et al., 2005; Luxen et al., 2009). Additionally, DUOX1 specifically
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produces H2O2 towards the apical extracellular region of epithelia upon activation
(Forteza et al., 2005), unlike the other NOX enzymes which predominantly produce O2(Lambeth, 2004). For this to happen, DUOX1, much like the other NOX enzymes, must
bind NADPH through which it can transfer electrons to O2 by passing them from a Cterminal FAD domain to the extracellular face via His residues localized in the
transmembrane segment (Finegold et al., 1996). DUOX1 activation can proceed through
multiple upstream triggers, but it is generally accepted that the main method of activating
DUOX1 is dependent on the binding of Ca2+ to its EF-hand motifs, and can be regulated
by protein kinase A phosphorylation (Rigutto et al., 2009).
DUOX1 has variable tissue expression and is generally concentrated to the
thyroid and lung/airway epithelial mucosa, where it can play different roles (Donko et al.,
2005). As mentioned before, in the thyroid it is generally utilized for the production of
thyroid hormone via iodine-mediated synthesis (Donko et al., 2005). Similarly DUOX1 is
generally thought to play roles in not only innate host defense, but also reparative
processes leading to epithelial regeneration (Fischer, 2009). It does this through the
production of H2O2 towards the extracellular space, which can act as a host defense
response, generate antimicrobial molecules for various other pathogen responses (e.g.
LPO-mediated production of HOSCN), and induce signaling for cellular migration in
response to damage via cytokine/chemokine secretion (van der Vliet et al., 2014).
DUOX1 can also induce increased mucus secretion in response to inflammatory stimuli
via liberation of EGFR ligands, which is similar to its involvement in wound healing
responses (Shao et al., 2005). DUOX1 activity can be induced in a variety of ways
including toll-like receptor ligand signaling (e.g. lipopolysaccharide insult) (Boots et al.,
40

2009; Koff et al., 2008), cellular wounding (Gorissen et al., 2013; Sham et al., 2013),
histaminergic signaling (Rada et al., 2014), or direct ATP stimulation as a mimic for
damage patterns associated with cellular wounding (Heppner et al., 2016; Sham et al.,
2013). Interestingly, it has been fairly recently described that DUOX1-induced H2O2 can
oxidize proteins in close proximity to DUOX1, likely through cellular import of H2O2
molecules via aquaporin channels (Bienert et al., 2014), leading to oxidation-dependent
protein activation (Sham et al., 2013; Heppner et al., 2016; Hristova et al., 2014).
Additionally, while it was previously seen that NOX2 is predominantly activated by
EGF-mediated signaling in the airways (Heppner et al., 2016), it has been demonstrated
that EGF can activate DUOX1 as well, leading to similar production of oxidants in the
context of keratinocyte signaling (Sirokmány et al., 2016). Epithelial DUOX1 signaling
also involves downstream activation and oxidation of Src and EGFR, as previously
described, which have been shown to play roles in wound healing (Heppner et al., 2016;
Sham et al., 2013). Interestingly, while these pathways are known to be heavily activated
in cancer development in other contexts, the role of DUOX1 in cancer is somewhat
mixed. It has been shown that, despite the critical role for DUOX1 in cellular migration,
it is actually loss of DUOX1 that is involved in cancer development and development of
more invasive cellular phenotypes/EMT (Little et al., 2016; Luxen et al., 2008), which
has been associated with nuclear EGFR translocation (Little et al., 2019).
Recent work from our lab has also shown that DUOX1 and EGFR are critical for
the induction of type 2 responses in the airways, in the acute stages of allergen challenge
(Hristova et al., 2016). Interestingly, it has also been seen that both asthmatics and mice
challenged with allergens have higher levels of DUOX1 (Dickinson et al., 2018;
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Habibovic et al., 2016), consistent with previous reports of DUOX1 involvement in
mucin expression (Shao et al., 2005). These observed increases are likely a result of the
higher levels of IL-4 and IL-13 in asthmatics, which are known to be involved in the
induction of DUOX1 expression (Harper et al., 2005). Recent work has also shown that
DUOX1-dependent induction of type 2 responses, as well as DUOX1 expression, can be
altered through estrogen receptor signaling in response to allergen challenge (Cephus et
al., 2020). In the same vein of airway diseases, a very recent study was published
similarly linking increases in DUOX1 expression to TGF-β/bleomycin-induced
pulmonary fibrosis, a disease in which other NOX enzymes have classically been
implicated that shares similarities with airway remodeling in asthma (Louzada et al.,
2020).

1.5. The Airway Epithelium in Innate Responses
The airway epithelium, specifically in the upper airways, makes up the first critical
barrier to the respiratory system (Holgate, 2011). This tissue, stacked heterogeneously
with various types of cells, carries out many important functions with respect to blocking
particulate, chemical, or pathogenic insults upon inhalation, minimizing the amounts that
eventually make it to deeper parts of the airways (Crystal et al., 2008). Generally, this is
achieved through mucociliary clearance of these molecules, where polarized epithelial
cells beat their cilia to move particulate-bound mucus through the airway, eventually
leading to clearance via swallowing or coughing (Bustamante-Marin et al., 2017).
However, while the airway epithelium contributes mechanically, it is also responsible for
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sending signals through the respiratory tissues to induce reparative responses that can be
helpful or harmful, depending on the context, frequency, and magnitude.
When a particulate or pathogen is introduced to the airway epithelium, there is
often a rapid response following this insult that serves to repair any damage that may
have occurred. This is what is known as an innate response, as it does not require
specialized activation of other cell types for increased specificity with respect to the
molecule in question (Chaplin, 2010). For example, common innate responses include the
binding of surfactant proteins to pathogens, the mobilization of antimicrobial peptides,
and/or the activation and phagocytosis of foreign matter by macrophages in the alveolar
regions of the airways (Bals et al., 2004). Additionally, innate responses can involve the
secretion of various cytokines and chemokines that can trigger critical activities in many
different cell types (Saenz et al., 2010). These different responses can function to address
an issue alone, or can be factors that trigger mobilization of the adaptive immune system,
which follows later with cells generated to address the specific problem via cytokine
secretion, antibody generation, and cell killing, in addition to developing a “memory” for
the insult in question (e.g. T cells and B cells) (Chaplin, 2010). In general, the airway
epithelium is the origin of innate respiratory responses as it is the first point of contact
and must act accordingly. This often manifests in the secretion of different factors, either
passively through destruction of various cells, or by active secretion mechanisms
following the binding of a ligand to a specific receptor. Most commonly, this operates in
the context of damage responses, which are activated by damage associated molecular
patterns (or DAMPs). One of the most common of these DAMPS is the secretion of ATP
from cells into the extracellular space, which is sensitive to ATP release due to a
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relatively low extracellular ATP concentration, leading to its interaction with purinergic
receptors (Vénéreau et al., 2015) and activating downstream responses (e.g.
phospholipase C and Ca2+ mobilization) (Schwiebert et al., 2003). Something as extreme
as physical injury can cause ATP mobilization, but these signals can also be induced by
much more subtle alterations such as mechanical stretching during breathing (Button et
al., 2007). Similarly, introduction of an allergen to the airway epithelium, such as house
dust mite (HDM, Dermatophagoides pteronyssinus) or the fungus Alterneria alternata
(ALT) can induce damage signal secretion (Kouzaki et al., 2011). Allergens can trigger
these responses in a variety of ways, but some of the most prevalent factors are allergen
proteases (e.g. Der P 1 in HDM), which are capable of cleaving parts of special receptors,
called protease activated receptors (PAR), activating the downstream mobilization of
different innate molecules and rapidly inducing appropriate responses through mediators
such as Ca2+ (Kauffman et al., 2006; Schiffers et al., 2020; Zhang et al., 2018).
Additionally, ATP mobilization can be induced by viral infection (Okada et al., 2011),
bacterial components like lipopolysaccharide (LPS) (Song et al., 2009), and various
material or chemical insults such as the pollutant biproduct ozone (Ahmad et al., 2005).
Another major piece of this response includes the release of various cytokines as triggers
for reparative or inflammatory downstream signaling following these insults. In general,
this involves three specific cytokines that can be released from the epithelium: IL-33, IL25, and thymic stromal lymphopoetin (TSLP), all classified as “alarmin” molecules, a
subset of DAMPs including various endogenous molecules released from cells to signal
for danger (Bianchi, 2007). These cytokines are all known to be released in response to
injury or other stimuli and are responsible for activating further downstream cytokine
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signaling and responses through various immune cells (Divekar et al., 2015). Epithelial
cytokine signaling can lead to different immune-related functions such as the induction of
mucus secretion, mobilization of neutrophils and eosinophils to sites of injury/insult, or
signaling for epithelial migration and wound healing (Divekar et al., 2015). This review
will specifically focus on IL-33, which is a major member within this group of molecules
(Lamkanfi et al., 2009; Rider et al., 2017).

1.6 Interleukin-33
Interleukin-33 (IL-33) is an epithelial derived cytokine in the IL-1 family that is involved
in many different innate responses to insults and injury as an alarmin. IL-33 often plays a
critical role in the resolving phases of minor injury, and a major role when signaling is
aberrantly overactive and/or repeatedly induced. IL-33 has gained notoriety in recent
years for its involvement in multiple diseases such as parasite responses (Hung et al.,
2013), obesity (Hasan et al., 2014; Miller et al., 2010), cardiac injury responses (Sanada
et al., 2007), intestinal damage relevant to colitis (Monticelli et al., 2015), as well as the
focus of this review: inflammatory lung diseases

1.6.1 IL-33 Biology
1.6.1.1 IL-33 Structure, Localization, and Secretion
IL-33 is a ~30 kDa protein predominantly expressed in the barrier cells of
multiple tissues (e.g. epithelia and endothelia), comprised of a chromatin binding nuclear
domain, as well as a central domain, and a c-terminal cytokine domain (Liew et al.,
2016). IL-33 also features numerous regulatory protease cleavage sites across these
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domains, a feature common among the IL-1 family (Dinarello, 2018). In contrast to the
inducible expression of many other cytokines, IL-33 is constitutively localized to the
nucleus of barrier cells through its chromatin binding domain, which led to its initial
description as a nuclear factor protein (Baekkevold et al., 2003; Carriere et al., 2007).
Like IL-1α, IL-33 considered a “dual function” cytokine that has both chromatin binding
capabilities and normal cytokine capabilities (Dinarello, 2018). While this domain does
allow it to bind to chromatin, however, there is little evidence for robust nuclear factor
activity (Travers et al., 2018) aside from a report demonstrating that it binds to, and may
regulate the expression of, the gene encoding for its receptor ST2 (commonly referred to
by its gene name IL1RL1 or interleukin-1 receptor like 1) (Shao et al., 2014). Despite the
lack of clear function for the chromatin binding nature of IL-33 in transcriptional
regulation, however, it has been demonstrated that truncated forms of IL-33 lacking the
chromatin binding domain do not localize to the nucleus of cells and instead induce
rampant and lethal inflammation in vivo (Bessa et al., 2014).
The constitutive expression of IL-33 in the nucleus of cells is believed to keep it
primed for release following cellular necrosis or acute injury from foreign material
(Cayrol et al., 2018). However, there are also more active secretion mechanisms by
which stimuli can induce cellular IL-33 secretion without cell death or injury. For
example, IL-33 secretion has been demonstrated in response to allergen exposure
(Kouzaki et al., 2011), mechanical strain (Kakkar et al., 2012), cigarette smoke extract
(Xia et al., 2015), and TLR agonist stimulation (Zhang et al., 2011) without causing
significant cell death. This mechanism of constitutive expression contrasts other IL-1
family members like IL-1β, which is not constitutively expressed and can be induced by
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various factors (e.g. microbial stimuli) prior to secretion and processing by NLRP3
inflammasomes, or IL-18 which is constitutively expressed in an inactive state until
cleavage. (Dinarello, 2018). IL-33 secretion is, however, similar to the secretion of IL-1α,
which is another constitutively expressed “dual function” cytokine localized to the
nucleus for rapid secretion in response to insults and localized inflammation (Di Paolo et
al., 2016).
It has been shown that there is a specific requirement for ATP and Ca2+
signaling in the context of allergen induction of IL-33 secretion (Kouzaki et al., 2011;
Uchida et al., 2017). In fact, it was seen that ROS generation is also critical for IL-33
secretion, which can impact ATP and Ca2+ secretion (Uchida et al., 2017), in addition to
oxidative stress being a regulator of IL-33 expression in response to viral challenge
(Aizawa et al., 2018). Interestingly, these are the same factors that are involved in the
activation of DUOX1 (Donko et al., 2005), the aforementioned NOX family member that
is heavily involved in epithelial responses. Indeed, our recent work has focused on the
involvement of DUOX1 in airway epithelial IL-33 secretion. We demonstrated that
DUOX1 activation is, in fact, necessary for IL-33 secretion and downstream type 2
responses through oxidation and activation of EGFR following acute allergen challenge
(Hristova et al., 2016). Consistent with our findings, it has recently been shown that
DUOX1-dependent IL-33 secretion in response to ALT can be controlled by hormone
signaling, specifically though estrogen receptor-α-mediated induction of DUOX1
expression (Cephus et al., 2020). DUOX1 additionally controls IL-33 signaling in more
chronic settings of allergen challenge that induce airway inflammation. A recent study
from our lab showed that primary cells from asthmatic patients, as well as mice subjected
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to chronic allergen challenge, have persistent and robust DUOX1-dependent oxidative
activation of both Src and EGFR. Similarly, it was observed that allergen challenged
mice developed higher levels of DUOX1-dependent IL-33 and type 2 cytokine secretion,
associated with elevated airway inflammation and hyperresponsiveness (Habibovic et al.,
2016). Overall, these findings demonstrate the involvement of DUOX1 in IL-33
secretion.

1.6.1.2 IL-33 Processing
As mentioned above, IL-33 can be secreted by either passive or active
mechanisms, however this is not enough to generate the most potent signaling form of the
protein. While having significant activity, the full-length form of IL-33 possesses far less
activity than certain truncated forms (Liew et al., 2016). Following cleavage of IL-33 by,
for example, inflammatory proteases or various other cellular proteases (e.g. neutrophil
elastase), it adopts a “mature” form of roughly 18 kDa that is significantly more active
than the full-length form (Lefrancais et al., 2012; Schmitz et al., 2005). Interestingly,
while IL-33 is thought to be cleaved by calpain and/or immune cell proteases into a more
active mature form, it is largely thought to be inactivated via cleavage by other proteases
associated with inflammasome activation and apoptosis such as caspases 1 and/or 3,
which are critical in the activation of other IL-1 family members such as IL-1β and IL-18
(Cayrol et al., 2009). This is also not consistent for its most similar IL-1 family member,
IL-1α, which is thought to be potentially regulated by these proteases via hematopoietic
cell pyroptosis (Lefrançais et al., 2012; Lefrancais et al., 2012; Sims et al., 2010). IL-33
inactivation by caspases is thought to possibly be acting as a safeguard in periods of high
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apoptosis and to prevent unregulated IL-33 release from dying cells (Cayrol et al., 2009).
Additionally, it has been shown that not only cellular proteases, but exogenous allergen
proteases can induce cleavage of IL-33 to multiple truncated forms as well, suggesting an
interesting additional explanation for the extreme responses observed during allergen
signaling (Cayrol et al., 2018; Scott et al., 2018).

1.6.1.3 IL-33 Signaling
Following release and cleavage, IL-33 signaling proceeds via the association of
IL-33 with its receptor ST2/IL1RL, a receptor thought to be an orphan receptor until the
discovery of IL-33 as its only known ligand (Schmitz et al., 2005). ST2 exists as a
transmembrane heterodimeric complex with the adaptor protein IL-1 receptor accessory
protein (IL-1RAcP), both of which bind multiple different intracellular proteins to form a
full ST2 receptor signaling complex. This complex often includes the myeloid
differentiation primary response 88 (MYD88), tumor necrosis factor receptor-associated
factor 6 (TRAF6), as well as multiple interleukin-1 receptor-associated kinase (IRAK)
proteins, similar to not only the IL-1 receptor family, but toll-like receptors as well
(Kakkar et al., 2008). ST2 is expressed in many different cells types, predominantly
including immune cells (e.g. macrophages, eosinophils, lymphocytes, dendritic cells)
(Kakkar et al., 2008; Löhning et al., 1998; Pecaric-Petkovic et al., 2009), but also
including barrier type cells such as epithelial cells (Yagami et al., 2010). In fact, it has
been seen that ST2 expression can be modulated in these barrier cells by downstream
products of IL-33 signaling, likely leading to more robust responses (Christianson et al.,
2015). Following the association of IL-33 to the ST2 receptor complex, these proteins
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can then send signals out to activate various inflammatory processes such as MAPK
signaling and NF-KB signaling (Schmitz et al., 2005), all of which can then lead to
downstream protein expression and induction of proper responses. Interestingly, there is
also a truncated or soluble splice variant form of ST2, known as soluble ST2 (sST2)
which is thought to antagonize IL-33 signaling by binding free IL-33 (Hayakawa et al.,
2007). Similarly, IL-33 can be regulated by rapid oxidation of critical Cys residues,
leading to the formation of intramolecular disulfide bonds that change its conformation
and reduce its affinity for ST2 (Cohen et al., 2015), making it more susceptible to
proteolytic degradation by exogenous allergen proteases (Scott et al., 2018) (Figure 1.5).
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Figure 1.5 IL-33 Secretion, processing, and signaling. IL-33 is released either actively
or passively from barrier cells (e.g. epithelial cells) in an active full length (FL-IL-33)
form, after which it is processed to a more potent “mature” form (M-IL-33). IL-33
signaling can proceed by binding its receptor ST2 on many different cell types, or it can
be antagonized by the soluble decoy receptor sST2, through apoptotic proteases
(caspases) prior to secretion, and through oxidation in the extracellular environment.
Following the association of IL-33 with ST2 on various immune cells, it can signal for
the activation of various reparative pathways.

IL-33 is critical for inducing the type 2 immune responses (Lott et al., 2015).
These responses are commonly associated with parasitic infections, such as helminth
infections, and comprise an entire subset of innate and adaptive immune cells and
responses. Notably, the induction of type 2 responses leads to the production of specific
type 2 cytokines, such as IL-4, IL-5, and IL-13. Accordingly, type 2 immune responses
and IL-33 are associated with multiple diseases such as asthma, cancers, COPD, acute
respiratory distress syndrome, and pulmonary fibrosis, among others (Liew et al., 2016;
Miller, 2011).

1.6.1.4 Type 2 Immune Responses and IL-33
While there are many responses triggered following airway insult and IL-33 mobilization,
some of the most critical are immune responses. Generally, epithelial cytokines have
downstream activity that can trigger inflammatory responses involving the recruitment of
immune cells to the site of injury. These immune responses can involve both arms of the
immune system (innate and adaptive) and are generally thought to be split between type 1
51

and type 2 responses (although Th17 responses do also exist), depending on the cell types
involved and signaling molecules secreted (Annunziato et al., 2015). Generally, type 1
(Th1) immune responses play a large role in the inflammatory responses to pathogenic
microorganisms (e.g. bacteria), often involving such mediators as interferon-γ and other
type 1 cytokines, usually leading to the activation of type 1 lymphocytes (Th1 cells),
phagocytotic cells (e.g. neutrophils), and death of infected cells through cytotoxic T cells
(Annunziato et al., 2015). Allergens and innate injury responses are instead thought to
predominantly induce signaling through the type 2 (Th2) immune responses. While these
responses are more commonly associated with responses to parasites (e.g. helminths)
(Anthony et al., 2007), they have also long been associated with allergens and allergic
inflammation (Fahy, 2015). Generally, Th2 signaling operates through the release of the
previously mentioned epithelial cytokines working in conjunction with pattern
recognition receptors to induce downstream activation of type 2 T cells and innate
lymphoid cells, all of which produce the classic Th2 cytokines IL-4, IL-5, and IL-13 in
response to IL-33 (Bartemes et al., 2012). Additionally, type 2 responses can be
associated with the downstream release of immunoglobulin E from B cells (Annunziato
et al., 2015). These cytokines can then induce responses from various cell types, ranging
from the recruitment of eosinophils via IL-5 as a response directed at killing the
infiltrating

pathogens,

to

the

polarization

of

various

immune

cells

(e.g.

polarization/alternative activation of macrophages), to the production of mucus via IL-13
signaling (Gordon, 2003; Koyasu et al., 2011). This is specifically critical to the airways,
as chronic activation of type 2 responses leads to various diseases involving airway
inflammation. Notably, these responses are linked with asthma pathogenesis, which
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includes over-activation of all of the aforementioned responses, hypersensitivity of the
airways to subsequent allergen challenges, and remodeling epithelial walls, and restricted
airflow (Lambrecht et al., 2019).
1.6.2 IL-33 in Lung Diseases
1.6.2.1 Asthma
In terms of the airways, the principal focus of IL-33 is its role in allergic
inflammation and asthma. Asthma is a complex and heterogeneous respiratory disease
that affects roughly 20 million people in the United States, with treatment that
encompasses

a

large

portion

of

annual

medical

(https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm).

expenditure
Generally,

asthma is characterized by chronic narrowing of the airways, elevated inflammation, and
mucus hypersecretion leading to suppressed airflow (Holgate, 2012; Wenzel, 2012).
Additionally, asthma can be broken down into various subtypes or subgroups (called
endotypes) based on the characteristics of the disease. For example, there are groups in
which symptoms must be triggered by some sort of airway insult (e.g. allergic/atopic
asthma, exercise-induced asthma, etc), differential contribution of immune responses
(e.g. Th2-high/eosinophilic vs Th2-low/neutrophilic), as well as asthma that presents a
constant and chronic impediment to respiratory function (e.g. severe asthma or obese
asthma), all of which can overlap to varying degrees (Wenzel, 2012). Many of these
responses can be attributed to higher levels of inflammatory cells and inflammatory
signaling, notably induced through the cytokine-producing actions of lymphocytes
(generally type 2/Th2 T helper cells and innate lymphoid cells) and the recruitment of
granulocytes (e.g. neutrophils and eosinophils) to the airways (Holgate, 2012) via
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chemotaxis (e.g. lymphocyte-generated IL-5 and epithelial-generated eotaxin recruiting
eosinophils) (Pelaia et al., 2015). Additionally, specifically in the case of allergic asthma,
inflammation is associated with B cell-mediated release of allergen-specific
Immunoglobulin E, an antibody type that is produced in response to allergens and
associates with various cells (such as mast cells), and a higher level of recruitment of
lymphocytes specifically producing asthma-relevant cytokines (e.g. Th2 cytokines)
(Platts-Mills, 2001). Once these cells are recruited to the airways, they can induce such
responses as inducing hyperresponsiveness, weakening cell monolayers, and contributing
to reparative pathways that may lead to remodeling of the airways, ultimately leading to
further restriction of airflow.
To date, there have been multiple large-scale genomic studies linking IL-33 and
ST2 to persistent asthmatic phenotypes, as well as bench studies confirming the
importance of its signaling in settings of chronic asthma (Divekar et al., 2015;
Gudbjartsson et al., 2009; Moffatt et al., 2010; Prefontaine et al., 2010; Schmitz et al.,
2005). Interestingly in chronic Th2 high asthma, there are also various IL-33 splice
variants that have been shown to result in cytoplasmic localization and persistent
secretion (Gordon et al., 2016). Similarly it has been shown that blocking IL-33 signaling
via a monoclonal antibody targeted to ST2 and/or IL-33 itself can block the development
of allergen-induced asthmatic or allergic phenotypes (Kearley et al., 2009; Lee et al.,
2014), which has been recapitulated through the use of IL-33 or ST2 deficient mice,
showing similar suppression of asthmatic phenotypes (Chu et al., 2013; Oboki et al.,
2010; Zoltowska et al., 2016). Further data has also demonstrated that IL-33 can directly
influence asthmatic responses, and that directly instilling recombinant IL-33 into the
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airways of mice can lead cause the development of airway inflammation similar to that of
an allergen challenge (Kondo et al., 2008). As mentioned previously, one of the main
responses initiated by IL-33 secretion are the type 2 responses, which are highly
associated with asthma development (Lott et al., 2015). For example, IL-33 can induce
the secretion of IL-5 and IL-13 from various downstream immune cells, which can then
initiate the infiltration of eosinophils into the airways, airway remodeling,

mucus

hypersecretion, and inflammation, all of which can which can lead to impaired airflow
(Bartemes et al., 2012). Furthermore, IL-33 plays a critical role in viral exacerbations of
asthma, where it has been shown that IL-33 can contribute to viral asthma exacerbations
with respect to rhinovirus (Jackson et al., 2014), as well as influenza (Ravanetti et al.,
2019), and can potentially suppress viral immune responses while promoting type 2
responses.

1.6.2.1.1 IL-33 Autoamplification
Another interesting factor of IL-33 secretion that has predominantly been observed in
asthma-related studies is the potential for feedback and/or feed-forward responses that
amplify the IL-33 signaling pathway. In fairly recent reports, it has been observed that
IL-13 secretion from type 2 T cells and innate lymphoid cells, induced by epithelial IL-33
secretion under periods of chronic allergen challenge, can feed back to the epithelium and
induce higher levels of both IL-33 and ST2 expression (Christianson et al., 2015), similar
to prior reports stating IL-33 can induce its own cellular expression utilizing citrine
reporter mice (Hardman et al., 2013). This would likely then lead to more severe
responses following repeated exposure. Additionally, it has been seen that allergen and
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IL-33 signaling can lead to feedback signaling between epithelial cells and mast cells,
both of which signal in an IL-33 and ST2 dependent manner (Altman et al., 2019). More
recently, it has been shown that repeated IL-33 exposure can induce autoamplification of
IL-33 expression and secretion, which is coupled to a rapid generation of
hyperresponsive and inflammatory lung phenotypes, a hallmark of asthma development.
(Magat et al., 2020). These findings suggest a critical need to deeply examine the
mechanisms behind this phenomenon in order to develop a better understanding of how
these responses are truly regulated with respect to disease development.

1.6.2.2 Pulmonary Fibrosis
Pulmonary fibrosis is a chronic and progressive lung disorder characterized by increased
lung stiffness, mediated by thickening of the pleura, EMT, increases in extracellular
matrix protein deposition (e.g. collagen and fibronectin), myofibroblast accumulation,
and epithelial injury (Gross et al., 2001). This effectively leads to a progressive decrease
in lung function and eventual death. The causes of pulmonary fibrosis are variable, with
some fibrosis caused by repeated insults to the airways by various chemicals (e.g. the
chemotherapeutic bleomycin), however pulmonary fibrosis can also arise completely
idiopathically (idiopathic pulmonary fibrosis, IPF) (Wilson et al., 2009). IPF is known to
involve marked increases in epithelial cell death and aberrant wound repair, leading to
heightened levels of reparative signaling such as increased transforming growth factor β
(TGF-β), as well as significant differentiation of fibroblasts into myofibroblasts (Duffield
et al., 2013). In association with this wound healing, there is also the apparent activation
of innate immunity associated with inflammation and a Th2-like phenotype that involves
56

a heightened level of eosinophilia, as well as IL-13 secretion (Gross et al., 2001; Wilson
et al., 2009). It has also been observed that IL-33 expression is upregulated in IPF patient
lungs (Luzina et al., 2012) as well as in the lungs of mice treated with the fibrosisinducing chemical bleomycin (Luzina et al., 2013), and is associated with a worsened
effect of bleomycin induced fibrosis (Luzina et al., 2013). Interestingly, it has also been
observed that individuals with autoimmune issues that carry a Th2-dominant phenotype,
such as sclerosis, have increased serum IL-33 associated increases in IPF and decreased
lung function (Yanaba et al., 2011). Additionally, it has been shown that bleomycin
induced lung fibrosis in mice involves increased expression and processing of IL-33,
which is associated with higher levels of alternatively activated macrophage polarization
and ILC2 activation, inducing higher levels of important profibrotic meditators such as
IL-13 and TGF-β (Li et al., 2014). While increased ROS and redox modulation of protein
activity are thought to be a critical aspect of fibrosis development, evidence
predominantly points to activation of NOX4 (Hecker et al., 2009), which has no known
direct link to IL-33 signaling and secretion to date. However, a recent study has
demonstrated that there may be a role for DUOX1 upregulation by Bleomycin/TGF-B in
IPF (Louzada et al., 2020), which could theoretically involve IL-33 secretion despite
limited evidence of Th2 response activation.

1.6.2.3 Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a lung dysfunction that
manifests as extreme airflow restriction characterized by tightening of the bronchial
airways and emphysema in the lower airways, affecting millions of Americans annually
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and resulting in 120,000-150,000 deaths per year (Qureshi et al., 2014). Generally, COPD
is the result of repeated damage to the airways from various insults, such as cigarette
smoke or pollutant material containing toxic particulates, leading to progressive
inflammation of the airways, mucus hypersecretion/goblet cell hyperplasia, airway
remodeling, and increased inflammatory protease activity (e.g. increased neutrophil
elastase, low levels of alpha-1 antitrypsin) in the parenchyma (Crystal, 1990; Hoenderdos
et al., 2013; James et al., 2007; Sutherland et al., 2003; Vestbo et al., 2013). Given the
induction of COPD through repeated toxic insults to the airway, it is similarly well
known that there is a high involvement of innate responses of the epithelial cells that can
lead to the induction of these responses, specifically due to the chronic secretion of
DAMPs and an increase in necrotic cell death (Pouwels et al., 2014). Accordingly, there
is a known role for IL-33 in the pathogenesis of COPD, where IL-33 typically serves to
exacerbate COPD through various factors. For example, it is known that IL-33 is
expressed at higher levels in the basal cells of COPD patients and mice with a COPD-like
phenotype following viral infection (Byers et al., 2013).

Similarly it has been

demonstrated that cigarette smoke is capable of priming IL-33 for release by inducing
higher levels of expression, which then allows for its secretion by viral infection while
altering ST2 expression and suppressing normal Th2 responses in favor of Th1-like
responses (Kearley et al., 2015). It has also been shown that bronchial epithelial IL-33
secretion can, in fact, be induced by cigarette smoke extract directly and in association
with co-stimulation with LPS, involving minimal cell death (Xia et al., 2015). Similarly,
IL-33 expression has been shown to be increased in response to ROS, both a product of
cells involved in COPD and common component of toxic insults known to induce COPD
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(MacNee, 2005), which can also further increase virally induced IL-33 expression
(Aizawa et al., 2018). With respect to DUOX1, there is not much known with respect to
COPD despite DUOX1 playing an important role in the suspected pathways leading to
COPD development, however one group did show that DUOX1 mRNA was decreased in
lung cells from COPD patients that were smokers in comparison to those who had never
smoked (Nagai et al., 2008).

1.7 Dissertation Scope
The scope of this dissertation is to address the role of Src oxidation within the
airway epithelium, with a specific focus on innate epithelial responses. As outlined
above, recent evidence has shown that acute epithelial activation is a crucial wound/insult
response process that controls normal epithelial regeneration and injury responses
following damage. It has been observed that these processes involve critical activation of
redox signaling pathways leading to downstream activation of kinase activity. This work
seeks to identify the processes resulting in, and regulating, epithelial responses to allergen
challenge with respect to redox activation of Src and airway epithelial IL-33 secretion.
Therefore, we hypothesize that oxidant production regulates airway epithelial IL-33
secretion and downstream type 2 signaling through Src cysteine oxidation.
The first aim of this dissertation is to understand the role of redox regulation
with respect to the activation of Src. We and others have seen that Src is regulated by Cys
oxidation downstream of various oxidant sources, notably including the NOX family
member DUOX1 in the airway epithelium. Utilizing quantitative proteomics, as well as
recombinant C to A mutants and C to A mutant Src constructs in cells, our goal was to
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specifically determine which Cys residues contribute to Src activation. Additionally,
utilizing molecular dynamics simulations, we set out to determine the impact of oxidation
on conformational changes in Src that may lead to activation.
The second aim focuses on determining the role of Src (redox) signaling with
respect to airway epithelial IL-33 secretion and downstream type 2 responses. Previous
work has demonstrated that DUOX1 is capable of inducing airway epithelial IL-33
secretion in an EGFR-dependent process, which similarly involves activation of the Src
kinase (Hristova et al., 2016). However, to date, the importance of Src in these responses
has never specifically been addressed, despite the implications for Src signaling in airway
inflammation and asthma. Additionally, while Src is known to be redox regulated in
airway epithelial cells, it is not known whether redox activation of Src through Cys
oxidation is necessary for proper cytokine responses in innate epithelial signaling,
specifically with respect to IL-33 secretion and downstream type 2 responses. Therefore,
we utilized Src inhibitors, as well as genetic knockout strategies in mice and isolated
cells, to determine the impact of Src in airway epithelial IL-33 secretion. Additionally,
using our C to A Src mutant constructs, we assessed the role of Src Cys oxidation on
airway epithelial IL-33 secretion. Lastly, we utilized genetic and pharmacological
strategies with mice and isolated epithelial cells to unravel the roles of Src and DUOX1
in an unexpected acute IL-33 autoamplification pathway.
Finally, this dissertation will provide a summary of the main findings of this
work, as well as future directions and efforts to expand these findings.
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2.1 Abstract
The Src kinase controls various aspects of cell biology and its activity is
regulated by intramolecular structural changes induced by protein interactions and
tyrosine phosphorylation. Recent studies indicate that Src is additionally regulated by
redox-dependent mechanisms, involving oxidative modification(s) of conserved cysteines
within the Src protein, although the nature and molecular-level impact of Src cysteine
oxidation are unknown. Using a combination of biochemical and cell-based studies, we
establish the critical importance of two Src cysteine residues, Cys-185 and Cys-277, as
major targets for H2O2-mediated sulfenylation (Cys-SOH) in redox-dependent kinase
activation in response to NADPH oxidase-dependent signaling. Molecular dynamics and
metadynamics simulations revealed the structural impact of sulfenylation of these
cysteines, indicating that Cys-277-SOH promotes rapid solvent exposure of Tyr-416 to
promote its (auto)phosphorylation and Cys-185-SOH destabilizes pTyr-527 binding to
the SH2 domain. These redox-dependent Src activation mechanisms offer unique
opportunities for development of Src-selective inhibitors in treatment of diseases in
which Src is aberrantly activated.
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2.2 Methods
Src Expression and Purification — Recombinant Src and variants were expressed in
BL21-AI E. coli (Thermo) containing the pEX-Src-C-His (Origene, Blue Heron Biotech)
and purified in a modified procedure as previously described(Seeliger et al., 2005) (see
Supplementary Information for further details).

Mass Spectrometry — Recombinant Src (~20 µg in dimedone experiments, ~13 µg in
BCN experiments, final DTT concentration 0.03-0.25 mM) was incubated with either 1.0
mM

5,5’-dimethyl-1,3-cyclohexanedione

hydroxymethylbicyclo[6.1.0.]nonyne

(BCN,

(dimedone;
Sigma),

Sigma),
or

5

100
mM

µM

9-

4-chloro-7-

nitrobenzofuran (NBD-Cl), and then reacted with 0-1.0 mM H2O2 (Sigma) for 1 hr at 25
°C. For quantitative analysis of sulfenylation, Src (~20 µg) was reacted with 0 or 1.0 mM
H2O2 in the presence of light (d0) or heavy (d6) dimedone(Seo et al., 2011), respectively,
for 1h, followed by catalase quenching. A 1:1 mixture of d0 and d6 labeled samples was
run on 10% SDS-PAGE gels and protein bands were excised, washed, and trypinized
(Promega V511A). Peptides were reconstituted with 2.5% CH3CN/2.5% formic acid and
analyzed by capillary LC–MS/MS on a LTQ (for initial studies with dimedone and NBDCl) or a Q-Exactive mass spectrometer coupled to an EASY-nLC (Thermo Fisher
Scientific, Waltham, MA, USA). Product ion spectra were searched using the SEQUEST
search engine implemented on the Proteome Discoverer 1.4 (Thermo Fisher). Percolator
node was included in the workflow to limit false positive rates to less than 1% in the data
sets. Scaffold 4.05 (Proteome Software) was used for sequence annotation. For
experiments involving quantification of dimedone-d0 and dimedone-d6 labeled peptides,
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targeted mass spectrometry experiments were performed. Mass spectrometry data were
acquired with alternating MS-SIM scans and PRM (2 scan groups in the method). Search
files (.msf) were then imported into Skyline for selecting the precursor or transitions for
quantitation. Four to six transitions were selected from, if possible, the third to the last
fragment ions in the product ion spectrum for quantification. Boundaries of integration
were manually evaluated.

Tyrosine Kinase Activity Measurements — Tyrosine kinase activity of recombinant Src
(1 ng in 15 µL with 2.0 mM DTT) was analyzed using the ADP-Glo (Promega) assay kit
according to the manufacture’s protocol (Supplementary Information). Src was treated
with H2O2 (Thermo) for 15 minutes prior to initiating catalysis for 60 minutes at 25 °C
within the linear kinetic range (data not shown). Reactions were measured for
luminescence and specific activity values were obtained from an ADP (Promega) linear
standard curve.

H292 cell transfection with Src-FLAG constructs — Src-FLAG constructs were
transiently transfected into NCI-H292 pulmonary mucoepidermoid cells (ATCC) at 8590% confluence using the Turbofect reagent (Thermo) according to a modified version of
the manufacturer’s protocol. Briefly, 1 µg of pCMV6-Src (Origene) was mixed with 8 µL
Turbofect and 100 µL serum-free RPMI media (per well) and allowed to incubate at RT
for 20 min. Cells were changed to 900 µL serum-free media prior to dropwise addition of
100 µL transfection mix. Cells were then incubated at 37 °C for 24 hrs, followed by PBS
washing and 24 hrs of full RPMI. Prior to experiments (~48-72 hrs post-transfection),
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cells were switched to serum-free RPMI for overnight incubation. H292 cell lines stably
expressing C-terminal FLAG-tagged Src were generated by transfecting ~70% confluent
cells with 1 µg of DNA from the pCMV6-Src (Origene) and 2 µL of Turbofect
Transfection reagent (Fisher) in RPMI media for 24 hrs as per manufacture’s protocol,
and selection over 10-15 days in serum containing media with 150 µg/mL of neomycin
(G418; Calbiochem).

Cell culture and treatments — H292 cells and transfected cell lines were cultured as
previously described(Heppner et al., 2016; Sham et al., 2013) and seeded at 100,000
cells/well in 24-well plates (Corning), and serum starved overnight. For in situ analysis of
protein sulfenylation (-SOH), cells were pre-loaded with 5 mM DYn-2 reagent(cite ref
21) (Kerafast) for 15-30 minutes, and subsequently stimulated with ATP (Sigma, St.
Louis, MO; 100 µM) for 10 minutes. Cells were then lysed in chelator-free HEPES lysis
buffer and clicked to biotin-azide (Kerafast) using established protocols (Supplementary
Information). As an alternative approach to detect sulfenylated proteins, cells were lysed
with Western solubilization buffer (WSB) containing 1 mM DCP-bio1 (Kerafast), as
described previously(Heppner et al., 2016; Hristova et al., 2016). FLAG-tagged Src and
mutants were purified using Anti-FLAG M2 magnetic beads (Sigma) and eluted with 3X
FLAG peptide (Sigma) as per manufacture’s protocol (Supplementary Information).

Western blotting — Derivatized cell lysates were separated by 10% SDS-PAGE gels and
transferred to nitrocellulose membranes, and probed using antibodies against p-Src Tyr
416 (1:400), p-Src Tyr 527 (1:400), Src (L4A1; 1:1000), FLAG (DDK; 1:1000) (Cell
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Signaling), or streptavidin peroxidase polymer ultrasensitive (1:10,000; Sigma). Primary
antibodies were probed with rabbit- or mouse-specific secondary antibodies conjugated
with HRP (Cell Signaling) and detected by enhanced chemiluminescence (Pierce).
Membranes were imaged with Amersham Imager 600 (GE Healthcare) and band
densities were quantified using ImageQuant TL (v8.1.0.0).

Molecular dynamics simulations — All simulations were performed with the
CHARMM36 force field(Best et al., 2012) in addition to our customized parameters for
the cysteine sulfenic acid (Cys-SOH). The parameters (i.e. for bonds, angles, and dihedral
angles) and partial charges for cysteine sulfenic acid were validated or modified
according to the density functional theory (DFT) calculations with B3LYP/6-31g** in
Jaguar(Becke, 1993; Bochevarov et al., 2013) (see Cysteine sulfenic acid force field
parameters of Supplemental Information). The protein models were constructed from the
autoinhibited Src structure (PDB ID: 2SRC)(Xu et al., 1999). A web-based graphical user
interface CHARMM-GUI(Jo et al., 2008) was used to prepare the initial models for
simulations, which contain our protein models, 17,000~26,000 TIP3P water molecules,
chloride potassium as counter ions, totaling near 58,400~85,400 atoms in a periodic box
85 × 89 × 82~94 × 94 × 94 Å3. After the equilibrium stage(Liao et al., 2016) for 10 ns in
the NAMD(Phillips et al., 2005) program, production runs of conventional MD
simulations (for 2-5 µs) were carried out on the specialized ANTON supercomputer
using the software program Anton 2.13.0(Shaw et al., 2009) and with the Desmond
program (Schrödinger, Inc.) on Graphical Processing Units (GPUs). Metadynamics
simulations were also carried out on GPUs to determine the two-dimensional, free-energy
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landscapes of conformational transition in the cysteine oxidation region in comparison
with corresponding non-oxidized cysteines, using two collective variables (CVs) that
were chosen based on conformational changes suggested by the conventional MD
simulations. To ensure convergence, we have calculated the free-energy difference every
10 ns after 80 ns: the key energy basins remain to the final 120 ns with a general standard
deviation of 0~0.68 kcal/mol for the maximum free-energy difference. A summary of our
simulations is provided in Table 2.4.

Statistical analysis — Data are expressed at means ± s.e.m. for the indicated number of
observations and comparisons are analyzed with student’s t test or 2-way ANOVA.

2.3 Introduction
The proto-oncogene protein tyrosine kinase Src is the prototypical member of the
Src-family kinases (SFKs) that participate in cell signaling pathways by catalyzing
phosphorylation of specific tyrosine residues in various target proteins(Yeatman, 2004).
Commonly activated by initial activation of cell surface receptors, Src activation controls
various cellular outcomes, including differentiation, adhesion, migration, and
proliferation(Bromann et al., 2004; Luttrell et al., 2004). As the first characterized protooncogene, it is well appreciated that aberrant Src activation and expression is associated
with malignant transformation and oncogenesis(Allgayer et al., 2002) establishing Src as
a chemotherapeutic target in the treatment of various cancers(Kim et al., 2009).
Additionally, pharmacological inhibition of Src and other SFKs have been shown to be
effective in several non-malignant human diseases(Rivera et al., 2007; Wang et al., 2017).
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Therefore, elucidation of factors that regulate Src activation is critical to understanding
its extensive roles in human disease and for development of effective treatments.
As a non-receptor tyrosine kinase, Src activity is regulated through protein
structural changes triggered by intramolecular domain interactions through the Src
homology (SH) 2 and 3 domains and by (de)phosphorylation of key tyrosine residues,
thereby

coupling

activation

of

Src

with

targeting

of

appropriate

cellular

substrates(Boggon et al., 2004). In its autoinhibited form, Src is phosphorylated at Tyr527 (pTyr)

(chicken sequence numbers are used throughout) within the C-terminal

domain, which promotes its binding to the SH2 domain, maintaining the protein in a
minimally active “clamped” confirmation(Xu et al., 1999). Upon dephosphorylation of
pTyr-527, Src unfolds inducing several structural changes, which in part allow for
binding to downstream targets(Xu et al., 1999). The structural hallmark of the maximally
active Src kinase is the unfolded activation loop (A-loop) α-helix, which exposes Tyr-416
for phosphorylation and sustains maximal kinase activity(Xu et al., 1999). Molecular
modeling studies describe a dynamic molecular model for Src kinase activation involving
initial conversion of the autoinhibited kinase to an active-like state, in a two-step process
with A-loop unfolding followed by αC-helix rotation(Gan et al., 2009; Meng et al., 2017).
These two states exist in equilibrium, favoring the autoinhibited conformation.
Subsequent (auto)phosphorylation of Tyr-416 by intermolecular encounter with another
active kinase then stabilizes the active form of Src(Meng et al., 2017; Meng et al., 2014).
In addition to Tyr-416, phosphorylation of additional tyrosines may also regulate SFK
function(Weir et al., 2016).
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In addition to regulation by tyrosine (de)phosphorylation events, accumulating
evidence indicates that Src activation occurs in association with increased cellular
production of reactive oxygen species (ROS)(Giannoni et al., 2014). ROS generated from
NADPH oxidases (NOX), respiring mitochondria, or other cellular sources are capable of
modulating cellular signaling pathways by reversible oxidation of conserved cysteine
(Cys) residues within target proteins(Holmstrom et al., 2014; Jones et al., 2015). Such
reversible redox modifications has been frequently implicated in regulation of tyrosine
phosphorylation, and is largely attributed to inactivation of protein tyrosine phosphatases
by reversible oxidation of their catalytic cysteines, thereby resulting in enhanced or
extended tyrosine phosphorylation(Tonks, 2005). However, tyrosine kinases themselves
are also subject to direct redox regulation by oxidation of their non-catalytic cysteine
residues(Corcoran et al., 2013; Heppner et al., 2016; Truong et al., 2013). Indeed,
tyrosine kinases such as epidermal growth factor receptor (EGFR) and SFK can interact
directly with NOX enzymes during their activation (Matsushima et al., 2016; Paulsen et
al., 2011; Sham et al., 2013), and recent studies by our group (Habibovic et al., 2016;
Heppner et al., 2016; Hristova et al., 2016; Sham et al., 2013) and others(Paulsen et al.,
2011; Truong et al., 2016) indicate that NOX-mediated activation of Src and EGFR
closely associates with cysteine oxidation within these kinases. The Src protein contains
nine cysteine residues, most of which are highly conserved among SFKs or related
kinases (Figure 2.1 and Table 2.1), and studies with Cys mutants have suggested the
involvement of several of these cysteines in ROS-mediated Src activation(Giannoni et al.,
2005; Kemble et al., 2009; Oo et al., 2003; Senga et al., 2008; Zhang et al., 2015).
However, the molecular mechanisms by which Cys oxidation promotes Src kinase
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activity remain unclear, and studies with recombinant Src proteins confoundingly indicate
that ROS or other thiol-reactive agents can also inactivate kinase activity(Kemble et al.,
2009; Oo et al., 2003; Senga et al., 2008).
Oxidation of Cys by H2O2, the main mediator of NOX-mediated redox signaling,
initially generates a sulfenic acid (Cys-SOH), but can also generate additional oxidative
modifications due to subsequent reactions(Heppner et al., 2016). Recent studies however
indicate that redox-dependent activation of tyrosine kinases such as Src or the epidermal
growth factor receptor (EGFR) closely associates with initial formation of Cys-SOH, the
proximal product of cysteine oxidation by H2O2, and that other oxidative modifications
such as S-glutathionylation do not enhance kinase activity(Heppner et al., 2016; Heppner
et al., 2017; Paulsen et al., 2013; Paulsen et al., 2011). Therefore, the present studies were
conducted to characterize the redox-sensitive cysteine residues within Src most
susceptible to sulfenylation and to identify the impact of this modification on tyrosine
kinase activity. We identified Cys-185 and Cys-277 as the primary Cys residues oxidized
to Cys-SOH by H2O2, and demonstrated that oxidation of both cysteines is critical for
redox-dependent kinase activation. Molecular dynamics (MD) simulations indicate that
modification of these cysteines to Cys-SOH induces local structural changes that directly
impact the regulatory pTyr-527 and Tyr-416 residues, respectively.
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2.4 Results
H2O2-mediated sulfenylation of Cys-185 and Cys-277 in recombinant Src protein
enhances intrinsic kinase activity
To identify the redox-active Src cysteine residues that are most susceptible to
sulfenylation by H2O2, we utilized various sulfenic acid-selective trapping reagents to
assess H2O2-induced cysteine modifications in recombinant Src using liquid
chromatography-tandem mass spectrometry (LC-MS/MS). First, recombinant Src (~20
µg) was treated with various concentrations of H2O2 (0.1-100 mM) in the presence of
5,5’-dimethyl-1,3-cyclohexanedione (dimedone) to trap intermediately formed Cys-SOH
species, and then trypsin digested for MS analysis. These analyses typically yielded
~80% peptide coverage, comprising all nine cysteine residues. In the absence of H2O2, all
9 cysteines were detected as iodoacetamide adducts, and no dimedone adducts were
observed (except at Cys-498), suggesting they were present in their reduced state. In
contrast, in H2O2-treated protein, Cys-S-dimedone modifications were observed in three
peptides, at Cys-185, Cys-277, and Cys-498, indicating that these cysteines were
oxidized to Cys-SOH species by H2O2 and were successfully trapped as dimedone
adducts (Figure 2.2; Table 2.2 and Supplemental Dataset 1). Other cysteine
modifications, such as sulfinic and sulfonic acids, were also identified on several
cysteines, but these modifications were also observed in untreated Src (Supplemental
Dataset 1), presumably due to autoxidation during Src purification and processing.
Oxidation of Src by high doses of H2O2 (100 mM) revealed overoxidized Cys-185 and
Cys-277 (to sulfonic acids; Supplemental Dataset 1), which further supports the notion
that Cys-185 and Cys-277 are redox active. Importantly, while no Cys-S-dimedone
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adducts were observed on any other cysteines within Src, oxidation of Src with high
amounts of H2O2 (> 1 mM) induced DTT-reducible mass shifts upon analysis by
Coomassie stained SDS-PAGE, indicative of intra- and/or intermolecular disulfide
crosslinking, which were in some cases independent of Cys-185 or Cys-277 (Figure 2.3).
One limitation of dimedone as a trapping molecule for Cys-SOH is its relatively
slow reaction rate with sulfenic acids, suggesting that some unstable intermediate CysSOH may have gone undetected. We therefore performed similar analysis with an
alternative sulfenic acid-reactive probe, bicyclo[6.1.0]nonyne (BCN), which is known to
react with Cys-SOH with a 100-fold faster reaction rate, to form –S(O)-BCN
adducts(McGarry et al., 2016; Poole et al., 2014). Global LC-MS/MS analysis did not
reveal formation of –S(O)-BCN adducts in unreacted Src, but such adducts were detected
on three cysteines during reaction of Src with H2O2, namely Cys-185, Cys-245, Cys-277,
although no adducts were observed on any other cysteines (Figure 2.4 and Table 2.2 and
Supplemental Dataset 2). It is worth noting that BCN can also react with reduced
thiols(Galardon et al., 2015; Gupta et al., 2016), but this caveat is easily addressed in MS
analyses, since reaction with -SOH yields a peptide [Cys-S(O)-BCN] that is +16 Da
heavier than reaction products with a thiol (Cys-S-BCN). Indeed, our MS analysis did not
reveal detectable peptides containing Cys-S-BCN in unreacted or H2O2-treated Src.
Finally, we also assessed cysteine sulfenylation in the presence of 4-chloro-7nitrobenzofurazan (NBD-Cl)(Conte et al., 2013; Paulsen et al., 2013) and observed that
H2O2-treated Src contained detectable Cys-S(O)-NBD adducts at Cys-277 and Cys-498,
consistent with Cys-SOH formation at these residues (Table 2.2 and Supplemental
Dataset 3).
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To more rigorously identify and quantify the most susceptible redox-sensitive Cys
residues within Src, we performed quantitative MS analysis of dimedone trapping using
labeling with light dimedone (dim-d0) and heavy dimedone (dim-d6) of non-oxidized and
H2O2-treated Src, respectively(Seo et al., 2011). Targeted mass spectrometry with parallel
reaction monitoring (PRM) was performed to monitor all cysteine-containing peptides
with dimedone/dimedone-d6 modifications.

The targeted analysis not only further

confirmed the dimedone labeled peptides identified from the exploratory mass
spectrometry experiments with higher S/N and sequence coverage, but also identified
other low abundant dimedone containing peptides that were not identified in the previous
data dependent mass spectrometry runs (Table 2.3 and Supplemental Dataset 4). All the
measured precursor masses of the identified Src peptides were within 0.5 ppm of the
theoretical masses and the tandem mass spectra (MS/MS) exhibited a continuous stretch
of y-ion series, and clear peak assignments, indicating confident identifications
(Supplemental Dataset 5). These analyses revealed Cys-277 and Cys-185 as the most
prominently oxidized cysteines, consistent with our previous dimedone and BCN
trapping experiments. In case of Cys-277, distinct peaks were observed for dim-d6 and
dim-d0 peptide ion isotopologues in the MS1 spectrum (Figure 2.5A). Extracted
chromatograms for dim-d6 and dim-d0 labeled ions (Figure 2.5B red and black,
respectively) enabled the determination of heavy to light (H/L) dimedone tagging ratios
indicating the degree of cysteine oxidation compared to non-oxidized controls. MS/MS
fragmentation spectra of dim-d6 and dim-d0 dimedone labeled Cys-277-containing peptide
ions confirmed the identity of this peptide with expected Cys-S-dim-d0/6 isotopedependent mass shifts (Figure 2.6C and D). Similar analysis was performed for Cys-185
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(Figure 2.6E-H) and the other cysteine-containing peptides (Table 2.3 and Supplemental
Dataset 4). Although these analyses also suggested increased sulfenylation of other
cysteines, as indicated by H/L ratios > 1, these observations were considered less robust
based on the high variance (standard deviation; SD) between triplicate replicates (Table
2.3 and Supplemental Dataset 4). Collectively, these various analyses indicate that Cys185 and Cys-277 were consistently identified as the main redox-sensitive cysteines
within Src that form detectable Cys-SOH species in response to H2O2. Previous reports
have similarly implicated Cys-277(Kemble et al., 2009; Zhang et al., 2015) and some
other cysteines (e.g. Cys-245(Giannoni et al., 2005) and Cys-498(Oo et al., 2003; Senga
et al., 2008)) as redox-sensitive cysteines in the context of ROS signaling, but to our
knowledge this is the first report implicating Cys-185. Examination of the structure of
autoinhibited Src (PDB ID: 2SRC) reveals that the redox active Cys-185 and Cys-277 are
located in close proximity (~5-10 Å) of pTyr-527 and Tyr-416, respectively, possibly
indicating that their oxidation may directly impact regulation of these critical tyrosines
(Figures 2.1B and 2.7)(Xu et al., 1999). In contrast, Cys-245 and Cys-498 are distant
from these regulatory sites (~20-30 Å) and are located in a region that is not significantly
altered during Src activation. Based on these considerations, our subsequent studies
focused on the role of Cys-185 and Cys-277 oxidation in regulating Src activation.
We evaluated intrinsic tyrosine kinase activity of recombinant Src in the presence
of various concentrations of H2O2 and, consistent with previous studies(Heppner et al.,
2016; Krasnowska et al., 2008), observed that kinase activity of wild-type (WT) Src is
enhanced linearly and correlated with H2O2 in a dose-dependent manner, ranging
between 10 and 30 µM (Figures 2.8B and 2.9), although higher H2O2 concentrations
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(>100 µM) did not enhance and even inhibited activity (Figure 2.10). In contrast, H2O2
was incapable of statistically increasing activity of mutant Src proteins containing either
C185A or C277A, even though both mutants retained significant intrinsic kinase activity.
It is important to note that, while the absolute H2O2 concentrations in these studies were
lower than those used in the MS analyses, the relative molar excess of H2O2 over Src was
considerably greater (which was necessary to overcome the high concentrations of DTT
in the kinase buffer). In any case, these results indicate that H2O2 can directly enhance
intrinsic Src tyrosine kinase activity, which is dependent on the presence of both Cys-185
and Cys-277, and is consistent with these residues being the most susceptible to
sulfenylation by H2O2.

Cys-185 and Cys-277 are critical for Src activation in response to cellular H2O2
production
We next addressed the impact of Cys-185 and Cys-277 on H2O2-mediated Src
activation in a cellular context. To this end, H292 mucoepidermoid epithelial cells were
either transiently or stably transfected with C-terminal FLAG-tagged Src constructs (SrcFLAG) or various Cys mutant Src constructs, and activation of Src-FLAG was assessed
in response to cell stimulation with exogenous ATP, known to enhance cellular H2O2
production by activation of the NADPH oxidase DUOX1(Heppner et al., 2016; Hristova
et al., 2014; Sham et al., 2013), by monitoring Src (auto)phosphorylation at Tyr-416.
While these cells express endogenous Src, we confirmed that expressed Src-FLAG
protein is distributed similarly with the cells (Figure 2.11), and can be efficiently purified
with M2 anti-FLAG methodologies (Figure 2.12). As expected(Heppner et al., 2016;
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Sham et al., 2013), ATP stimulation of H292 cells expressing WT Src-FLAG resulted in
its enhanced phosphorylation, as determined by enhanced phosphorylation at Tyr-416 of
immunopurified Src-FLAG (Figure 2.13, 2.14, and 2.15). No significant changes were
observed in Src phosphorylation at pTyr-527 (Figure 2.15), which would suggest that
ATP-mediated activation of Src may occur independent of pTyr-527 dephosphorylation.
Comparative ATP stimulation of H292 cells expressing either C185A or C277A SrcFLAG variants showed markedly reduced Tyr-416 phosphorylation within these proteins
(Figure 2.13, 2.14, and 2.15), indicating that these constructs were not activated in
response to ATP-induced H2O2. To associate these observations with cysteine oxidation
within these various Src constructs, cells expressing WT, C185A, and C277A Src-FLAG
were pre-loaded with the alkyne derivative of dimedone (DYn-2)(Paulsen et al., 2011)
prior to stimulation with ATP. Following lysis, DYn-2-tagged proteins were conjugated
to biotin azide by click-mediated ligation and affinity purified with M2 anti-FLAG
antibodies, to visualize formation of Cys-SOH within Src-FLAG variants by streptavidinHRP blotting. Consistent with previous studies(Heppner et al., 2016), ATP stimulation
induced enhanced sulfenylation within WT Src, whereas sulfenylation was dramatically
attenuated in C185A and C277A variants (Figures 2.13 and 2.14), indicating that both
Cys-185 and Cys-277 are sulfenylated during DUOX1-dependent activation of Src. In
similar experiments, ATP-stimulated H292 cells expressing Src-FLAG constructs were
derivatized during cell lysis with biotin-conjugated dimedone (DCP-Bio1), after which
Src-FLAG proteins were affinity purified and analyzed for pTyr-416 or biotin
incorporation, which yielded highly similar results (Figure 2.15). Hence, these collective
findings indicate that Src is redox regulated within a cellular context and that both Cys93

185 and Cys-277 are sulfenylated in response to DUOX1-mediated H2O2 production and
are critical for Src activation.

Molecular dynamics simulations reveal structural alterations associated with
sulfenylation of Cys-277 and Cys-185.
Activation of Src involves significant structural alterations, but it is unclear how
oxidation of specific cysteines to Cys-SOH results in structural alterations that promote
kinase activation. To address this, we performed both microsecond-long molecular
dynamics (MD) simulations as well as metadynamics simulations to assess the structural
perturbations induced by substitution of Cys-185 and Cys-277 in the autoinhibited Src
structure with their sulfenylated form, Cys-SOH. It is not intuitive how such a small
modification (conversion of a cysteine sulfhydryl to a sulfenic acid) would induce
significant structural alterations, but recent MD simulations indicate significant impact of
sulfenylation of specific cysteines in other proteins(Scalvini et al., 2016; Truong et al.,
2016). As Cys-SOH is a weak acid, it could potentially be present in its deprotonated
Cys-SO- state. Various estimates indicate pKa values for sulfenic acids ranging from 6-10
in the context of small molecules(Nagy et al., 2007; Tadashi et al., 1992), consistent with
density functional theory calculations of model compounds (See supplementary
information). More recent estimates in dipeptides and selected proteins indicate pKa
values for Cys-SOH of ~5.9-7.2(Gupta et al., 2016; Portillo-Ledesma et al., 2018),
implying that a significant fraction of Cys-SOH may exists in its protonated state under
physiological conditions. Based on this, and the fact that previous MD simulations of
Cys-SOH indicated structural changes when modeling the protonated state(Scalvini et al.,
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2016; Truong et al., 2016), we performed our MD simulations based on protonated forms
of Cys-SOH as well as Cys-SH. To incorporate the Cys-SOH into these MD simulations,
we derived and benchmarked CHARMM36-compatible force field parameters for the
cysteine sulfenic acid (Methods and Figure 2.16).
We first simulated the effect of Cys-SOH at the Cys-277 position (Cys-277SOH), which is located on the solvent accessible G-rich loop and within ~10 Å from Tyr416 on the A-loop α-helix(Xu et al., 1999). The wild-type inactive Src structure (PDB ID:
2SRC), as well as other systems in which Cys-277 is in the reduced (Cys-SH) state, were
considered control structures used for comparison to structural changes induced by Cys277-SOH. We measured the helicity at the A-loop (residues 406-423), which consists of
two helical segments (res. 407-410 and res. 414-418) steadily folded throughout the MD
simulations of all control structures (Figure 2.17; Movie S1). In stark contrast, when Cys277-SH was substituted with Cys-277-SOH, a significant loss in the helicity of the Aloop was observed in both simulations of 5 µs (2.18B). One of these simulations showed
rapid unfolding of the A-loop (Cys-277-SOH #1 in 2.18B; Movie S2), while the other
underwent a slower process with major unfolding in the segment of res. 407-410 (Cys277-SOH #2 in 2.18B). These findings suggest that Cys-277-SOH-dependent A-loop
unfolding is a complex mechanism comprising of multiple paths towards unfolding of the
A-loop. Focusing on the detailed interactions around the A-loop, we analyzed these two
Cys-277-SOH simulations and the other six control simulations (all Cys-SH, Cys-185SOH, and Cys-498-SOH). In control groups, the key regulatory Tyr-416 residue resides
near or within H-bonding distance with Asp-386 of loop res. 383-389, with the side chain
phenol positioned away from the solvent and within the catalytic cleft (Figure 2.17B).
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Additionally, these simulations identified another possible key residue, Arg-419, which
occasionally swings to interact with Asp-386. The sulfenylated form of Cys-277 (Cys277-SOH) likely competes with Tyr-416 for H-bonding interactions with Asp-386. As a
result of the sulfenylation of Cys-277, there is a shuffle in these residues when Cys-277SOH interacted with Asp-386, Arg-385 was found to pair with Asp-444 due to the
displacement of loop residues 383-389 (Figure 2.17A, Figure 2.19B). Subsequently, Arg419 is able to pair with Asp-386, enabling the exposure of Tyr-416 to solvent making it
accessible for phosphorylation.
The impact of Cys-277-SOH on the unfolding of A-loop is further evident from
the free-energy landscapes obtained from metadynamics simulations (Figure 2.18C).
According to the interactions revealed from the above MD simulations, we chose the pair
distances of (Tyr-416) - (Asp-386) and (Arg-419) - (Asp-386) as two collective variables
(CVs) and carried out metadynamics simulations on the Cys-277-SOH and wild-type
(Cys-277-SH) systems, respectively. Large increases of these pair distances due to
sulfenylation of Cys-277 would be expected to ultimately lead to unfolding of the A-loop,
thus further confirming the impact of Cys-277-SOH on A-loop unfolding. In the wildtype structure, the lowest free-energy conformation is found when Tyr-416 is ~5 Å from
Asp-386 and Arg-419 is ~15 Å from Asp-386. However, when Cys-277 is replaced with
Cys-SOH, the lowest free-energy conformations appear in two distinguishing areas: a
small region that is similar to the wild-type and a larger region where both Tyr-416 and
Arg-419 are at significantly longer distances of 17~22 Å from Asp-386. This latter “longdistance” conformation corresponds to the unfolded conformation of the A-loop (yellow
in 2.18A), which is energetically favorable. Results from these simulations therefore
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indicate that sulfenylation of Cys-277 induces activation of the Src kinase by promoting
rapid and thermodynamically favorable unfolding of the Src A-loop and solvent exposure
of Y416 for phosphorylation.
Next, we simulated the effect of sulfenylation of Cys-185, located within the SH2
domain near the regulatory active site that binds pTyr-527 located on the Src C-terminal
tail. Simulations of reduced Cys-185-SH show that pTyr-527 forms H-bonds with Arg175 and Arg-155, while Cys-185-SH, at a distance of ~4-6 Å away from pTyr-527 or
Arg-175, is otherwise non-interacting with these residue side chains (Figure 2.19A,
Movie S3). In contrast, when Cys-185-SH is substituted for Cys-185-SOH, it now
engages in H-bonding with the phosphate moiety of pTyr-527 (Figure 2.20A). We did not
observe full dissociation of pTyr-527 within the limited length of our simulations, but
such a dissociation may be indicated by the increasing number of water solvent contacts
with pTyr-527 induced by sulfenylation of Cys-185 as comparison with reduced (Cys185-SH) states (Figure 2.20B), which likely contributes to complete solvent exposure of
pTyr-527 and access to tyrosine phosphatases to promote its dephosphorylation and Src
unclamping.
In line with these conventional simulations, metadynamics simulations revealed
that the presence of Cys-185-SOH significantly alters the free-energy landscape of pTyr527 binding to the SH2 domain. In these simulations, we chose pair distances of (pTyr527) - (Arg-175) and (pTyr-527) - (Arg-155) as CVs since these positive arginine side
chains enable tight electrostatic binding of the negative pTyr-527 and observed increases
in pair distances would ideally model the dissociation of pTyr-527 from the SH2 domain.
In wild-type Src (Cys-185-SH), the lowest free-energy conformation is observed when
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pTyr-527 is located nearby (~4-6 Å) Arg-175 and Arg-155 (right panel of Figure 2.20C),
consistent with the structure of autoinhibited Src. In contrast, when Cys-185 is present as
a sulfenic acid, the lowest free-energy conformation is located where pTyr-527 is
completely dissociated from the SH2 domain, at a distance of 13~18 Å from Arg-175 and
Arg-155 (yellow in Figure 2.20A and left panel of Figure 2.20C). These findings further
support the notion that oxidation of Cys-185-SH to Cys-185-SOH critically destabilizes
the binding of the autoinhibitory pY527 in a mechanism where first solvent accessibility
to pTyr-527 is enhanced via hydrogen bonding eventually leading to complete exergonic
dissociation from the SH2 domain.
Finally, since our mass spectrometry analysis also indicated sulfenylation at Cys498 (Table 2.2), we decided to also carry out simulations of two replicas for the Cys-498SOH system for a total of 10 µs. However, only subtle conformational changes were
observed at the helical bundles where Cys-498 locates (Figure 2.21A and B), and
metadynamics simulations show comparable energy basins for the Cys-498-SH and Cys498-SOH systems (Figure 2.21C). These findings together indicate a minimal structural
impact of Cys-498-SOH within the Src kinase C-lobe, and thus a minimal role for Cys498 oxidation for Src kinase activation.

2.5 Discussion
While several studies have suggested that the Src kinase is regulated by direct
redox mechanisms, the identity of the redox-sensitive cysteine residues and the
mechanism(s) by which their oxidation impacts kinase activation are unknown(Giannoni
et al., 2005; Kemble et al., 2009). Following our recent findings indicating that redox98

dependent activation of Src in biochemical and cellular contexts closely associates with
formation of sulfenic acids (Cys-SOH) within the Src protein(Heppner et al., 2016;
Hristova et al., 2016), we now identify Cys-185 and Cys-277 as the main cysteines
oxidized to Cys-SOH by H2O2 and demonstrate that sulfenylation of both cysteines
contribute to H2O2-dependent enhancement of Src kinase activity, based on experimental
studies as well as MD simulations. Recent studies featuring MD simulations have
indicated significant structural consequences of sulfenylation of specific cysteines in
other proteins, e.g. epidermal growth factor receptor(Truong et al., 2016)
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monoacylglycerol lipase(Scalvini et al., 2016), which are structurally distinct from Cys185 or Cys-277 in Src. Interestingly, the structural alterations characterized in these MD
simulations were attributed to the introduction of novel electrostatic interactions with
nearby amino acids upon formation of a sulfenic acid, consistent with our present studies,
which similarly indicate that sulfenylation of Cys-185 and Cys-277 within Src similarly
induces novel electrostatic interactions through H-bonding within their respective
regions.
Combined crystallography and computational modeling studies have generated a
molecular model for Src kinase activation, involving initial conversion of the
autoinhibited kinase to a Tyr-416 unphosphorylated active-like state and subsequent
phosphorylation of Tyr-416 resulting in stabilization of the active form of the Src
kinase(Boggon et al., 2004; Foda et al., 2015; Meng et al., 2017; Tong et al., 2017). Our
findings indicating Cys-185 and Cys-277 as principal redox-active targets, and their
proximity to regulatory tyrosine residues, respectively Tyr-527 and Tyr-416, would
suggest that their oxidation directly modulates activation. Cys-277 resides on the solvent99

accessible G-rich loop near the A-loop, and is readily accessible to solvent H2O2.
Computational studies using Markov state models by Roux and colleagues highlight Aloop unfolding as the first step on the pathway to the active-like state, occurring on a time
scale of ~100 µs(Meng et al., 2017; Meng et al., 2016). These modeling studies were
based on simulations of the Src kinase domain in the absence of the two regulatory SH2/3
domains. Importantly, our conventional and metadynamics simulations of the entire
autoinhibited Src protein show that Cys-277-SOH destabilizes the folded A-loop
containing Y416 towards a more favorable unfolded state on a shorter, ~1.5-3.5 µs
timescale, which would imply that oxidation of Cys-277 accelerates the conversion of the
autoinhibited state to the active-like state, which is potentially stabilized in the absence of
Tyr-416 phosphorylation (Figure 2.18). Our MD simulations also indicate that Cys-277SOH induces A-loop unfolding in the absence of other activating structural changes, such
as SH2/3 domain dissociation and αC-helix rotation, which is expected to occur at longer
time scales(Meng et al., 2017). The importance of Cys-185 in redox regulation of Src
activity has not been recognized previously, although it was recently implicated in
substrate binding through intermolecular disulfide bonding(Evans et al., 2012). This
cysteine residue is relatively unique in Src since all other SFKs contain a serine at the
corresponding position (Table 2.1), but proximally located cysteines are found within the
phosphotyrosine binding region of other SH2 domains(Evans et al., 2012). Previous work
has shown that Ala and Ser variations of Cys-185 result in tighter binding of
phosphorylated peptides, suggesting that Cys-185-SH modifications impact the binding
of the autoinhibitory pTyr-527(Bradshaw et al., 1999). Our MD simulations indicating
that Cys-185-SOH significantly destabilizes pY527 binding to the SH2 domain (Figure 5)
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would suggest that sulfenylation of Cys-185 prevents autoinhibition of Src by lowering
the binding affinity of pY527 to the SH2 domain. Additionally, it should be noted that
Cys-185 within the autoinhibited Src structure is obscured from solvent, which limits its
accessibility by H2O2, although it is expected to be redox-active due to its proximity to
the positive Arg-175. Since Cys-185 is fully solvent exposed in activated Src (PDB ID
1Y57), it is more likely that oxidation of Cys-185 occurs in cooperation with dissociation
of pTyr-527 by alternative mechanisms, and thereby enhances or prolongs Src activation.
Our collective experimental and molecular modeling studies have led us to
propose a step-wise mechanism for the regulation of Src activity by oxidation of Cys-185
and Cys-277 (Figure 2.22). Based on our experimental findings indicating Cys-277 as the
primary oxidizable target within Src, we propose that initial oxidation of Cys-277-SH by
H2O2 triggers the structural conversion of the autoinhibited state to an active-like state by
destabilizing the A-loop helical fold allowing for the exposure of Tyr-416 for
phosphorylation. Further structural changes associated with Src activation, such as
rotation of the αC-helix, likely proceed from this state although they were not observed in
our MD simulations as they are computed to be beyond our time scale(Meng et al., 2017).
These structural changes put the kinase into an active-like state, even in the absence of
pTyr-527 dephosphorylation, since the structural changes promoting A-loop unfolding
occurred in the absence of dissociation of the autoinhibitory loop and unclamping of the
Src protein (Figure 2.22 middle). We suggest that unfolding of the A-loop by Cys-277
oxidation may induce semi-“unclamping” of the SH2/3 domains, as the binding of these
domains are coupled to the fold of the A-loop(Foda et al., 2015; Tong et al., 2017; Xu et
al., 1999), thereby enhancing solvent accessibility of Cys-185 to H2O2 and facilitating its
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oxidation. Formation of Cys-185-SOH in turn appears to enhance solvent accessibility of
pY527, based on our metadynamics simulations, to promote full dissociation of pY527
from the SH2 domain. Although not specifically addressed in the present study, initially
formed Cys-SOH readily reacts with cellular thiols such as glutathione (GSH) to form
mixed disulfides (e.g. S-glutathionylated cysteine, Cys-SSG), and our previous studies
indicate that H2O2-mediated activation of Src is associated with sequential formation of
Cys-SOH and Cys-SSG within Src(Heppner et al., 2016; Hristova et al., 2014). Although
S-glutathionylation may not directly activate Src(Heppner et al., 2016), we propose that
formation of Cys-SSG species on Cys-185 or Cys-277 would induce steric and
electrostatic alterations that may enhance structural perturbations. For example, Cys-185SSG is expected to preclude inactivating interaction of pTyr-527 with the SH2 domain,
thereby extending redox-dependent Src activation until Cys-185-SSG is reduced by e.g.
glutaredoxins (Figure 2.22 right). Our model therefore suggests that Src activity is
controlled by sulfenylation of both Cys-185 and Cys-277 in a cooperative and dynamic
mechanism, after which subsequent S-glutathionylation both extends Src activation and
facilitates reversal to the inactive state by glutaredoxin-mediated regeneration of reduced
cysteines.
It is important to highlight some limitations of our present studies. First, our MD
simulations were based on protonated forms of Cys-SOH, as this is the initial product of
reaction of Cys-S- with H2O2 justified by benchmarked pKa values for simple models due
to the variability in experimental estimates.(Nagy et al., 2007; Tadashi et al., 1992)
However, in light of more recent biochemical estimates of the Cys-SOH pKa nearer or
below physiological pH,(Gupta et al., 2016; Portillo-Ledesma et al., 2018) we cannot rule
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out the possibility that Cys-SOH may also exist in its deprotonated state (or dynamic
equilibrium mixture) due to unique and yet uncharacterized second sphere coordination
environments of the specific redox-active cysteine residues reported in this work and is
the subject of ongoing studies in our labs. We do anticipate that the more anionic CysSO- would induce alternative or additional structural changes. Another limitation is that
the present study did not address the role of other Src Cys residues that have also been
implicated redox-dependent Src activation in previous studies(Giannoni et al., 2005;
Rahman et al., 2010; Zhang et al., 2015). Our MS studies indeed indicate that other
cysteines (e.g. Cys-238, Cys-498) may also be oxidized to Cys-SOH. Moreover, our
relative inability to trap Cys-SOH with either dimedone or BCN on these other cysteines
does not necessarily mean that these cysteines are not oxidized, but might instead be a
result of their rapid condensation to disulfide species. Indeed, studies with recombinant
Src indicated the formation of DTT-reducible higher molecular weight species in the
presence of high doses of H2O2 reflecting formation of inter- or intra-molecular
disulfides. Chiarugi and co-workers suggested that redox-dependent Src activation during
cell adhesion depends on the presence of both Cys-245 within the SH2 domain and Cys487 in the kinase domain, and proposed that oxidation of these cysteines may induce
structural alterations via an intramolecular disulfide(Giannoni et al., 2005), although this
seems highly unlikely based on long distances (~30-60 Å) between these cysteine
residues in existing structures(Xu et al., 1999). Other studies have implicated Cys-498 as
a target for S-nitrosylation in activation of Src, although the molecular mechanism was
not addressed(Rahman et al., 2010). Our MD simulations of sulfenylated Cys-498
indicate minimal structural changes in the kinase domain C-lobe containing this Cys
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residue, but since Cys-498 is located near the myristate binding pocket within the Src
kinase domain,(Patwardhan et al., 2010) it is plausible that oxidation of Cys-498 might
interfere with Src myristoylation. Alternatively, it is possible that these alternative Cys
oxidations may regulate Src-dependent signaling in a cellular context by enhancing
interactions with regulatory proteins or substrates through e.g. disulfides, as was recently
demonstrated for Cys-185(Evans et al., 2012), rather than by inducing structural
transitions that would promote intrinsic kinase activity. Finally, the field of thiol-based
redox signaling has recently expanded with the recognition that a significant fraction of
protein cysteines in biology may actually exist in the form of persulfides (ie. Cys-SSnH).(Fukuto et al., 2018) Indeed, we recently reported that cellular Src may also contain
Cys-SSn-H species, which are more susceptible to oxidation compared to corresponding
cysteines(Heppner et al., 2018). The functional consequences of such persulfide
oxidation for Src activation are unclear and were not addressed in the present study, since
our experimental approaches included DTT in sample workup, and would have
eliminated such (oxidized) polysulfides prior to analysis. Addressing the relevance of
such (oxidized) polysulfide species would require additional experimental approaches
that are technically challenging(Bogdándi et al.) alternative MD simulations, and would
form interesting avenues for future exploration.
In summary, we demonstrate that the redox-dependent regulation of the Src
kinase involves protein structural alterations induced by the oxidation of 2 cysteine
residues, Cys-185 and Cys-277, to intermediate sulfenic acids. Cys-277 is also present in
other SFKs such as Yes and Fgr, which may therefore be subject to similar redoxdependent activation, but Cys-185 is not found in other SFKs (Table 2.1). Therefore, the
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redox-dependent mechanisms of kinase activation may be relatively unique to Src
compared to other SFKs,and may be informative with respect to current drug
development efforts towards selective Src inhibitors. Current Src inhibitors in clinical
development are relatively non-selective since they target the kinase ATP-binding pocket
(Fabian et al., 2005). Recent efforts to develop covalent Src-selective inhibitors that
target Cys-277 may enhance selectivity, but may also be compromised when this Cys is
oxidized(Gushwa et al., 2012). Instead, approaches to target the oxidized states of these
cysteines may enhance efficacy and drug selectivity. Finally, targeting of oxidant-induced
structural changes with allosteric inhibitors, as opposed to ATP competitive inhibitors,
may offer further selectivity for situations with pathologically elevated ROS(Zhang et al.,
2009). Therefore, a more complete understanding of the molecular details of redoxdependent mechanisms of the Src family kinases as well as other redox-sensitive
kinases(Corcoran et al., 2013; Truong et al., 2013) may offer exciting new directions for
drug discovery.
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FIGURES

Figure 2.1 – Localization of 9 cysteine residues within Src. The Src kinase contains
three cysteine residues within the SH2 domain and six within the kinase domain. A)
Distribution of cysteine residues within the Src sequence. B) The autoinhibited structure
of Src (PDB ID 2SRC) with cysteine residues, Tyr-416, pTyr-527, and ATP binding site.
Adapted from Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.2 - Identification of H2O2-oxidizable Cys residues in Src by dimedone
trapping. Recombinant Src (~0.6 µg/µL) was reacted with 0.5 mM H2O2 in the presence
of ~0.03 mM DTT and 1.0 mM dimedone and trypsin digested for LC-MS/MS analysis.
Spectra of peptides and ions observed for: A) Cys-185 GAYC#LSVSDFDNAK, B) Cys277 LGQGC#FGEVWMGTWNGTTR, C) Cys-498 MPCPPECPESLHDLMCQC#WRK
where #- indicates a dimedone tagged cysteine. Peptides were identified in a dataset
limited to <1% FP and the corresponding MSMS spectra visualized with Scaffold 4.05.
Adapted from Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.3 - H2O2 induces disulfide-mediated crosslinking in recombinant Src. A)
Src (~10 µg) was incubated with indicated concentrations of H2O2, and analyzed by SDSPAGE and Coomassie stained. DTT-reducible shifts in several high-molecular weight
bands were detected in response to increasing concentrations of H2O2, suggesting the
formation of intra- or intermolecular disulfides. B) Formation of inter- or intramolecular
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disulfides in WT or C185A or C227A variants of Src upon reaction with 20 mM H2O2.
Adapted from Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.4 - Identification of H2O2-oxidizable Cys residues in Src by trapping with
BCN. Recombinant Src (~0.4 µg/µL) was reacted with 0.5 mM H2O2 in the presence of
~0.25 mM DTT and 100 µM BCN and trypsin digested for LC-MS/MS analysis. Spectra
of peptides and ions observed for: A) Cys-185 GAYC#LSVSDFDNAK, B) Cys-245
LTTVC#PTSKPQTQGLAK C) Cys-277 LGQGC#FGEVWMGTWNGTTR, where #
indicates a BCN tagged cysteine. Peptides were identified in a dataset limited to <1% FP
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and the corresponding MSMS spectra visualized with Scaffold 4.05. Adapted from
Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.5 - LC-MS/MS Quantification of Cys-277 Sulfenylation. Recombinant Src
(~ 0.6 µg/µL) was either incubated with 1.0 mM of light dimedone (dim-d0) in the
absence of H2O2 or treated with 1.0 mM H2O2 in the presence of 1.0 mM heavy
dimedone (dim-d6) to trap sulfenylated cysteine residues. Equal amounts of dim-d0 and
dim-d6 Src were combined prior to trypsin digestion and LC-MS/MS analysis. A)
Representative MS1 spectrum exhibiting peaks corresponding to the dim-d0- (m/z 1119.5,
inset) and

dim-d6-conjugated

(m/z

LGQGCFGEVWMGTWNGTTR (2+

1122.5) Cys-277
charge).

B)

containing peptide

Representative

fragment

extracted

ion

chromatograms (with deuterated version eluting slightly earlier) from peptide-targeted
parallel reaction monitoring (PRM) of dim-d0 (black, relative intensity multiplied by 10)
and dim-d6 (red) enabling the determination of relative amounts of dim-d6/dimd0 corresponding to a heavy to light (H/L) ratio of 78.57 ± 5.54 (triplicate analysis). H/L
ratio was calculated from the 5 transitions from 3 experimental replicates. Adapted from
Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.6 - Quantitative analysis of Src sulfenylation using LC-MS/MS. A) MS1
spectrum of the dimedone-labeled (DIM light) and deuterated dimedone (DIM-d6 heavy)
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labeled

LGQGCFGEVWMGTWNGTTR

(containing

Cys-277).

Corresponding

precursors (at m/z 1119.53 and m/z 1122.53, respectively) are indicated. PRM was
simultaneously carried out with MS-SIM in the same workflow, as described in the
Materials and Methods. The transitions for quantification were selected using the Skyline
software. B) Corresponding extracted ion chromatograms of the isotopologues eluting at
around the same retention time (with deuterated version eluting slightly earlier). The
peaks of elution are indicated by arrows. H/L ratio was calculated from H/L ratios of the
5

transitions

from

3

experimental

replicates.

C,D)

MS/MS

spectra

of

LGQGC(dim)FGEVWMGTWNGTTR and LGQGC(dim-d6)FGEVWMGTWNGTTR
acquired during peak elution of the target, and annotated according to the Proteome
Discoverer search results. E) MS1 spectrum of the dimedone-labeled (DIM light) and
deuterated dimedone (DIM-d6 heavy) labeled GAYC(dim/dim-d6)LSVSDFDNAK
peptide (which contains Cys-185). Due to low abundance, no corresponding precursors
(at m/z 814.369 and m/z 817.338, respectively) were observable in the MS-SIM scans
(top left), and their quantification were carried out using parallel reaction monitoring
(PRM). F) Extracted ion chromatograms of the PRM transitions of the isotopologues
eluting at around the same retention time (with deuterated version eluting slightly
earlier). The peaks of elution are indicated by arrows. The heavy/light (H/L) ratio was
calculated from H/L ratios of the six transitions from 3 experimental replicates. G,H)
MS/MS spectra of GAYC(dim)LSVSDFDNAK and GAYC(dim-d6)LSVSDFDNAK
acquired during peak elution of the target and annotated according to the Proteome
Discoverer search results. Adapted from Heppner et al., 2018. Used with permission from
Nature Publishing Group.
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Figure 2.7 - Autoinhibited Src (PDB: 2SRC) structure zoom in of A) Cys-185 near
pTyr-527 and Arg-175 and B) Cys-277 near the ATP binding site and A-loop.
Adapted from Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.8 - H2O2 enhances Src tyrosine kinase activity depending on Cys-185 and
Cys-277. A) Coomassie-stained SDS-PAGE gel of 5 ng of WT, C185A, and C277A
recombinant Src. B) Analysis of kinase activity of recombinant Src variants following
H2O2 treatment measured with ADP Glo kinase activity kit. Data are expressed as means
± s.e.m. of at least 3 replicates from 3 independent experiments. Analyzed with 2-way
ANOVA where * p < 0.01 compared to WT [H2O2] = 0 µM; ‡ p < 0.0001 compared to
WT [H2O2] = 30 µM; † p < 0.0001 compared to WT [H2O2] = 10 µM; § p < 0.005
compared to C185A [H2O2] = 10 µM. Adapted from Heppner et al., 2018. Used with
permission from Nature Publishing Group.
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Figure 2.9 - Correlation of Src specific activity with H2O2 concentration for WT and
mutant proteins. Plots of specific activity versus [H2O2] and linear regression analysis
of WT, C185A, and C277A Src recombinant protein (based on data presented in Figure
2B). Least squared fits to straight lines and correlation analyses show WT Src specific
activity is linearly dependent on [H2O2] (slope = +0.027, Pearson r = +0.98) while C185A
(slope = -0.016, Pearson r = -0.63) and C277A (slope = +0.00095, Pearson r = +0.45) are
not impacted by H2O2. Adapted from Heppner et al., 2018. Used with permission from
Nature Publishing Group.
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Figure 2.10 - H2O2-dependent wild-type Src tyrosine kinase activity at 100 µM H2O2.
Effect of H2O2 on tyrosine kinase activity of WT recombinant Src and measured with
ADP Glo kinase activity kit (same as in Fig. 3B at 0, 10 and 30 µM). Data are expressed
as means ± s.e.m. of at least 3 replicates from 3 independent experiments. Adapted from
Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.11 - FLAG-Src co-localizes with endogenous Src in transfected stable H292
cell lines. Immunofluorescent analysis of WT FLAG-Src or MOCK transfection
(pCMV6 empty vector) transfected H292 cells. Cells were stained with both α-Src (red)
and α-FLAG (green) primary antibodies and corresponding fluorescent secondary
antibodies. Nuclei were counterstained with DAPI (blue). Adapted from Heppner et al.,
2018. Used with permission from Nature Publishing Group.
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Figure 2.12 - Western blot analysis of stable H292 cell lines expressing WT, C185A,
and C277A Src compared to MOCK transfected cells. Blots indicate that FLAGtagged Src protein at a molecular weight of ~65 kDa and non-specific binding at ~60 kDa
after FLAG immunoprecipitation with M2 anti-FLAG magnetic beads. Adapted from
Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.13 - ATP stimulation of H292 cells causes Src sulfenylation at Cys-185 and
Cys-277 which promote pTyr-416 phosphorylation. A) NCI-H292 cells were
transiently transfected with c-terminal FLAG-tagged WT, C185A, and C277A Src (SrcFLAG), and preloaded with DYn-2 and stimulated with 100 µM ATP for 10 min.
Derivatized cell lysates or α-FLAG-purified were analyzed by Western blot with
indicated antibodies. A) Representative Western blots of 2 separate experiments. B)
Normalized ratios of phosphorylation-to-total Src. C) Normalized ratios of biotinylationto-total Src. Data represent mean ± s.e.m from at least 4 replicates. Data was analyzed
with student t-test comparing control to ATP treated cells. *: p < 0.01. Adapted from
Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.14 - ATP stimulation of H292 cells causes Src sulfenylation at Cys-185 and
Cys-277 which promote pTyr-416 phosphorylation. A) NCI-H292 cells stably
transfected with c-terminal FLAG-tagged WT, C185A, and C277A Src (Src-FLAG) were
preloaded with DYn-2 and stimulated with 100 µM ATP for 10 min. Derivatized cell
lysates or α-FLAG-purified were analyzed by Western blot with indicated antibodies.
Representative Western blots of 2 separate experiments are shown. Adapted from
Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.15 - ATP-dependent stimulation of H292 cells requires Src Cys-185 and
Cys-277 for pTyr-416 phosphorylation in association with sulfenylation of Cys-185
and Cys-277. A) NCI-H292 cells stably expressing c-terminal FLAG-tagged WT,
C185A, and C277A Src (Src-FLAG) were stimulated with 100 µM ATP for 10 min and
changes in Src phosphorylation at Tyr-416 and Tyr-527 were analyzed by Western blot
after FLAG-tag protein purification. B) Cells were stimulated as in A), but lysed in the
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presence of DCP-bio1 to conjugate with Cys-SOH species followed by purification of
FLAG-tag proteins and analysis Cys-SOH amounts by blotting for biotin conjugation to
WT, C185A, and C277A Src-FLAG. C) Normalized ratios of phospho-to-total Src or
biotinylation-to-total Src. Western blot experiments are representative of at least 3
independent experiments. Data represent mean ± s.e.m of phosphorylation changes of at
least 4 replicates, normalized ratio of phosphorylation/total WT ATP-treated of 1.0. Data
was analyzed with student t test comparing control to ATP treated cells ** p < 0.01.
Adapted from Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.16 - Dihedral profiles of –C-S-O-H from DFT calculations using B3LYP/631G** (blue), total potential (red) and dihedral term energy (orange) with our parameters
implemented in CHARMM force field. A model molecule, CH3-CH2-SOH, is used to
compare our parameters for -SOH with DFT calculations geometrically and energetically
in dihedral scanning. Three optimized conformation with dihedral angle as 0, 90, 180
degrees are displayed. Adapted from Heppner et al., 2018. Used with permission from
Nature Publishing Group.
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Figure 2.17 – Final Structures for C277 analysis in MD Simulations. (A) Final
structures of Cys-277-SOH from two MD replicas labeled as #1 and #2. (B) Final
structures of wild-type group from two MD replicas labeled as #1 and #2. The cysteine
oxidation to Cys-277-SOH induced the helicity loss at residues 406 to 423 (yellow). Key
residues that interact with the A-loop region are labeled. Cys-277-SOH is likely to
compete with Tyr-416 to interact with Asp-386, which weaken the interactions of Tyr416 with the nearby residues. Also, Arg-385 was found to pair with Asp-444 by hydrogen
bonding when Cys-277-SOH interacts with Asp-386, which induces a displacement of
the loop (res. 383-389) that contains Asp-386 and Arg-385 (see Figure 2.17B). Adapted
from Heppner et al., 2018. Used with permission from Nature Publishing Group.
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Figure 2.18 - Cysteine oxidation to Cys-277-SOH promotes unfolding of the Src Aloop α-helix. A) A final snapshot of Cys-277-SOH system (purple blue) from MD
simulation superposed with it from metadynamics simulation that displays the unfolded
conformation of the A-loop (residues 406 to 423, yellow). Detailed structures compared
with wild-type group are shown in Figure 2.17, 2.19. Key residues that interact with the
A-loop region are labeled. B) Percent α-helix fold of residues 406 to 423 throughout the
MD simulation of Cys-277-SOH system (two replicas are in red and pink) in comparison
with control groups (green and cyan). C) Free-energy landscapes of Cys-277-SOH
system and Cys-277-SH system, respectively. Two collective variables (CVs), pair
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distances of Tyr-416-Asp-386 and Arg-419-Asp-386, are used in metadynamics
simulations. Adapted from Heppner et al., 2018. Used with permission from Nature
Publishing Group.
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Figure 2.19 – Position and interactions of C185 in Src MD Simulations. (A) A final
snapshot of Cys-185-SH system. (B) Displacement of loop res. 383-389 associated with
Cys-277-SOH - Asp-386 pair in Cys-277-SOH system (purple blue) superposed with the
wild-type group (grey). Adapted from Heppner et al., 2018. Used with permission from
Nature Publishing Group.
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Figure 2.20 - Sulfenylation of Cys-185 destabilizes autoinhibitory pTyr-527 binding
to SH2 domain. A) A final snapshot of Cys-185-SOH system (purple blue) from MD
simulation superposed with it from metadynamics simulation that displays the dissociated
pTyr-527 (yellow). Key residues that interact with pTyr-527 are labeled. B) Number of
water solvent contacts with pTyr-527 over time in Cys-185-SOH system (two replicas are
in blue and light blue) in comparison with control groups (green and cyan). C) Freeenergy landscapes of Cys-185-SOH system and Cys-185-SH system, respectively. Two
collective variables (CVs), distances of pair pTyr-527-Arg-175 and pair pTyr-527-Arg155, are used in metadynamics simulations. Adapted from Heppner et al., 2018. Used
with permission from Nature Publishing Group.
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Figure 2.21 – Positioning and metadynamics simulations reveal little impact of C498
oxidation. (A) Structural superpositions of Cys-498-SOH system (light blue) with wildtype groups (grey). Final snapshots from two replicas are presented for each system. (B)
Two collective variables, center-of-mass distances of helical res. 489-499 and helical res.
446-457 and res. 360-371 respectively, are used to characterize the dissociation of helical
res. 489-499 from the helices bundle in metadynamics simulations. The displacement of
res. 489-499 from metadynamics simulation is in yellow cartoon with reference to a final
snapshot from MD simulation. (C) Free-energy landscapes of wild-type group (left panel)
and Cys-498-SOH system (right panel). Comparable energy basins for the Cys-498-SH
and Cys-498-SOH systems suggest that the oxidation of Cys-498 has a minor to absent
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impact on the dissociation of the C-lobe. Adapted from Heppner et al., 2018. Used with
permission from Nature Publishing Group.
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Figure 2.22 - Concerted roles of Cys-185 and Cys-277 oxidation induces structural
changes that contribute to the activation of Src activity. Initially, the solvent exposed
Cys-277 is oxidized to sulfenic acid inducing A-loop unfolding and semi-“unclamping”
of the autoinhibited Src structure (middle). The resulting weakened SH2 and c-terminal
tail binding enables oxidation of Cys-185 from solvent H2O2 leading to the full activation
of Src (right). It is expected that Cys-185 and Cys-277 sulfenic acids eventually become
S-glutathionylated, which permanently obstruct the refolding of Src into the autoinhibited
state thereby extending kinase activity. Aapted from Heppner et al., 2018. Used with
permission from Nature Publishing Group.
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TABLES
Table 2.1 - Cysteine conservation within the Src-family kinases
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Table 2.2 - MS data of representative cysteine-containing peptides from Src
modified by dimedone, BCN, or NBD, during oxidation by H2O2.
a) Src + 500 µM H2O2 + dimedone
Cysteine
Cys-185
Cys-277
Cys-498

Peptide Sequence
GAYC*LSVSDFDNAK
LGQGC*FGEVWMGTWNGTTR
MPC#PPEC#PESLHDLMC#QC*WRK

XCorr
3.26
4.56
3.52

Charge
+2
+2
+3

MH+ (Da)
1626.82
2239.28
2813.58

ΔM (Da)
-0.46
0.63
0.47

XCorr
2.65
3.86
3.97

Charge
+2
+2
+2

MH+ (Da)
1655.76816
1940.05826
2266.03911

ΔM (ppm)
1.34
-2.5
-4.66

XCorr
3.12
4.2

Charge
+2
+3

MH+ (Da)
2280.012
2724.031

ΔM (ppm)
-470.4358
-362.306

b) Src + 500 µM H2O2 + BCN
Cysteine
Cys-185
Cys-245
Cys-277

Peptide Sequence
GAYC†LSVSDFDNAK
LTTVC†PTSKPQTQGLAK
LGQGC†FGEVWMGTWNGTTR

c) Src + 200 µM H2O2 + NBD-Cl
Cysteine
Cys-277
Cys-498

Peptide Sequence
LGQGC@FGEVWMGTWNGTTR
MPC#PPEC#PESLHDLMC#QC@WRK

Peptides listed were identified in a dataset limited to <1% FP
*-denotes dimedone tagged cysteine residue (+138.068 Da).
†-denotes BCN-S(O)-tagged cysteine residue (+166.099 Da).
@-denotes NBD-S(O)-tagged cysteine residue (+178.997 Da).
#-denotes carbamidomethylated reduced cysteine residue (+57.0215 Da).
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Table 2.3 - Quantitative analysis of Src sulfenylation using LC-MS/MS
H:L
Cysteine Residue

Peptide Sequence

Charge

m/z

ratioa

SDb

GAYC(dim)LSVSDFDNAK

2+

814.369

15.48

2.25

GAYC(dim-d6)LSVSDFDNAK

2+

817.388

HADGLC(dim)HR

2+

523.745

17.36

11.44

HADGLC(dim-d6)HR

2+

526.764

LTTVC(dim)PTSKPQTQGLAK

3+

637.680

2.25

1.40

LTTVC(dim-d6)PTSKPQTQGLAK

3+

639.693

LGQGC(dim)FGEVWMGTWNGTTR

2+

1119.509

78.57

5.54

LGQGC(dim-d6)FGEVWMGTWNGTTR

2+

1122.528

AANILVGENLVC(dim)KVADFGLAR

2+

741.405

13.07

9.84

AANILVGENLVC(dim-d6)KVADFGLAR

2+

744.424

MPC(dim)PPECPESLHDLMCQCWR c

2+

1342.548

31.39

24.08

MPC(dim-d6)PPECPESLHDLMCQCWR c

2+

1345.567

Cys-185

Cys-238

Cys-245

Cys-277

Cys-400

Cys-483

a

Heavy to light ratio

b

c

Standard deviation (n=3)

Quantification of Cys-483 H/L ratio was performed in Xcalibur using 3 transitions. The three cysteines c-

terminal to
Cys-483 are carbamidomethylated. All other peptides were quantified by Skyline using 4-6 transitions from
the targeted mass spectrometry experiments with PRM.

140

Table 2.4 - Summary of all-atom MD simulations
No. of
System

Box size (Å3) No. of atoms water

Simulation lengths (µs)

molecules
Autoinhibited Src

94×94×94

85439

26037

5.0,

2.2

C185-SOH

85×89×82

58370

17030

5.1,

5.1

C277-SOH

85×89×82

58370

17030

5.5,

5.2

C498-SOH

87×90×83

60699

17805

5.0,

5.0

(wild-type)

Metadynamics simulations
Wild-type (C185-

Simulation lengths (ns)

94×94×94

85439

26037

120

94×94×94

85439

26037

120

94×94×94

85439

26037

120

C185-SOH

85×89×82

58370

17030

120

C277-SOH

85×89×82

58370

17030

120

C498-SOH

87×90×83

60699

17805

120

SH)
Wild-type (C277SH)
Wild-type (C498SH)
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Supplementary Materials and Methods

Recombinant Src expression and purification. The plasmid pEX-Src-C-His (Origene,
Rockville, MD and Blue Heron Biotech, Bothell, WA) was used to transform BL21-AI E.
coli (Thermo). The C185A and C277A mutants were generated from the pEX-Src-C-His
plasmid with the QuickChange Mutagenesis kit (Agilent Technologies, California) with
the following primers:

C185A Forward:
C185A Reverse:
C277A Forward:
C277A Reverse:

CGAAAGGTGCCTACGCCCTCTCAGTGTCTGAC
GTCAGACACTGAGAGGGCGTAGGCACCTTTCG
CTGGGCCAGGGCGCCTTTGGCGAGGTG
CACCTCGCCAAAGGCGCCCTGGCCCAG

Colonies containing the mutated plasmid DNA were selected on Ampicillin plates, grown
in 5 mL cultures (LB with ampicillin), and the plasmid DNA was isolated using the
Zippy Plasmid Miniprep kit (Zymo Research, Irvine, CA). Each mutation was confirmed
by

DNA

sequencing

using

the
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following

sequencing

primers:

(GGACTTTCCAAAATGTCG;

ATTAGGACAAGGCTGGTGGG;

ATTGCTCAGCGGTTATCGTG). The mutated plasmid DNA was then transformed into
BL21-AI cells and colonies were selected for subsequent growth in the expression
studies.

BL21-AI E. Coli (ThermoFisher) containing the pEX-Src-C-His vector was grown
overnight at 37 ºC in LB broth (Invitrogen) supplemented with 100 µg/mL ampicillin
(Fisher). The following day, cultures were pelleted and resuspended in fresh LB broth for
inoculation of TB broth (Sigma) supplemented with 100 µg/mL ampicillin. TB cultures
were further incubated at 37 ºC until an optical density of 0.6-1.2 was reached (~ 3 hrs).
Cultures

were

cooled

and

supplemented

with

1

mM

isopropyl

β-D-1-

thiogalactopyranoside and 0.2% arabinose to induce expression, followed by overnight
incubation at 18 ºC. Cells were pelleted and stored frozen at -20ºC.
Recombinant Src-His tagged protein was purified using a modified version of
the protocol described previously(Seeliger et al., 2005). Frozen pellets were thawed and
resuspended in 4 mL Src A buffer (50 mM Tris, 500 mM NaCl, 25 mM Imidazole, pH
8.0) per gram of cell paste and lysed via sonication. Lysate was treated with DNAse I
(Qiagen) to reduce viscosity for 10 minutes prior to centrifugation. The lysate supernatant
was then diluted twofold with buffer and loaded on a chelating sepharose column (GE
Life Science) preloaded with Nickel Sulfate (Sigma) and equilibrated to Src A buffer.
The bound protein was washed with Src A buffer until the flow-through showed minimal
absorbance at 280 nm (less than 0.05 AU). Protein was then eluted with Src B buffer (50
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mM Tris, 500 mM NaCl, 500 mM Imidazole, pH 8.0). Fractions were analyzed for
protein content using 10% SDS-PAGE with Coomassie Brilliant Blue stain.
Positive fractions were pooled and supplemented with 1 mM DTT, followed by
overnight dialysis against QA buffer (25 mM Tris, pH 8.0) using Slide-a-Lyzer dialysis
cassettes (Thermo). The following day, protein was collected and supplemented with 1
mM DTT. Protein was then loaded on a Q-sepharose column (GE Life Science) preequilibrated with QA buffer containing 1 mM DTT and washed with QA buffer + DTT
until the flow-through showed minimal absorbance at 280 nm. Src was then eluted from
the column with a 400 mL gradient of 0.0-1.0 M NaCl. Protein was detected using
Bradford assay and SDS-PAGE. Positive fractions were pooled and buffer exchanged
into storage buffer (50 mM Tris, 100 mM NaCl, 5% glycerol, 1 mM DTT, pH 8.0) and
quantified with the Bradford assay. Stock solutions were kept at 1-3 mg/mL and stored at
-20ºC.

Analysis of Src Oxidation by Mass Spectrometry. Sample preparation. For global
sulfenylation analysis, recombinant Src (~20 µg for dimedone experiments; ~13 µg for
BCN experiments) buffered in 100 mM Tris-HCl, 20 mM MgCl2, 2 mM EGTA, 0.02%
Brij-35, 1.0 mM DTT at pH 7.4 was preincubated with either 1.0 mM 5,5’-dimethyl-1,3cyclohexanedione

(dimedone;

Sigma)

or

with

100

µM

9-

hydroxymethylbicyclo[6.1.0.]nonyne (BCN, Sigma) for 10 min and then reacted with
H2O2 (Sigma) for 1 hr at room temperature in a total volume of 30 µL. The final DTT
concentration in these experiments was ~0.25 mM in the BCN studies and ~0.03 mM in
the dimedone studies. In separate analyses, Src was also reacted with H2O2
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simultaneously with 5 mM 4-chloro-7-nitrobenzofuran (NBD-Cl), which modifies
reduced thiols (Cys-SH) as well as sulfenic acids to generate adducts with +16 mass
difference(Conte et al., 2013; Paulsen et al., 2013) and reacted for 1 hr at 25°C. For
quantitative analysis of dimedone labeling by targeted mass spectrometry with parallel
reaction monitoring (PRM), 20 µg of recombinant Src was treated with 0 mM H2O2
(“non-oxidized”) in the presence of dimedone (dim-d0), and analogous samples were
treated with 1.0 mM H2O2 (“oxidized”) in the presence of the deuterium-containing
variant of dimedone (dim-d6; Kerafast). Prior to SDS-PAGE desalting and gel extraction,
excess H2O2 was quenched with 1 µL of 42,000 U/mL catalase and equal amounts of d0
and d6 samples were mixed.
Protein samples were separated on 10% SDS-PAGE gels and visualized by
Coomassie staining. Bands positive for Src (~60 kDa) were excised and transferred to
clean microcentrifuge tubes. Gel pieces were then washed with 250 µl H2O for 15 min
and destained with 50 mM ammonium bicarbonate in 50% acetonitrile. Following
complete removal of coomassie stain, gel pieces were washed with 500 µl H2O. Pieces
were then dehydrated using 100% CH3CN, which was removed using a speed vac
(Labconco) prior to reduction with 200 µl 10 mM DTT in 100 mM NH4HCO3 for 1 h at
56°C. Free Cys residues were then alkylated by subsequent incubation in 55 mM
iodoacetamide in 100 mM NH4HCO3 in the dark for 45 min at room temperature. After
removal of iodoacetamide, gel pieces were washed with 100 mM NH4HCO3 and
dehydrated with 100 µl CH3CN for 10 min, which was repeated once, after which
dehydrated gel pieces were dried in a Speed Vac, and re-swelled with 12 ng/µL trypsin
(Promega V511A, 5–20 µg/ml; to achieve trypsin:protein ratio of 1:20 to 1:100 w/w) at
145

4 °C for 30 min and subsequently incubated overnight at 37 °C for complete protein
digestion. Peptides were extracted with sequential treatments of 5% formic acid (FA)
in H2O, 5% FA in 50% acetonitrile, and finally 100% acetonitrile. Extracted peptide
solution was then Speed-vac dried and kept at -20°C. Dried peptides were reconstituted
with 2.5% CH3CN/2.5% formic acid for LC–MS/MS analysis.

MS analyses. Samples from BCN-related experiments were analyzed by capillary LC–
MS/MS on a Q-Exactive mass spectrometer coupled to an EASY-nLC (Thermo Fisher
Scientific, Waltham, MA, USA). The samples were loaded onto a 100 μm x 120 mm
capillary column packed with Halo C18 (2.7 μm particle size, 90 nm pore size, Michrom
Bioresources, CA, USA) at a flow rate of 300 nl min-1. Peptides were separated using a
gradient of 2.5-35% CH3CN/0.1% FA over 150 min, 35-100% CH3CN/0.1% FA in 1 min
and then 100% CH3CN/0.1% FA for 8 min, followed by an immediate return to 2.5%
CH3CN/0.1% FA and an isocratic hold at 2.5% CH3CN/0.1% FA until the next injection.
Peptides were introduced into the mass spectrometer via a nanospray ionization source
and a laser pulled ~3 μm orifice with a spray voltage of 2.0 kV. Mass spectrometry data
was acquired in a data-dependent “Top 10” acquisition mode with lock mass function
activated (m/z 371.1012; use lock masses: best; lock mass injection: full MS), in which a
survey scan from m/z 350-1600 at 70,000 resolution (AGC target 1e6; max IT 100 ms;
profile mode) was followed by 10 higher-energy collisional dissociation (HCD) tandem
mass spectrometry MS/MS scans on the most abundant ions at 17,500 resolution (AGC
target 5e4; max IT 100 ms; centroid mode). MS/MS scans were acquired with an isolation
width of 1.6 m/z and a normalized collisional energy of 26%. Dynamic exclusion was
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enabled (peptide match: preferred; exclude isotopes: on; underfill ratio: 1%; exclusion
duration: 30 sec).
Samples from dimedone and NBD-Cl experiments were analyzed on a linear ion
trap (LTQ) mass spectrometer coupled to a Surveyor MS Pump Plus (Thermo Fisher
Scientific, MA). Half of the digest was loaded directly onto a 100 µm×120 mm capillary
column packed with MAGIC C18 (5 µm particle size, 20 nm pore size, Michrom
Bioresources, CA) at a flow rate of 500 nL/min, and peptides were separated by a
gradient of 3–35% CH3CN/0.1% FA over 45 min, 35–100% CH3CN/0.1% FA in 1 min,
and 100% CH3CN/0.1% FA in 9.5 min. Peptides were introduced into the linear ion trap
via a nanospray ionization source and a laser pulled ~3 μm orifice with a spray voltage of
1.8 kV. Mass spectrometry data were acquired in a data-dependent “Top 10” acquisition
mode, in which a survey scan from m/z 400 -2000 is followed by 10 collision-induced
dissociation (CID) tandem mass spectrometry MS/MS scans of the most abundant ions.
MS/MS scans were acquired with the following parameters: isolation width: 2 m/z,
normalized collision energy: 35%, Activation Q: 0.250 and activation time = 30 ms.
Dynamic exclusion was enabled (repeat count: 2; repeat duration: 30 sec; exclusion list
size: 500; exclusion duration: 60 sec). The minimum threshold was 500.
Product ion spectra were searched using the SEQUEST search engine
implemented on the Proteome Discoverer 1.4 (Thermo Fisher Scientific, Waltham, MA,
USA) against a curated Uniprot homo sapiens database (downloaded on Feb 17 2015) in
forward and reverse orientations. Search parameters were as follows: (1) full trypsin
enzymatic activity, (2), maximum missed cleavages = 2, (3) min. peptides length = 6, (4)
Mass tolerance: LTQ: 2 Da for precursor ions and 0.8 Da for fragment ions, Q-Exactive:
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20 ppm for precursor ions and 0.02 Da for fragment ions (5) Dynamic modifications on
cysteine (BCN / +166.099 Da, Dimedone / +138.068 Da, Oxidation / +15.9949 Da,
Dioxidation / +31.990 Da, Trioxidation / +47.985 Da, Carbamidomethylation / +57.0215
Da) for dimedone experiments and (NBD-Sulfoxide (SO-NBD) / +178.997 Da, NBDthioether (S-NBD)/ +163.002 Da, Oxidation / +15.9949 Da, Dioxidation / +31.990 Da,
Trioxidation / +47.985 Da, Carbamidomethylation / +57.0215 Da) for NBD-Cl, and (6) 4
maximum dynamic modifications allowed per peptide. False positive rates were limited
to less than 1% in the data sets by including Percolator node in the workflow.(Käll et al.,
2007) The search results were further analyzed using Scaffold 4.05 (Proteome Software,
OR) for sequence annotation.
For targeted mass spectrometry experiments involving quantification of
dimedone-d0 and dimedone-d6 labeled peptides, mass spectrometry data was acquired
with alternating MS-SIM scans and PRM (2 scan groups in the method). Full scans were
acquired from m/z 340 - 1,400 at 70, 000 resolution (AGC target 3e6; max IT 200 ms;
profile mode). PRM were carried out with HCD MS/MS scans at 17,500 resolution on
the precursors imported into the inclusion list, with the following settings: AGC target 2
e5; max IT 100 ms; isolation width of 1.2 m/z and a normalized collisional energy of
28%. The dimedone and dimedone-d6 labeled Src peptide pairs with various charge
states (CS) were monitored [AANILVGENLVCK (CS: 2; m/z: 741.4053, 744.4241);
AANILVGENLVC(dim/dim-d6)KVADFGLAR (CS: 3; m/z: 771.0875, 773.1000);
GAYC(dim/dim-d6)LSVSDFDNAK

(CS:

2;

m/z:

814.3691,

817.3879);

HADGLC(dim/dim-d6)HR (CS: 3; m/z: 351.5120, 349.4994); LGQGC(dim/dimd6)FGEVWMGTWNGTTR (CS: 2;

m/z: 1119.5090, 1122.5279); LTTVC(dim/dim148

d6)PTSKPQTQGLAK

(CS:

3;

m/z:

637.6801,639.6926);

MPCPPECPESLHDLMCQCWR (with 1 dim/dim-d6 modified cysteine and 3
carbamidomethylated cysteines; CS: 2; m/z: 1342.5483, 1345.5672)]
MS/MS spectra were searched against the Src sequence using SEQUEST on
Proteome Discoverer. For the quantification experiments involving dimedone/dimedoned6, the search files (.msf) were then imported into Skyline for selecting the precursor or
transitions for quantitation. Data was exported from XCalibur and Skyline to GraphPad
Prism 7 for chromatogram/spectrum plotting. Four to six transitions were selected from,
if possible, the third to the last fragment ions in the product ion spectrum for
quantification. Boundaries of integration were manually evaluated. For MPC(dim/dimd6)PPECPESLHDLMCQCWR (the other 3 cysteines were carbamidomethylated), its
quantification was performed with transitions 1342.5483 m/z → [y3]+, [y7]+, and [y13]+
(dim labeled) and 1345.5672 m/z → [y3]+, [y7]+, [y13]+ (dim-d6 labeled) using peak
integration in XCalibur. Data was exported from XCalibur and Skyline to GraphPad
Prism 7 for plotting chromatograms and spectra.

Tyrosine kinase activity measurements. Tyrosine kinase activity of recombinant Src and
Cys-to-Ala variants was analyzed using the ADP-Glo (Promega) assay kit according to
the manufacturer’s protocol in kinase buffer containing 2.0 mM DTT. WT, C185A, and
C277A Src (~1 ng) was pre-treated at room temperature with hydrogen peroxide (H2O2;
Thermo) for 15 min in a volume of 15 µL, prior to initiating catalysis with substrate
(poly[4Glu:Tyr]; Sigma) and ATP (Promega), resulting in a final reaction volume of 25
µL, for 60 min at room temperature within the linear kinetic range (data not shown).
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Reactions were quenched with ADP Glo reagent for 40 min, further incubated with
detection reagent for 30 mins, and measured for luminescence. Specific activity (µmol
ATP/min/µg protein) was obtained from an ADP (Promega) standard curve.

Analysis of disulfide cross-linking by non-reducing SDS-PAGE. To assess the capability
of Src to form disulfide bonds, recombinant Src (10 µg) buffered in 100 mM Tris-HCl,
20 mM MgCl2, 2 mM EGTA, 0.02% Brij-35, 1.0 mM DTT at pH 7.4 was incubated with
increasing concentrations of H2O2 at room temperature for 1h. Following 1h incubation,
protein was treated either with 100 mM DTT or with water for 30 min, followed by the
addition of non-reducing laemmli buffer. Samples were boiled at 100°C for 5 minutes
prior to SDS-PAGE, and proteins were visualized using coomassie blue staining.

Cell culture and treatments. Human pulmonary mucoepidermoid NCI-H292 cells
(American Type Culture Collection) were grown in RPMI 1640 medium containing 10%
fetal bovine serum and 1% penicillin/streptomycin at 37°C and 5% CO2. Src-FLAG
constructs were generated by transiently transfecting H292 cells at 85-90% confluence
using the Turbofect reagent (Thermo) according to a modified version of the
manufacturer’s protocol. 1 µg of corresponding pCMV6-Src (Origene) was mixed with 8
µL Turbofect and 100 µL serum-free RPMI media (per well) and allowed to incubate at
RT for 20 min. Cells were changed to 900 µL serum-free media prior to dropwise
addition of 100 µL transfection mix in each well. Cells were then incubated at 37 °C for
24 hrs to allow for complete DNA transfection, followed by PBS washing to remove any
cells that may have died during the process. Following transfection, cells were grown
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again for 24 hrs with full RPMI media to allow for regeneration. Prior to subsequent
experiments (generally ~48-72 hrs post-transfection, depending on visual assessment of
viability), cells were switched to serum-free RPMI for overnight incubation. Stable H292
cell lines expressing C-terminal FLAG-tagged WT Src, C185A, and C277A, were
generated by transfecting ~70% confluent cells in a 24-well dish (Corning) with 1 µg of
DNA from the pCMV6-Src (RC208622 Origene Rockville, MD) and 2 µL of Turbofect
Transfection reagent (Fisher) in serum free media for 24 hrs as per manufacture’s
protocol. Mutant plasmids were generated using identical methods and primers as
mentioned above with the pEX-Src-C-His vector. Cells were then washed with PBS
(Gibco) and then cultured for 24 hrs with serum containing media. Cells were then
selected over 10-15 days in serum containing media with 150 µg/mL of neomycin (G418
sulfate). Successful transfection was confirmed on the basis of Western blot for FLAGtagged Src at a molecular weight of ~65 kDa (Figure 2.12). For experimentation, cells
were seeded at 100,000 cells/well in 24-well plates (Corning). Upon reaching confluence,
cells were cultured overnight in the absence of serum and placed in fresh serum-free
medium for 1-2 hrs before stimulation with exogenous ATP (Sigma, St. Louis, MO; 100
µM) for 10 minutes.

Western blotting. Cell lysates were collected by placing cells on ice in 100 µL Western
solubilization lysis buffer (50 mM HEPES, 250 mM NaCl, 1.5 mM MgCl2, 1% TritonX100, 10% glycerol, 1 mM ethyleneglycol-bis-(β-aminoethylether)-N,N,N9,N9-tetraacetic
acid, 1 mM phenylmethylsulfonyl fluoride, 2 mM Na3VO4, 10 mg/mL aprotinin, and 10
mg/mL leupeptin; pH 7.4) per well for 30 min. Lysates were collected by scraping,
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briefly sonicated, and cleared of insoluble material by centrifugation (14,000 rpm, 5 min)
for analysis. Lysates containing equal amounts of protein (15–35 µg, measured using
BCA protein assay kit; Pierce) were loaded on 10% SDS-PAGE gels and transferred to
nitrocellulose membranes, and probed using antibodies against p-Src Tyr 416 (Cell
Signaling 1∶400), p-Src Tyr 527 (Cell Signaling 1∶400), Src (Cell Signaling L4A1;
1∶1000), DYKDDDDK (FLAG) (Cell Signaling 1:1000) & streptavidin peroxidase
polymer ultrasensitive (1:10,000). Primary antibodies were probed with rabbit or mousespecific secondary antibodies conjugated with HRP (Cell Signaling) and detected by
enhanced chemiluminescence (Pierce). Western blot band densities were quantified using
ImageQuant TL (v8.1.0.0).

Analysis of protein sulfenylation. For analysis of protein sulfenylation (-SOH), cells were
lysed in Western solubilization buffer containing 1 mM DCP-bio1 (Kerafast or EMD
Millipore), 200 U/mL catalase (Worthington, Lakewood, NJ) and 10 mM Nethylmaleimide (Sigma) and incubated for 1 hr on ice. FLAG-tagged WT, C185A, and
C277A Src was purified from cell lysates (~300 µg for WT, C185A and ~900 µg for
C277A) with ~40 µL packed volume of Anti-FLAG M2 magnetic beads (Sigma) as per
manufacture’s protocol. M2 beads were washed 5 times with 1 mL of 50 mM Tris and
150 mM NaCl pH 7.4 and collected using a DynaMag2 magnetic particle separator.
FLAG-tagged proteins were eluted with 2x washes of Tris buffer containing 150 µg/mL
3X FLAG peptide (Sigma). Eluted proteins were combined with sample buffer and run
on 10% SDS PAGE gels. Additionally, to further probe for in situ sulfenylation, cells
were pre-loaded with 5 mM DYn-2 (Kerafast) for 15-30 min prior to ATP stimulation.
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Cells were then lysed with HEPES lysis buffer (50 mM Hepes, 150 mM NaCl, 1% NP40, 0.1% SDS, pH 7.4) supplemented with 10 mM NEM, Halt protease and phosphatase
inhibitor cocktail (no added EDTA, Thermo), and 200 U/mL catalase. ~100 ug of protein
lysate was the pre-cleared of endogenously biotinylated proteins with NeutrAvidin
agarose resin for 1 hr prior to incubation with a 1:1 ratio click reaction mix (200µM
Biotin-Azide (Kerafast), 500 µM CuSO4, 1 mM Tris[(1-benzyl-1H-1,2,3-triazol-4yl)methyl]amine (TBTA, Sigma), and 5 mM Sodium L-ascorbate. pH 7.0) for 1h with
gentle agitation. This reaction was then quenched with the addition of 1 mM EDTA and
analyzed in the same manner as DCP-Bio1 conjugated samples.

Immunofluorescence. H292 cells stably expressing either FLAG-Src WT or pCMV6
(Origene, Rockville, MD) empty vector controls were seeded on Millicell 8-well glass
chamber slides (Millipore, Billerica, MA) at a density of 75,000 cells/well and grown to
~95-100% confluence. Cells were serum starved overnight prior to washing with PBS,
fixation with 4% Paraformaldehyde, and permeabilization with 0.2% Triton X-100 in a
1% BSA/PBS solution for 15 min. Cells were washed prior to blocking with 10% normal
goat serum (Life Technologies, Carlsbad, CA) for 1h. After blocking, cells were then
washed prior to overnight incubation at 4°C with α-Src (36D10 rabbit, 1:500, Cell
Signaling Technologies, Danvers, MA) and M2 α-FLAG (F1804 mouse, 1:500, Sigma,
St. Louis, MO) antibodies. The following day, cells were washed prior to incubation with
AlexaFluor-conjugated α-rabbit (A-21245 AlexaFluor 647, 1:500, Life Technologies,
Carlsbad, CA) and α-mouse (A-21422 AlexaFluor 555, 1:500, Invitrogen, Carlsbad, CA)
secondary antibodies. Cells were then washed, followed by nuclear counterstaining with
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10 µg/mL 4, 6-diamidino-2-phenylindole (DAPI, Invitrogen, Carlsbad, CA) for 15 min in
1% BSA. Finally, cells were washed and a glass coverslip was mounted to the slide.
Images were collected using a Zeiss LSM 510 META laser scanning confocal
microscope (Zeiss, Jena, Germany).

Molecular dynamics simulations. Model Preparation. The protein models were
constructed from the autoinhibited Src structure (PDB: 2SRC)(Xu et al., 1999). The
models containing sulfenic acid cysteines at C185, C277, and C498 were constructed
using Maestro (Schrödinger Inc.). Since both Cys-SH and Cys-SOH are weak acids, they
could potentially be present in their deprotonated forms. We therefore calculated pKa
values of simple CH3CH2-SH and CH3CH2-SOH models using pKa calculations in Jaguar
(Schrödinger Inc.) with DFT method (B3LYP, pka-geopt* basis, water solvent), which
revealed pKa values of 10.3 for the thiol and 8.7 for the sulfenic acid form, and therefore
performed MD simulations based on protonated states of Cys-SH and Cys-SOH. A webbased graphical user interface CHARMM-GUI(Jo et al., 2008) was used to prepare the
initial models for simulations, which contain our protein models, 17,000~26,000 TIP3P
water molecules, chloride potassium as counter ions, totaling near 58,400~85,400 atoms
in a periodic box 85 × 89 × 82~94 × 94 × 94 Å3. The parameters (i.e. for bonds, angles,
and dihedral angles) and partial charges for cysteine sulfenic acid, which were initially
generated using CHARMM General Force Field (CGenFF)(Vanommeslaeghe et al.,
2010) in CHARMM-GUI(Jo et al., 2008), were validated or modified using quantum
calculations at the density functional theory (DFT) level (see Cysteine sulfenic acid force
field parameters for parametrization). Since both Cys-SH and Cys-SOH are weak acids,
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they could potentially be present in their deprotonated forms. We therefore calculated pKa
values of simple CH3CH2-SH and CH3CH2-SOH models using pKa calculations in Jaguar
(Schrödinger, Inc.) with DFT method (B3LYP, pka-geopt* basis, water solvent), which
revealed pKa values of 10.3 for the thiol and 8.7 for the sulfenic acid form, and therefore
performed MD simulations based on protonated states of Cys-SH and Cys-SOH.

Simulation Setup. We set up two replica simulations for each system in Table S2. All
simulations were performed with the CHARMM36 force field(Best et al., 2012) in
addition to our customized parameters for the Cysteine Sulfenic Acid (Cys-SOH). For
each construct, we employed an equilibrium strategy including stages of minimization,
equilibration, and a short simulation (for 10 ns) in the NAMD(Phillips et al., 2005)
program. After equilibrium, the long simulations (for 1-5 µs) were carried out on the
specialized ANTON supercomputer using the software program Anton 2.13.0(Shaw et
al., 2009) and with the Desmond program on GPUs (Schrödinger, Inc.). All our
simulations were performed with the NPT ensemble (300 K, 1 bar, Nose-Hoover
coupling scheme). The van der Waals and short-range electrostatics were cut off at
12.0 Å with a switch at 10.0 Å. Hydrogen atoms were constrained using the SHAKE
algorithm. A summary of our simulations is provided in Table S2.

Metadynamics simulations. Metadynamics simulations were carried out to determine the
two-dimensional free-energy landscapes of conformational transition in the cysteine
oxidation region in comparison with it of wild type. Metadynamics simulations were
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setup in Desmond (Schrödinger, Inc.). By adding a time-dependent bias in the form of
repulsive Gaussians as a function of carefully chosen collective variables (CVs), the
system is coaxed to escape stable free energy minima where it would normally be
trapped.(Clark et al., 2016) According to the key residue interactions in MD simulations,
two collective variables (CVs) were chosen to characterize the conformational change
around each cysteine oxidation region as following. (1) The pair distances of Y416-D386
(CV1) and R419-D386 (CV2) are used to characterize the dissociation of A-loop in the
Cys-277 system (Figure 4). (2) The pair distances of pY527-R175 (CV1) and pY527R155 (CV2) are used to characterize the dissociation of pY527 from SH2 region in the
Cys-185 system (Figure 5). (3) The center-of-mass distances of helix 489-499 to helix
446-457 (CV1) and center of mass distances of helix 489-499 to helix 360-371 (CV2) are
used to characterize the dissociation of helix 489-499 from the helices bundle near the Cloop in the Cys-498 system (Figure 2.21). The upper boundary of all CVs are within the
range of 20~25 Å. The gaussians width is set as 0.05. To examine the convergence of
free-energy landscape, we have calculated the free-energy difference every 10 ns after 80
ns: the key energy basins remain to the final 120 ns with a general standard deviation of
0~0.68 kcal/mol for the maximum free-energy difference.

Simulation Data Analysis. Our simulation data analysis includes helicity percentage and
solvent contacts, which were performed with TCL scripts implemented in VMD
1.9.2(Humphrey et al., 1996) and plotted by Prism (version 7.0a). Visualizations were
performed with the programs VMD(Humphrey et al., 1996) and Pymol (Schrödinger,
Inc.). Helicity percentage was calculated for residues 406-423. Solvent contacts were
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calculated by counting the number of water molecules around pTyr-527 within radius of
6 Å.

Cysteine sulfenic acid force field parameters. The CHARMM36 force field parameters
for the cysteine sulfenic acid, which include the structural parameters (i.e. for bonds,
angles, and dihedral angles) and partial charges, were initially generated using
CGenFF(Vanommeslaeghe et al., 2010) in CHARMM-GUI(Jo et al., 2008). These
parameters have been validated or modified according to DFT optimized models. To
obtain partial charges for the cysteine sulfenic acid, a model (+H3N-C(CH2SOH)-COOwas constructed in Maestro and several representative conformations were obtained from
a

Low-Mode

Conformational

Search

using

MacroModel

BatchMin

v10.4).

Representative partial atomic charges from electrostatic potentials (ESP) were obtained
from single point calculations on the resulting conformation using DFT with B3LYP/631g** in Jaguar v8.4 (Becke, 1993; Bochevarov et al., 2013). Van der Waals parameters
were set to those for the disulfide (-S-S-) sulfur atoms since the sulfenic acid oxidation
state is similar to that of a disulfide. The bond-stretching and angle-bending parameters
obtained from CGenFF(Vanommeslaeghe et al., 2010) are reliable with penalties below
10, while the parameters for dihedral angle –C-S-O-H we were to apply to the
CHARMM force filed needed further validation. Therefore, we performed relaxed scan
for dihedral angles using the program Jaguar (Schrödinger, Inc.). In a relaxed scan, the
structure will be optimized at each scan point.
We used the CH3CH2-SOH model system to compare our parameters for -SOH
with DFT calculations geometrically and energetically in dihedral angle scanning. We
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scanned the dihedral angle –C-S-O-H from 0 degrees to 180 degrees, over 10-degree
increments from point to point in implicit water using the Poisson-Boltzmann model. At
each scan point, a series of single-point energy calculations using DFT with B3LYP/631g** was applied while geometry optimization was also carried out, which is a general
force-filed parameterization scheme.(Wildman et al., 2016) The total energy difference
by relaxed dihedral scanning using DFT calculations was displayed in blue line in Figure
2.16.

The dihedral term in the CHARMM force filed was given by,

Kϕ is the dihedral force constant, n is the multiplicity of the function, ϕ0 is an equilibrium
angle. The best fitting dihedral parameter is: Kϕ, n, and ϕ0 values as 3.2, 2, and 0,
respectively. Here, we chose Kϕ of 1.1, referring to other value given to similar groups
used in the CHARMM force filed, for example, -C-C-O-H; the less energy barrier may
contribute to faster dynamics and easier rotation for–C-S-O-H, within conformational
error range. The dihedral term energy calculated from equation (s1) is shown in orange
line in Figure 2.16, which generated standard deviation of 2.2 kcal/mol. Accordingly, the
total energy difference of each structure generated from Jaguar’s relax-scanning were
calculated in NAMD program and displayed in red line in Figure 2.16. Generally, our
dihedral-angle-dependent energy profile is consistent with DFT calculations, which
validate the dihedral angle geometry preference for the sulfenic acid group (-SOH). The
cysteine sulfenic acid force field parameters are displayed below.
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>>>Topology File Parameters
RESI SOH
0.00
GROUP
ATOM N NH1 -0.47 ! |
ATOM HN H
0.31 ! HN-N
ATOM CA CT1 0.07 ! | HB1
ATOM HA HB1 0.09 ! | |
GROUP
! HA-CA--CB--SG
ATOM CB CT2 -0.20 ! | | \
ATOM HB1 HA2 0.14 ! | HB2 O1--H1
ATOM HB2 HA2 0.14 ! O=C
ATOM SG SO1 -0.05 ! |
ATOM O1 OH1 -0.43
ATOM H1 H
0.40
GROUP
ATOM C C
0.51
ATOM O O -0.51
BOND CB CA SG CB N HN N CA
BOND C CA C +N CA HA CB HB1
BOND CB HB2 SG O1 O1 H1
DOUBLE O C
IMPR N -C CA HN C CA +N O
CMAP -C N CA C N CA C +N
DONOR HN N
DONOR H1 O1
ACCEPTOR O C
ACCEPTOR SG O1
IC -C CA *N HN 1.3479 123.9300 180.0000 114.7700 0.9982
IC -C N CA C 1.3479 123.9300 180.0000 105.8900 1.5202
IC N CA C +N 1.4533 105.8900 180.0000 118.3000 1.3498
IC +N CA *C O 1.3498 118.3000 180.0000 120.5900 1.2306
IC CA C +N +CA 1.5202 118.3000 180.0000 124.5000 1.4548
IC N C *CA CB 1.4830 111.2000 125.1000 116.1800 1.5584
IC N C *CA HA 1.4830 111.2000 -118.3000 105.2000 1.0837
IC N CA CB SG 1.5330 109.1000 -132.2000 114.0000 1.8280
IC SG CA *CB HB1 1.8280 114.0000 118.2000 110.7000 1.1134
IC SG CA *CB HB2 1.8280 114.0000 -122.4000 112.7000 1.1124
IC CA CB SG O1 1.5320 114.0000 -49.8000 99.8000 1.6580
IC CB SG O1 H1 1.8280 99.8000 -75.7000 113.7000 0.9940
END

>>>Parameters included in CHARMM forcefield parameter file
BONDS
!
!V(bond) = Kb(b - b0)**2
!Kb: kcal/mole/A**2
!b0: A
!
!atom type Kb
b0
SO1 OH1 200.000 1.7090 !
SO1 CT2 198.000 1.8230 !
ANGLES
!
!V(angle) = Ktheta(Theta - Theta0)**2
!Ktheta: kcal/mole/rad**2
!Theta0: degrees
!
!atom types Ktheta Theta0
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CT1
SO1
CT2
SO1

CT2
OH1
SO1
CT2

SO1
H
OH1
HA2

50.000 115.3000 !
50.000 110.1000 !
50.000 99.0000 !
46.100 107.0000 !

DIHEDRALS
!
!V(dihedral) = Kchi(1 + cos(n(chi) - delta))
!Kchi: kcal/mole
!n: multiplicity
!delta: degrees
!
!atom types
Kchi n delta
CT1 CT2 SO1 OH1 0.2000 3 0.00 !
NH1 CT1 CT2 SO1 0.2000 3 0.00 !
H C CT2 SO1 0.2000 3 0.00 !
C CT2 SO1 OH1 0.2000 3 0.00 !
HA2 CT2 SO1 OH1 0.2000 3 0.00 !
H OH1 SO1 CT2 1.1000 2 0.00 !
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3.1 Abstract
The respiratory epithelium forms the first line of defense against inhaled pathogens, and
acts as an important source of innate cytokine responses to environmental insults. One
critical mediator of these responses is the IL-1 family cytokine, IL-33, which is rapidly
secreted upon acute epithelial injury as an alarmin and induces type 2 immune responses.
Our recent work highlighted the importance of the NADPH oxidase dual oxidase 1
(DUOX1) in acute airway epithelial IL-33 secretion by various airborne allergens,
associated with H2O2 production and redox-dependent activation of Src kinases and
epidermal growth factor receptor (EGFR) signaling. Here, we show that IL-33 secretion
in response to acute airway challenge with house dust mite (HDM) allergen critically
depends on the activation of Src by a DUOX1-dependent oxidative mechanism.
Intriguingly, HDM-induced epithelial IL-33 secretion was dramatically attenuated by
siRNA- or antibody-based approaches to block IL-33 signaling through its receptor
IL1RL1(ST2), indicating that HDM-induced IL-33 secretion includes a positive feedforward mechanism involving ST2-dependent IL-33 signaling. Moreover, activation of
type 2 cytokine responses by direct airway IL-33 administration was associated with
ST2-dependent activation of DUOX1-mediated H2O2 production and redox-based
activation of Src and EGFR, and was attenuated in Duox1-/- and Src+/- mice, indicating
that IL-33-induced epithelial signaling and subsequent airway responses involve
DUOX1/Src-dependent pathways. Collectively, our findings suggest an intricate
relationship between DUOX1, Src and IL-33 signaling in the activation of innate type 2
immune responses to allergens, involving DUOX1-dependent epithelial Src/EGFR
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activation in initial IL-33 secretion and in subsequent IL-33 signaling through ST2
activation.

3.2 Materials and Methods
Reagents — All reagents, unless otherwise noted, were purchased from Thermo Fisher
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO) at the appropriate quality
grade available and/or at grades appropriate for cell culture/in vivo use, depending on the
application.

Mouse strains and experiments — C57BL/6J mice aged 8-12 weeks were purchased from
Charles River Laboratories (Wilmington, MA) and were allowed to acclimate for at least
1 week prior to experimentation. Src-deficient mice (B6;129S7-Src tm1Sor/J) were
obtained from Jackson Laboratories (Bar Harbor, ME), and were bred to obtain Src+/mice and littermate Src+/+ WT controls (Soriano et al., 1991). Animal genotypes were
confirmed via supplier’s genotyping protocols using a universal reverse primer (GAG
TTG AAG CCT CCG AAG AG) and the forward primers (TCC TAA GGT GCC AGC
AAT TC) for WT and (CGC TTC CTC GTG CTT TAC GGT AT) for KO. Duox1-/- mice
were originally provided by Miklós Geiszt (Donkó et al., 2010) and were backcrossed
onto C57BL/6NJ background (Jackson Laboratories, Bar Harbor, Maine), for at least 5
generations.
Mice were anaesthetized with isoflurane briefly before all instillation procedures.
Src Inhibitor AZD0530 (Saracatinib; APExBIO, 677 ng/kg in saline prepared from a
stock solution in DMSO) and α-ST2/IgG (R&D Systems, 20 µg/mouse) were instilled
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intranasally (50 µL/mouse) 1-2h prior to allergen challenge. House dust mite extract
(Dermatophagoides pteronyssinus, HDM, Greer Laboratories, 50 µg/mouse in PBS Lot
#269206) or recombinant mouse IL-33 (BioLegend, 1.0 µg/mouse in PBS) were instilled
oropharyngeally at a volume of 50 μL/mouse either once or on 4 consecutive days prior
to sacrifice and harvest. Following sacrifice, bronchoalveolar lavage fluid (BALF,
collected by 500 uL injection of PBS three times) and lung tissues were collected for
analysis. In all cases, males and females were interspersed through experiments as evenly
as possible. All procedures were reviewed and approved by the University of Vermont
Institutional Animal Care and Use Committee prior to experiments.

Cell culture and treatments — Primary mouse tracheal epithelial cells (MTEC) were
isolated from WT or Duox1-/- C57BL/6NJ mice, as well as WT and Src+/- mice, and
grown as previously described (Gorissen et al., 2013), NCI-H292 human pulmonary
mucoepidermoid cells were purchased from ATCC (Manassas, VA) and were grown on
plastic in RPMI-1640 (Gibco) supplemented with 10% fetal bovine serum and 1%
Pen/Strep (Gibco). Upon reaching confluence, plated cells were starved (serum-free
medium for H292, or medium without EGF for MTEC) overnight prior to
experimentation. Media was refreshed 2h prior to treatment, and cells were pretreated for
30 min with inhibitors (1 µM AZD0530, 1 µM AG1478) or mouse α-ST2 blocking
mAb/IgG (2 µg/mL; R&D Systems). Cells were then treated with HDM (50 µg/mL), A.
alternata extract (ALT, Greer Laboratories, 50 µg/mL), ATP (Sigma, 100 µM), or with
human/mouse recombinant IL-33 (Peprotech/BioLegend, respectively, 100 ng/mL) and
media was collected at appropriate times for analysis of cytokines/growth factors or ATP
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release. Cells were lysed utilizing Western Solubilization Buffer (WSB, 50 mM HEPES,
250 mM NaCl, 1.5 mM MgCl2, 1% Triton-X100, 10% glycerol, 1 mM EDTA, 1
mM phenylmethylsulfonyl fluoride, 2 mM Na3VO4, 10 mg/ml aprotinin, and 10 mg/ml
leupeptin (pH 7.4)) or GeneJet RNA extraction kit lysis buffer (Invitrogen) supplemented
with 2% β-mercaptoethanol, for analysis of protein or RNA, respectively.

siRNA silencing — Silencing of gene expression in H292 cells or MTEC was carried out
when cells were 60-70% confluent using the DharmaFECT reagent (Dharmacon),
according to manufacturer protocol. Briefly, cells were treated with siRNA mixed with
Dharmafect reagent and serum-free media at a concentration of 100 nM 72h prior to
experimentation. After 24h, media was removed and replaced with full growth media for
24h, followed by starvation media 24h prior to treatment. Specific RNA used were OnTarget Plus Smartpool NS siRNA, targeting either human or mouse Src, or Il1rl1 (ST2),
(Dharmacon).

DUOX1

was

silenced

(GCUAUGCAGAUGGCGUGUAtt; antisense,

using

siRNA

reagents

UACACGCCAUCUGCAUAGCtg;

sense) and control siRNA (Invitrogen) as previously described (Wesley et al., 2007).

ELISA analyses — BALF harvested from mice or cell supernatants were analyzed for IL33, IL-5, IL-13, and amphiregulin (Areg) using DuoSet ELISA kits (R&D systems)
according to manufacturer protocol and were read on a BioTek Synergy HT plate reader.

H2O2 detection assay — Production of H2O2 from H292 cells was analyzed using
peroxidase-catalyzed tyrosine crosslinking, as previously described (Hristova et al.,
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2014). Reaction mixtures were analyzed by high performance liquid chromatography and
fluorescence detection of dityrosine and compared to exogenous standards generated
using H2O2.

Analysis of protein sulfenylation — Protein sulfenylation was measured as previously
described (Dustin et al., 2019; Heppner et al., 2016). Briefly, following 10-min
stimulation of either H292 cells or MTEC, cells were lysed in WSB containing 1 mM
DCP-Bio 1, 200 U/mL Catalase, and 10 mM N-ethylmaleimide for 1h on ice. Equal
amounts of protein (~100-500 µg), measured by BCA assay, were then loaded on to
Amicon Ultra-0.5 filtration units and washed with 6 changes of 20 mM Tris-HCl.
Washed proteins were then added to prewashed NeutrAvidin beads (Pierce) and rotated
overnight at 4°C. Following multiple washes, Biotin-tagged proteins were then eluted
from the beads with a 50 mM Tris, 2% SDS, 1 mM EDTA buffer pH 7.4 and boiling for
10 min, followed by mixing the supernatant solution with 6x Laemmli buffer for analysis
by SDS-PAGE and western blot.

Western blotting — Cell culture lysates were analyzed with BCA Assay (Pierce) and
mixed with Laemmli sample buffer and briefly boiled. Equal amounts of protein from
each sample were separated using Criterion 10% SDS-PAGE (Bio-Rad), then transferred
to nitrocellulose membranes. Membranes were then blocked with either 5% BSA or nonfat milk and probed with antibodies against pY1068 EGFR (1:1000, 3777S), pY845
EGFR (1:1000, 2231S), EGFR (1:1000, 2646S), p-Src Tyr 416 (1:1000; 2101S), Src
(L4A1; 1:1000; 2110S) (Cell Signaling Technologies) and β-Actin (1:5000, A5441,
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Sigma), in manufacturer recommended diluent and supplemented with 0.05% Sodium
Azide overnight at 4°C. Membranes were then probed with horseradish peroxidase
(HRP)- conjugated secondary antibodies and detected using Pico or Femto
chemiluminescence substrates (Fisher and GeneTex, respectively) and an AI600
Chemiluminescent Imager (GE Lifesciences).

RT-PCR — Tissue RNA was isolated from mouse inferior lobes as previously described
(Habibovic et al., 2016). RNA from cultured cells was isolated using GeneJet RNA
extraction kit lysis buffer (Invitrogen) supplemented with 2% β-mercaptoethanol. RNA
from both tissues and cultured cells was then purified using GeneJet RNA purification
kits (Invitrogen) according to manufacturer protocol. cDNA was synthesized using the
iScript cDNA synthesis kit (Bio-Rad) and/or applied biosystems High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) according to manufacturer protocol.
Quantitative RT-PCR was performed using Sybr Green PCR supermix (Bio-Rad) 0.5 µL
cDNA and 0.5 µM primer mix as previously described (Schiffers et al., 2020).

Immunohistochemistry — Immunohistochemistry analyses were performed as previously
described (Habibovic et al., 2016). Tissue slides were then quenched of endogenous
peroxidase activity with 3% H2O2 and incubated with antibodies against (Src pY416,
EGFR pY1068, same as above) at a 1:600 dilution overnight. Finally, samples were
conjugated with biotinylated secondary antibodies and streptavidin-HRP (strep-HRP)
using the Vectastain ABC kit (Vector Laboratories) according to the manufacturer’s
protocol. Antibodies were then visualized by reacting strep-HRP with 3,3’168

diaminobenzidine and monitored until color was sufficiently developed for analysis.
Quantification of positive staining was calculated as a percentage against total
counterstained airway using MetaMorph imaging software (Molecular Devices).

Measurement of Airway Hyperresponsiveness — Following 4-day IL-33 challenge, mice
were anesthetized on day 5 and their tracheas were cannulated. Following paralysis with
pancuronium bromide (0.8 μg/kg), mice were connected to a flexiVent ventilator
apparatus (SIREQ) and exposed to aerosolized PBS or increasing doses of methacholine
(12.5, 25, and 50 mg/mL) after stabilizing. Newtonian resistance (Rn), tissue damping
(G), and tissue elastance (H) we measured by forced oscillation analysis using a constant
phase model of impedance (Chapman et al., 2015; Tomioka et al., 2002).

Analysis of Inflammatory Cells from BALF — Following animal harvest, BALF were
briefly centrifuged and the supernatant was collected for analysis. Pelleted cells were
resuspended in PBS or hemolyzed with 100 μL water to remove any erythrocytes found
in the pellet. Cells were counted using a hemocytometer prior to loading into an EZ
Cytofunnel (Thermo Scientific) and centrifuged at 600 RPM for 10 minutes. Slides were
then fixed and stained using the Hema 3 kit (Thermo Scientific) according to
manufacturer protocol, followed by cover slip mounting. Cells differentials were counted
out of 200 cells per slide and were evaluated for the presence of macrophages,
lymphocytes, eosinophils, and neutrophils.
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Statistical Analyses — All data are represented as means and SEMs. Statistical
significance was evaluated using 2-way ANOVA, unless otherwise noted, through the
GraphPad Prism Software (Version 7.0, GraphPad Software, La Jolla, CA). All values
were considered significant if P<0.05.

3.3 Introduction
The airway epithelium plays an essential role in respiratory function as a first-line
defense against inhaled pathogens (Knight et al., 2003; Lambrecht et al., 2012).
Additionally, the respiratory epithelium plays a crucial role in signaling processes and
mediator production to aid in tissue regenerative processes following injury (Hiemstra et
al., 2015; Knight et al., 2003). Among the key initial features of these innate epithelial
responses is the rapid production of IL-1 family cytokines, particularly the alarmin
cytokine IL-33 (Liew et al., 2016) which critically contributes to the activation of type 2
immune responses that are important for tissue regeneration due to e.g. parasitic
infections or other forms of injury (Humphreys et al., 2008; Oboki et al., 2010) but have
also been strongly associated with development of allergic diseases such as asthma
(Moffatt et al., 2010; Prefontaine et al., 2010).
IL-33 is a member of the IL-1 cytokine family that is constitutively expressed in
epithelial cells in barrier tissues as a chromatin-bound nuclear factor, and additionally
functions as an extracellular cytokine (Carriere et al., 2007; Liew et al., 2016; Moussion
et al., 2008; Travers et al., 2018) as the only known ligand for the heterodimeric IL1RL1
(ST2) receptor expressed on many effector cells (Schmitz et al., 2005). Following
damage to the epithelium, IL-33 can be released either passively due to epithelial necrosis
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or actively through secretion pathways that are incompletely understood (Drake et al.,
2017). Released IL-33 then binds the ST2 receptor on various target cells, forming an
intracellular signaling complex (involving e.g. MyD88 and TRAF6), inducing type 2
immune responses and other various inflammatory processes (Lott et al., 2015; Yagami et
al., 2010). Activation of IL-33 cytokine function also involves its proteolytic processing
to a more potent, truncated 18 kD form (Lefrancais et al., 2012), by exogenous proteases
released from inflammatory cells or proteases associated with various allergens (Cayrol
et al., 2018; Scott et al., 2018). Extracellular IL-33 activity can also be regulated by its
binding to a soluble truncated form of ST2 that acts as a decoy receptor for IL-33
(Hayakawa et al., 2007), or through cysteine oxidation within IL-33 to an intracellular
disulfide which reduces its cytokine function (Cohen et al., 2015). We and others have
recently shown that IL-33 secretion from the respiratory epithelium in response to various
airborne allergens is mediated by an active signaling mechanism initiated by early
damage signals such as ATP, activation of Ca2+-dependent signaling, and H2O2
production by the NADPH oxidase family member dual oxidase 1 (DUOX1), which
subsequently results in redox-dependent activation of cell signaling pathways, including
epidermal growth factor receptor (EGFR) signaling (Habibovic et al., 2016; Hristova et
al., 2016; Schiffers et al., 2020). Activation of EGFR signaling is well-known to
contribute to reparative and secretory processes within the airway epithelium (Burgel et
al., 2004; Sham et al., 2013), and has also been implicated in allergic asthma (Le Cras et
al., 2011). Recent studies have shown that redox-dependent regulation of EGFR involves
increased kinase activity and autophosphorylation due to oxidation of a cysteine in its
ATP-binding region to a sulfenic acid (Paulsen et al., 2011; Truong et al., 2016).
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However, DUOX1-mediated redox regulation of EGFR appears to occur largely at the
level of EGFR transactivation by initial activation of G-protein coupled receptors and
intermediate non-receptor kinases such as the Src kinase, a proto-oncogene involved in
wound repair and cancer (Heppner et al., 2016; Sham et al., 2013). Indeed, we recently
observed that DUOX1 also mediates allergen-induced activation of Src within the airway
epithelium (Hristova et al., 2016), but the importance of Src in allergen-induced IL-33
secretion or related responses has not yet been established.
Src is an extensively studied non-receptor tyrosine kinase that is involved in many
critical cellular processes, such as cell migration, proliferation, and survival (Roskoski,
2015; Yeatman, 2004). As a non-receptor kinase, Src activity is regulated by allosteric
mechanisms and conformational changes resulting in the “unclamping” and activation of
its tyrosine kinase domain, which is further enhanced by autophosphorylation at Tyr 416
within the kinase activation loop (Harrison, 2003; Roskoski, 2005; Xu et al., 1999; Xu et
al., 1997). Emerging findings also suggest that Src function is regulated by oxidation of
one or more of its cysteines (Dustin et al., 2019), and our recent studies have shown that
Src activity can be enhanced by direct oxidation of two of its cysteines, Cys185 in its
SH2 domain and Cys277 near the ATP-binding region of the kinase domain (Heppner et
al., 2018). The relevance for these oxidative events for allergen-induced IL-33 secretion
and activation of type 2 immune responses is, however, still unclear.
The present studies were designed to specifically address the importance of
DUOX1-dependent Src activation in acute IL-33 secretion and activation of downstream
type 2 responses induced by the asthma-relevant allergen, house dust mite (HDM). In the
process of these studies, we uncovered an unanticipated autoamplification mechanism in
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which IL-33 appears to promote its own secretion by activating ST2-dependent signaling
within the epithelium. Following this, we now demonstrate that DUOX1-dependent
oxidative Src activation represents an important component of IL-33-dependent signaling
and activation of type 2 cytokine responses.

3.4 Results
Src mediates airway epithelial IL-33 secretion in response to acute airway HDM
challenge
We previously demonstrated that acute challenge of the airway epithelium with
allergens results in secretion of IL-33, which was associated with redox-dependent
activation of Src and EGFR (Habibovic et al., 2016; Hristova et al., 2016). To address the
role of Src in such acute airway epithelial responses, mice were pretreated with the Src
family kinase (SFK) inhibitor AZD0530 (Saracatinib) (Hennequin et al., 2006), prior to
acute airway challenge with HDM, after which BAL fluids and lung tissues were
harvested (Figure 3.1A). Consistent with previous findings (Heppner et al., 2016; Sham
et al., 2013), IHC analysis showed increased Src and EGFR activation following HDM
administration at 1 and 6h, which was in both cases diminished with AZD0530 treatment
(Figure 3.1B and Figure 3.2A and B). This suggests that EGFR activation was mediated
by Src-mediated transactivation (Sham et al., 2013), since AZD0530 is not known to
directly inhibit EGFR (Green et al., 2009). As expected (Hristova et al., 2016), HDM
challenge caused significant IL-33 secretion into the BALF after 1h, which returned to
baseline levels at 6h. HDM-induced IL-33 secretion was significantly attenuated
following SFK inhibition, suggesting that Src activity is involved in IL-33 secretion
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following HDM exposure (Figure 3.1C). HDM challenge also induced airway secretion
of IL-13 and IL-5 at 6h, consistent with their induction by IL-33 secretion and signaling,
and these responses were similarly inhibited following SFK inhibition by AZD0530
(Figure 3.1C). Finally, we observed corresponding increases in mRNA expression of
these cytokines, which were similarly suppressed following AZD0530 treatment,
indicating that Src also regulates transcriptional regulation of Il33, as well as Il5 and Il13,
after HDM challenge (Figure 3.2C).
While clinically relevant, AZD0530 does not discriminate among the different
SFK members (Green et al., 2009) and therefore does not provide insight into the relative
contribution of different SFKs (e.g. Fyn, Yes, etc.). To address this concern, we utilized
heterozygous Src knockout mice in similar HDM challenge studies (Figure 3.1D). We
observed a trend (p=0.066) towards decreased HDM-induced IL-33 secretion into the
BALF of Src+/- mice compared to WT mice at 1h, and significant suppression of IL-13
and IL-5 secretion at 6h (Figure 3.1D). In summary, these findings demonstrate that
HDM-induced secretion and expression of IL-33, and IL-33-induced type 2 cytokines,
are dependent on Src activation and signaling.
To assess the specific impact of Src in epithelial responses, we performed
similar analyses of in vitro HDM-stimulated MTEC, after siRNA silencing of
endogenous Src expression (Figure 3.2D). We treated MTEC with HDM for 1 or 6 hrs
and analyzed cytokines secreted into the media. Consistent with our in vivo studies, we
observed increased IL-33 (Figure 3.1E) secretion at 1h which returned to baseline at 6h.
Consistent with previous studies (Habibovic et al., 2016; Hristova et al., 2016;
Allahverdian et al., 2008; Wu et al., 2010), MTEC were also capable of producing IL-5
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and IL-13 upon HDM challenge, which were increased at 6h likely due to induction by
initially secreted IL-33. In both cases, these responses were significantly diminished after
Src silencing (Figure 3.1E) Interestingly, we did not see any significant change to Il33
gene expression in these cells in response to HDM treatment (Figure 3.2E). Overall, these
findings demonstrate that Src is involved in IL-33 secretion from epithelial cells
following HDM challenge.

Oxidation of Src C185 and C277 are involved in Src-dependent IL-33 secretion
We previously showed that HDM-induced epithelial IL-33 secretion is
dependent on initial production of H2O2 by the NADPH oxidase DUOX1 and redoxdependent activation of Src and EGFR (Hristova et al., 2016). Extending these previous
findings, we found that oxidation and activation of Src and EGFR in response to HDM
treatment were markedly attenuated after siRNA-dependent silencing of Src, indicating
that HDM-induced EGFR oxidation and activation were dependent on Src-mediated
transactivation (Figure 3.2F). We recently reported that H2O2 can directly enhance Src
activation by oxidizing Cys185 and Cys277 within the Src protein (Heppner et al., 2018).
To address the importance of Src C185 or C277 residues in HDM-mediated secretion of
IL-33, we transfected H292 cells with FLAG-tagged WT Src as well as C185A and
C277A mutant constructs. HDM-induced IL-33 secretion was increased after transfection
with WT Src, compared to empty vector control, but cells transfected with either C185A
or C277A mutants displayed lower HDM-induced IL-33 secretion compared to WT Src
cells as well as non-transfected (empty vector) controls (Figure 3.1G). These findings are
consistent with the proposed importance of these Cys residues in Src activation and also
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suggest that oxidant-resistant Src may act in a dominant-negative fashion, since Src
activation may involve the formation of Src dimers (Spassov et al., 2018). Overall, these
results indicate that HDM-induced IL-33 secretion involves redox-dependent activation
of Src and is dependent on two critical Cys residues within Src that influence oxidantmediated kinase activation.

HDM-induced IL-33 secretion involves an autoamplification mechanism involving IL-33
signaling
In an attempt to verify whether HDM-induced production of type 2 cytokines,
such as IL-13 or IL-5, are indeed due to initial IL-33 secretion and signaling through its
receptor, ST2, we used an ST2-targeted monoclonal blocking antibody (mAb) to prevent
IL-33 signaling. To our surprise, we observed that ST2 receptor blockade also markedly
suppressed HDM-induced secretion of IL-33 itself into the BALF (Figure 3.3A and B).
Follow-up studies of HDM-challenged MTEC treated with the ST2 mAb (Figure 3.3C) or
with ST2-targeted siRNA (Figure 3.3D and Figure 4.6A) showed similar findings, as
both approaches markedly attenuated HDM-induced IL-33 secretion compared to
corresponding controls. Similar findings were obtained with alternative insults such as A.
alternata extract (a fungal allergen) or exogenous ATP (as a direct mimic of damage
response) (Figure 3.3E). Collectively, these findings indicate that IL-33 secretion induced
by HDM or other injurious insults appears to largely depend on a feed-forward
mechanism in which initially-released IL-33 further enhances its own secretion.
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Src and EGFR contribute to IL-33-induced type 2 cytokine production
We next sought to explore whether IL-33 signaling can directly activate Src
and/or EGFR within the epithelium and thereby contribute to type 2 cytokine secretion.
To this end, we first challenged WT or Src+/- mice with recombinant IL-33 (Figure 3.4A),
and indeed observed that IL-33-induced production of both IL-5 and IL-13 within the
BALF were significantly reduced in Src+/- mice compared to WT controls (Figure 3.4B).
We also observed significant upregulation of Il33, Il13, and Il5 mRNA at 6h following
IL-33 challenge but this was apparently independent of Src (Figure 3.5A). Similarly,
siRNA silencing of Src in MTEC also significantly attenuated IL-13 secretion induced by
IL-33 (Figure 3.4C), and pharmacological inhibition of either Src (AZD0530) or EGFR
(AG1478) similarly suppressed IL-33-induced IL-13 secretion in H292 cells (Figures
3.4D and E). Consistent with these findings, we showed that IL-33 stimulation of either
H292 cells or MTEC increased activation of both Src and EGFR, as measured by Src
autophosphorylation at Y416 and EGFR phosphorylation at Y845 (a Src target) and
Y1068 (autophosphorylation) (Figure 3.5D and Figure 3.7E).
Src has been implicated in EGFR transactivation, but may also be involved in
the activation of EGFR ligands (Sham et al., 2013). One such EGFR ligand that is
strongly involved in type 2 immune responses is amphiregulin (AREG), which
contributes to epithelial regeneration and remodeling (Zaiss et al., 2015). Indeed, we
observed rapid Areg mRNA expression and AREG secretion in response to airway HDM
challenge, which was inhibited by the Src inhibitor AZD0530 (Figure 3.6B). Moreover,
AREG secretion from MTECs in response to HDM was also Src-dependent (Figure
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3.6C). Finally, ST2 blockade indicated that HDM-induced AREG secretion critically
depends on IL-33 signaling (Figure 3.6 D), and AREG was secreted into the BALF of
mice upon in vivo IL-33 treatment, in a Src-dependent manner (Figure 3.6E).
Collectively, although Src and EGFR are not typically implicated in canonical IL-33dependent signaling through ST2, our findings demonstrate that activation of Src and
EGFR are both important for epithelial type 2 cytokine production in response to IL-33,
and may also involve IL-33-dependent activation of AREG.

IL-33-induced signaling in airway epithelial cells is DUOX1-dependent
Our findings implicating Src and EGFR in IL-33 signaling prompted us to
explore the potential contribution of DUOX1 to IL-33-induced epithelial responses given
our previous findings demonstrating DUOX1-dependent regulation of Src and EGFR
(Habibovic et al., 2016; Hristova et al., 2016). Indeed, Duox1-/- mice challenged with IL33 displayed diminished IL-5 and IL-13 secretion into the BALF compared to WT mice
(Figure 3.7A and B), suggesting that DUOX1 is involved in downstream cytokine
secretion in response to IL-33 signaling, in addition to its previously reported role in
initial secretion by allergen challenge (Hristova et al., 2016). Consistent with our in vivo
findings, IL-33-induced production of IL-13 (and to a lesser extent IL-5) was also
suppressed in MTECs from Duox1-/- mice or in H292 cells in which Duox1 was silenced
(Figures. 3.7 C, Figures 3.5B and C). To demonstrate whether IL-33 signaling through
ST2 is in fact capable of activating DUOX1, we assessed the ability of IL-33 to stimulate
epithelial H2O2 production. Indeed, we observed an increase in extracellular H2O2 in
H292 cells following IL-33 stimulation, which was attenuated when Duox1 was silenced
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using siRNA (Figure 3.7D). Additionally, we examined whether IL-33 induces oxidative
activation of Src and/or EGFR. Indeed, IL-33-dependent activation of Src and EGFR in
either H292 cells or MTECs (Figure 3.5D and Figure 3.7E) was in both cases DUOX1dependent and corresponded with DUOX1-mediated cysteine oxidation within both Src
and EGFR (Figure 3.7E and Figure 3.5D).

IL-33 induces Ca2+ signaling and ATP secretion
Our results suggest that IL-33-mediated cytokine signaling involves DUOX1
activation and redox-dependent activation of Src and EGFR, which is necessary for type
2 cytokine secretion. However, the mechanisms by which IL-33 mediated activation of
ST2 results in DUOX1 activation is still enigmatic, since DUOX1 activation typically
requires the activation of Ca2+-mediated signaling(Donko et al., 2005; Wesley et al.,
2007) and PKC, which are not typically activated during canonical IL-33 signaling (Liew
et al., 2016). Since DUOX1 activation by allergen challenge involves initial ATP
secretion, which subsequently initiates Ca2+ signaling by purinoceptor signaling
(Habibovic et al., 2016; Hristova et al., 2016), we evaluated whether IL-33 similarly
induces ATP secretion from epithelial cells. Indeed, stimulation of MTE cells with IL-33
resulted in rapid ATP secreted into the medium, which was prevented by ST2 mAb
blocking (Figure 3.8 A) or ST2 silencing via siRNA (Figure 3.8B). In comparison, ATP
release by HDM challenge was independent of ST2. To test the potential importance of
IL-33-mediated ATP release, we used siRNA silencing of the P2Y2 receptor, previously
shown to be involved in HDM-mediated activation of DUOX (Sham et al., 2013), to
confirm that IL-33-induced ATP secretion is causing the activation of DUOX1. To
179

address this, we treated cells with either HDM or IL-33 following P2Y2R silencing and
measured the extracellular H2O2 generation. However, while P2Y2R silencing
significantly attenuated HDM-induced H2O2 production, indicating DUOX1 activation, it
did not significantly alter IL-33-induced H2O2 production (Figure 3.8C). Further
demonstrating the distinct mechanisms involved in IL-33-mediated activation compared
to HDM challenge, addition of the calcium chelator BAPTA-AM markedly diminished
ATP secretion induced by IL-33 but did not affect ATP secretion in response to HDM
treatment (Figure 3.8D).
We recently showed that HDM-induced epithelial DUOX1 activation and IL-33
secretion involves the activation of TRPV calcium channels (Schiffers et al., 2020).
Intriguingly, pre-treating H292 cells with the TRPV1 inhibitor capsazepine markedly
suppressed IL-33-induced IL-13 secretion, suggesting Ca2+ signaling is in fact important
for IL-33 signaling (Figure 3.8E). Together, these results suggest that IL-33 signaling
leads to DUOX1 activation through Ca2+ mobilization via a currently unknown
mechanism.

Repeated IL-33 exposure induces DUOX1- and Src-dependent type 2 inflammation.
Our results so far demonstrate that IL-33 can induce its own secretion from the
airway epithelium and that DUOX1-mediated activation of Src is critical for such IL-33
autoamplification and activation of EGFR and type 2 cytokine responses. Based on a
recent study demonstrating that development of eosinophilic inflammation and airway
hyperresponsiveness in response to chronic airway challenge with exogenous IL-33 is
largely dependent on endogenous IL-33 (Magat et al., 2020), we wondered whether
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DUOX1 and/or Src could similarly contribute to such outcomes. Therefore, we exposed
Duox1-/- or Src+/- mice or their corresponding littermate controls to repeated airway IL-33
challenge on 4 consecutive days, after which we assessed type 2 cytokine responses,
inflammation, airway remodeling, and airway hyperresponsiveness by flexiVent analysis
(Figure 3.9A) Consistent with our previous findings in the context of acute challenge, we
observed significant increases in BAL IL-33, IL-13, and IL-5 levels in response to
chronic IL-33 challenge, which was in each case markedly attenuated in both Duox1-/- or
Src+/- mice (Figure 3.9B and C). Similar findings were observed with respect to AREG
secretion under these conditions (Figure 3.10A and B). As expected, chronic IL-33
challenge also significantly increased lung tissue mRNA levels of Il33, Duox1, Il5, Il13,
and l1rl1, but not Areg (Figs 3.10 C and D), however, neither response was significantly
altered in Duox1- or Src-deficient mice, suggesting that DUOX1 and Src primarily affect
these cytokine responses at the level of secretion. Intriguingly, repeated IL-33 challenge
resulted decrease in lung tissue Src mRNA expression (Figs 3.10 C and D), which may
potentially reflect a negative feedback mechanism in chronic conditions of IL-33-driven
inflammation.
As expected (Magat et al., 2020), chronic IL-33 challenge resulted in increased
airway inflammation, illustrated by marked increases in total BALF cell counts, which
were largely represented by increased eosinophils, and to a lesser extent neutrophils and
lymphocytes. However, neither were significantly altered in Duox1-/- mice or Src+/- mice,
with the exception of a slight increase in neutrophils in IL-33 challenged Duox1-/- mice
(Figure 3.9D and E). Additionally, we observed an increase in the mucus metaplasia
marker Muc5ac following IL-33 challenge, but this was not altered in Duox1-/- or Src+/181

mice (Figure. 3.10C and D). Similarly, repeated IL-33 challenge enhanced expression of
remodeling/fibrosis markers Col1a1 and Col3a1, this was similarly not different between
the various mouse groups (Figure 3.10C and D). Finally, we observed that chronic IL-33
challenge increased airway hyperresponsiveness (AHR), indicated by increases in
Newtonian resistance, tissue damping, as well as tissue elastance, in response to
increasing methacholine dosage (Figure 3.9F and G). Interestingly, all three AHR
parameters were attenuated in Duox1-/- mice (Figure 3.9F), consistent with recent
findings indicating that increases in AHR due to exogenous IL-33 challenge largely
depend on endogenously secreted IL-33 (Magat et al., 2020). However, no significant
decrease was observed in IL-33-induced AHR in Src+/- mice compared to corresponding
WT mice, and instead there was an apparent increase in Newtonian resistance and tissue
elastance (Figure 3.9G). Moreover, Src+/- mice also appeared to display decreased tissue
damping and elastance in PBS treatment groups. Overall, these results suggest that
DUOX1 and to a lesser extent Src contribute to type 2 cytokine responses and associated
airway hyperresponsiveness in mice following repeated IL-33 challenge.

3.5 Discussion
Type 2 immune signaling and wound responses are critical regenerative
processes of various tissues in response to injury due to e.g. parasitic infections, toxins,
etc. (Allen et al., 2014). The importance of SFKs in wound healing has been recognized
for some time, illustrated by a critical role for Fyn signaling in tail fin regeneration in
zebrafish (Yoo et al., 2012), or previous findings implicating Src in airway epithelial
wound responses (Sham et al., 2013). Building on this, the present findings highlight the
specific involvement of Src in the secretion of the alarmin IL-33 from airway epithelial
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cells in response to airway challenge with HDM, a common asthma-inducing allergen,
and in subsequent production of type 2 cytokines such as IL-13 and IL-5. Therefore,
epithelial Src may be important for innate host defense against acute non-microbial
triggers and allergen challenge, which largely rely on type 2 immune activation, but
could also contribute to dysregulated type 2 inflammation during e.g. allergen
inflammation, similar to previously demonstrated role(s) of EGFR in the context of
chronic allergen challenge that more closely resembles diseases such as allergic asthma
(Habibovic et al., 2016; Le Cras et al., 2011). Indeed, Src has been implicated in various
aspects of asthma (Randhawa et al., 2012; Tundwal et al., 2012), based on its
involvement in e.g. smooth muscle proliferation (Krymskaya et al., 2005) or TNF-αinduced disruption of epithelial barrier integrity (Hardyman et al., 2013). Our present
findings implicating Src in chronic type 2 inflammation may further justify selective Src
targeting approaches as a potential therapeutic strategy for allergic airways diseases
associated with increased type 2 inflammation.
Our findings also further highlight the importance of redox-based regulation of
Src in the context of IL-33-mediated type 2 inflammation. Consistent with our previous
findings implicating the importance of specific cysteines within Src in regulating its
activity (Heppner et al., 2018), we show that allergen-induced IL-33 secretion is
dependent on the oxidation of specific Cys residues, namely C185 and C277. Moreover,
we demonstrate that such redox-dependent Src activation is mediated by the epithelial
NADPH oxidase DUOX1, which was previously implicated in airway epithelial injury
responses (Habibovic et al., 2016; Heppner et al., 2016; Hristova et al., 2016). The Cys
residues implicated in these responses are largely unique to Src within the SFK family
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(Heppner et al., 2018) and C277 has been exploited as a target for covalent Src inhibitor
development (Du et al., 2020). However, our observations of unique redox-based
regulation of Src may have implications for such covalent inhibitor approaches, and may
warrant alternative redox-based inhibitor strategies that selectively target Src and avoid
off-target effects related to inhibition of other SFKs or related kinases.
An intriguing aspect of our present findings is the observation of an apparent
feed-forward autoamplification mechanism with respect to epithelial IL-33 secretion in
the context of acute allergen challenge. It has been well-recognized that airway epithelial
expression of IL-33 and its receptor ST2 are subject to positive feedback regulation by
paracrine mechanisms, e.g. by IL-13 generated by ILC2 (Christianson et al., 2015). More
recently, a similar paracrine amplification of epithelial IL-33 expression was attributed to
mast cells that shift from the submucosa to the epithelium during allergic asthma, and in
fact involve mast cell-derived IL-33 (Altman et al., 2019). Moreover, recent studies
indicate that inflammatory responses induced by repeated airway administration of IL-33
are largely mediated by endogenous IL-33 production and activation (Magat et al., 2020).
Our findings reveal an alternative epithelial-specific feed-forward mechanism, in which
IL-33 induces further secretion of IL-33 from epithelial cells in the context of acute
allergen challenge. This feed-forward mechanism depends on ST2 receptor signaling but
appears to be independent of transcriptional IL-33 regulation, as it was not associated
with increased epithelial IL-33 mRNA. Furthermore, our present findings demonstrate
that the previously reported involvement of DUOX1 and redox-dependent Src/EGFR
activation in acute IL-33 secretion in response to protease allergens such as HDM
(Hristova et al., 2016) may in fact largely be due to their role(s) in IL-33-dependent
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signaling in this feed-forward mechanism. Since epithelial IL-33 secretion by injurious
triggers may involve diverse mechanisms (Drake et al., 2017), including both passive IL33 release from necrotic cells as well as cell signaling mechanisms initiated by early
damage signals (e.g. ATP) through receptor-mediated signaling, we speculate that the
feed-forward IL-33 secretion mechanism observed in our present study may reflect initial
effects of early passive IL-33 secretion amplified by subsequent IL-33 secretion via IL-33
signaling and DUOX1/Src/EGFR activation.
We do not fully understand how IL-33 signaling through ST2 leads to the
activation of DUOX1. DUOX1 activation in e.g. wound responses typically requires the
activation of Ca2+ signaling, initiated by activation of ionotropic or metabotropic
receptors, such as purinergic receptors (activated by initial ATP release as a damage
signal) (Sham et al., 2013), histaminergic receptors (Rada et al., 2014), or TRP channels
such as TRPV1 (Schiffers et al., 2020). IL-33 signaling typically involves the formation
of a heterodimeric receptor complex between ST2 and IL-1RAcP, which then can
complex with multiple signaling proteins (e.g. MyD88, TRAF6, various IRAKs),
inducing MAP kinase signaling and other downstream kinase responses (Liew et al.,
2016; Pinto et al., 2015), but emerging findings indicate that IL-33 can also induce Ca2+
mobilization, e.g. in neurons (Liu et al., 2016) or in IgE-sensitized mast cells (Ball et al.,
2018), although the mechanisms are yet unestablished. However, the overlap of canonical
IL-33 signaling, or the potential for an alternative signaling pathway, with the known
DUOX1 activation pathway should be addressed.
Another intriguing aspect of our findings is the apparent close association
between IL-33 and the EGFR ligand AREG, which are both produced acutely upon HDM
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challenge. It has recently been shown that EGFR and ST2 are closely associated in type 2
T helper cells (Th2 cells), and that the association of IL-33 and AREG with their
receptors is not only required for this association, but necessary for the production of IL13 by these cells (Minutti et al., 2017). Also, IL-33 signaling and ST2 expression are
closely linked with EGFR/AREG signaling during e.g. injury responses within the
intestinal and airway epithelia (Monticelli et al., 2015). We recently reported that IL-33 is
capable of inducing DUOX1-dependent AREG secretion in epithelial cells (Habibovic et
al., 2016), and our present findings indicate the importance of IL-33 signaling in
epithelial AREG secretion in response to HDM. Both IL-33 and AREG are known to be
important in the context of epithelial injury and wound responses (Liew et al., 2016;
Zaiss et al., 2015), and our current findings offer further insight into the potential
relationship between these mediators, and highlight the potential importance of DUOX1
and Src in such interrelations.
In summary, our current findings reveal the central importance of Src in HDMinduced airway epithelial type 2 responses, specifically in responses involving IL-33
secretion and signaling. Additionally, we have identified a novel autoamplification
mechanism with respect to acute IL-33 secretion mechanisms, which is mediated by
redox-dependent activation of Src and EGFR, and further demonstrate the intricate
relationship between IL-33, AREG, and EGFR signaling in the context of innate injury
responses and in chronic airway diseases characterized by increased type 2 inflammation.
With respect to the physiological significance of our findings, DUOX1-mediated type 2
cytokine responses were associated with increased AHR in the context of chronic IL-33
challenge, as was previously observed in the context of HDM-mediated allergic airways
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disease (Habibovic et al., 2016), but this did not appear to apply to Src as IL-33-mediated
AHR was not attenuated and perhaps even enhanced in Src+/- mice. This latter finding
could potentially be due to the use of heterozygous mice rather than Src-null mice or to
the fact that Src is ubiquitously present in all cell types, and that non-selective Src
deletion in other lung cell types may have unanticipated consequences impacting on
overall lung function. Epithelial-specific targeting of Src may therefore have greater
benefit. Lastly, the fact that DUOX1 (and possibly Src) impair IL-33 driven responses
with respect to type 2 cytokine production and also AHR, without significantly affecting
IL-33-mediated inflammation or remodeling, may suggest that IL-33 (or related type 2
cytokines), via DUOX1 and/or Src, may activate sensory nerves in the airways as an
important mechanism in promoting AHR (Campion et al., 2019; Kabata et al., 2019; Liu
et al., 2016; Tränkner et al., 2014). Future studies that go beyond the scope of the present
work would be required to test this possibility.
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FIGURES

Figure 3.1— Src activity and oxidation are involved with airway epithelial type 2
responses. (A) Experimental setup for mouse experiments using Src inhibitor AZD0530
(Saracatinib) or Src WT/Src+/- mice. (B) Representative IHC analysis of lung sections
from mice with α-pY416 Src and α-pY1068 EGFR antibodies. (C) ELISA analyses of
BALF collected from the various mouse groups. Data were normalized to the average
concentrations seen in WT HDM 1h (IL-33) or WT HDM 6h (IL-13 or IL-5). (D). ELISA
analyses of BALF collected from mice, normalized to the average concentrations seen in
WT HDM 1h (IL-33) or WT HDM 6h (IL-13 or IL-5). (E). 72 hours post-transfection
with Src-targeted siRNA or corresponding non-silencing control (NS), MTEC were
serum starved overnight and stimulated with 50 μg/mL HDM for 1 or 6 hours. Media was
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then collected and analyzed by ELISA for IL-33, IL-5, or IL-13 secretion. (F). H292 cells
were transfected with FLAG-WT, FLAG-C185A, FLAG-C277A or empty vector control
(EV), stimulated with HDM for 2h, and collected media was analyzed by ELISA for IL33. Results are expressed as mean ± SEM from two separate experiments. AZD inhibitor
studies were conducted with an n=4 for PBS control n=6 for HDM treated mice per
group. WT/Src+/- experiments were conducted with an n=6 for PBS control and n=8 for
HDM treated mice per group. Data were analyzed for significance using 2-way ANOVA
where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 3.2—Src signaling is critical for EGFR transactivation and oxidation, as well
as type 2 cytokine expression in the airway. Quantification of positive airway staining
for pY416 Src (A) and pY1068 EGFR (B) in mouse lung tissue sections vs. total
counterstained airway using MetaMorph imaging software. (C) mRNA expression of
Il33, Il5, and Il13 genes measured in whole lung homogenates from mice treated with 50
μg HDM following DMSO or AZD0530 treatment for indicated timepoints, analyzed
using qRT-PCR. (D) MTEC were treated with Src targeted siRNA for 72h prior to serum
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starvation. Lysates were collected and analyzed via western blot. (E) mRNA expression
of Il33 gene in MTEC treated with HDM following siRNA-mediated Src silencing (F)
Western Blot analysis showing phosphorylation (pY416 Src and pY1068 EGFR) and
sulfenylation (DCP-BIO1 alkylation and streptavidin detection) of Src and EGFR
following siSrc-mediated silencing of Src expression in MTEC. Following overnight
starvation, cells were challenged for 10 min 50 μg/mL HDM and harvested. Results are
expressed as Mean ± SEM. In vivo studies were conducted with an n=4 for PBS control
n=6 for HDM treated mice per group. Data were analyzed for significance using 2-way
ANOVA where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 3.3— Airway epithelial IL-33 secretion is dependent on IL-33 signaling. (A)
Experimental setup for in vivo α-ST2 experiment. (B) Analysis of BALF from HDMtreated mice for IL-33 secretion using ELISA. (C). Following overnight serum starvation,
MTEC were treated with 2 μg/mL IgG or α-ST2 blocking mAb for 30 min prior to 50
μg/mL HDM challenge. Media was collected and analyzed for IL-33 secretion by ELISA.
(D) 72h post-transfection with Il1rl1 (ST2) siRNA, cells were serum starved and treated
with 50 μg/mL HDM. Media was collected and analyzed for IL-33 secretion with ELISA.
(E) Following overnight serum starvation, MTEC were treated with 2 μg/mL IgG or αST2 blocking mAb for 30 min prior to 50 µg/mL ALT or 100 µM ATP challenge for 2h.
Media was collected and analyzed for IL-33 secretion by ELISA. Results are expressed
as Mean ± SEM. In Vivo analyses were conducted with n=6 for PBS Controls and n=12
for HDM treated mice per group. Data were analyzed for significance using 2-way
ANOVA where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

196

Figure 3.4— Epithelial IL-33 signaling involves Src and EGFR activation. (A)
Experimental setup. (B) Analysis of IL-5 and IL-13 secretion in BALF of mice treated
with IL-33 or PBS by ELISA. (C) MTEC were serum starved overnight and treated with
IL-33 72h after treatment with siRNA. Media was collected and analyzed for IL-13
secretion by ELISA. (D, E) H292 cells were treated for 30 min with either a Src inhibitor
(AZD0530, 1 μM; D) or the EGFR inhibitor AG1478 (1μM; E) followed by 24h
stimulation with 100 ng/mL IL-33. Conditioned media was analyzed for IL-13 secretion
by ELISA. Results are expressed as Mean ± SEM. In vivo analyses were conducted
where n=5-6 for PBS control and n=8 for IL-33 treated mice per group. Data were
analyzed for significance using 2-way ANOVA where *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001.
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Figure 3.5— DUOX1 and Src contribute to IL-33-induced cytokine secretion, as
well as oxidation and activation of Src and EGFR. (A) mRNA expression of Il33, Il5,
and Il13 genes measured in whole lung homogenates from mice treated with 1 µg IL-33
for indicated timepoints, analyzed using qRT-PCR. (B) MTEC from WT or Duox-/- mice
were treated with 100 ng/mL IL-33 for 1 or 6 hours following overnight starvation.
Media was collected and analyzed for IL-5 using ELISA. (C) H292 cells were treated
with Duox1 targeted siRNA for 72h prior to serum starvation and stimulation with 100
ng/mL IL-33 for 24h. Media was collected and analyzed for IL-13 using ELISA. (D)
H292 cells were treated with Duox1 targeted siRNA for 72h prior to serum starvation and
stimulation with 100 ng/mL IL-33 for 10 min. Cells were lysed and analyzed for
phosphorylation (pY416 Src and pY1068 EGFR) and sulfenylation (DCP-BIO1
alkylation and streptavidin detection) of Src and EGFR using western blot. Results are
expressed as Mean ± SEM. In vivo analyses were conducted where n=5-6 for PBS
control and n=8 for IL-33 treated mice per group. Data were analyzed for significance
using 2-way ANOVA where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 3.6— Src signaling, as well as IL-33 feedback signaling, induces AREG
secretion and expression. (A) Expression of ST2 gene (Il1rl1) following siST2mediated knockdown of ST2 expression, followed by HDM stimulation. (B) AREG
secretion measured in cell media from cells treated with 50 μg/mL HDM for 2h following
30 min treatment with 2 mg/mL IgG/α-ST2 mAb or ST2-targeted siRNA for 72h prior to
serum starvation and challenge. (C) mRNA expression of Areg gene measured in whole
lung homogenates from mice treated with 50 μg HDM following DMSO or AZD0530
treatment for indicated timepoints, analyzed using qRT-PCR. (D) Cells treated with Srctargeted siRNA for 72h prior were serum starved and challenged with 50 μg/mL HDM
for indicated timepoints. (E). AREG secretion in BALF from WT or Src+/- mice treated
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with IL-33 for 1 or 6h measured by ELISA. Media was collected and analyzed by
ELISA. Results are expressed as Mean ± SEM. In vivo studies were conducted with an
n=4 for PBS control n=6 for HDM treated mice per group in (B) and n=5-6 for PBS
control and n=8 for IL-33 treated mice per group for (E). Data were analyzed for
significance

using

2-way

ANOVA

where

****P<0.0001.
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*P<0.05,

**P<0.01,

***P<0.001,

Figure 3.7— IL-33 signaling is dependent on DUOX1 activation in the airway
epithelium. (A) Experimental design. (B) BALF IL-13 secretion from WT or KO mice
instilled with IL-33 analyzed by ELISA. (C) IL-13 secretion analyzed by ELISA in media
collected from MTEC isolated from WT or KO mice treated with 100 ng/mL IL-33
following overnight serum starvation. (D) DUOX1 activation analyzed by LPO-mediated
dityrosine crosslinking as a measure of H2O2 secretion. H292 were cells stimulated with
100 ng/mL IL-33 72h after treatment with either NS or DUOX1 siRNA and media was
collected for analysis. (E) Western blot analysis of phosphorylation and oxidation
(sulfenylation, measured by DCP-BIO1 alkylation and biotin affinity purification) of Src
and EGFR from WT or Duox1-/- MTEC treated with 100 ng/mL IL-33 for 10 min.
Results are expressed as Mean ± SEM. In vivo analyses were conducted where n=4 fpr
PBS treated mice and n=8-9 for IL-33 treated mice per group. Mouse data were analyzed
for statistical significance using a T-Test with Welch’s Correction where *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001. All other data were analyzed for significance
using 2-way ANOVA where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001
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Figure 3.8— Epithelial IL-33 secretion involves Ca2+-mobilization. Serum starved
MTEC were treated with either 50 μg/mL HDM or 100 ng/mL IL-33 for 10 min
following either (A) α-ST2 blocking mAB (30 min) treatment or (B) 72h post-siST2
transfection. Media was collected and analyzed for ATP secretion using the Molecular
Probes ATP determination kit. (C) Serum starved H292 cells 72h post-siP2Y2R
transfection were treated with 50 μg/mL HDM or 100 ng/mL IL-33 for 10 min, followed
by HPLC analysis of H2O2 as previously described. (D) Serum starved H292 were treated
with either 50 μg/mL HDM or 100 ng/mL IL-33 for 10 min following 30 min treatment
with 100 μM BAPTA-AM and media was collected for ATP analysis as previously
described. (E) H292 cells were serum starved overnight and treated with 10 μM TRPV
channel inhibitor Capsazepine for 30 min, following 24h stimulation with 100 ng/mL IL33. Media was subsequently collected and analyzed for IL-13 secretion with ELISA.
Results are expressed as Mean ± SEM and were analyzed for significance using 2-way
ANOVA where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 3.9— Role of DUOX1 and Src in type 2 inflammation and airways
hyperresponsiveness upon repeated IL-33 challenge. (A) Experimental design for both
experiments. (B,C) Cytokine secretion analyzed from BALF collected following 4-day
IL-33 challenge in Duox1-/- (B) or Src+/- mice (C). (D,E) Measurement of total and cell
differentials (expressed as percentage of total cell counts) in BALF from IL-33 exposed
WT, Duox1-/- (D) or Src+/- mice (E). Analysis of central airway (Newtonian) resistance,
tissue damping, and tissue elastance in response to increasing methacholine dosage by
flexiVent in WT, Duox1-/- (F) and Src+/- (G) mice. Results are expressed as Mean ± SEM.
Experiments were conducted where n=3 for PBS control and n=4-5 for IL-33 treated
mice per group. Data were analyzed for significance using 2-way ANOVA where
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Flexivent results are expressed as Mean
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± SEM. Experiments were conducted where n=3 for PBS control and n=4-5 for IL-33
treated mice per group. Data were analyzed for significance using 1-way ANOVA for 50
mg/mL methacholine dose where *P<0.05 vs WT PBS and #P<0.05 vs WT IL-33.
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Figure 3.10— Repeated IL-33 challenge induces DUOX1- and Src-dependent AREG
secretion, as well as gene expression independent of both proteins. AREG secretion
analyzed from BALF collected following 4-day IL-33 challenge in WT/Duox1-/- (A) or
WT/Src+/- (B) mice. mRNA expression of Il33, Duox1, Muc5ac, Il5, Il13, Areg, Src, and
Il1rl1 (ST2) genes measured from whole lung homogenates following 4-day IL-33
challenge in WT/Duox1-/- (C) or WT/Src+/- (D) mice analyzed by qRT-PCR. Results are
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expressed as Mean ± SEM. Experiments were conducted where n=3 for PBS control and
n=4-5 for IL-33 treated mice per group. Data were analyzed for significance using 2-way
ANOVA where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 3.11— Schematic representation of hypothesized acute IL-33 signaling and
autoamplification pathway. Allergen-induced IL-33 activates DUOX1, which leads to
oxidative activation of Src and EGFR, both of which are critical for downstream IL-33
secretion and type 2 responses. Current observations suggest that this secreted IL-33 can
similarly activate DUOX1, as well as Src and EGFR, which are involved in downstream
IL-33 secretion and type 2 responses as evidenced by inhibition and gene
knockout/silencing strategies.
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TABLES
Table 3.1. Primers used in RT-qPCR Analyses
Gene

Primer

Sequence

Src

F

GAC CGA GCT CAC CAC TAA GG

R

CTG TGG CTC AGC GAA CGT AA

F

GAT GGG AAG AAG GTG ATG GGT G

R

TTG TGA AGG ACG AAG AAG GC

F

CCA CGG CCC CTT CTA ATG A

R

GCC TCT CCC CAG CAA AGT CT

F

ATG GAG ATT CCC ATG AGC AC

R

CCC ACG GAC AGT TTG ATT CT

F

AAC GGT GTG GAG AAA AAT CC

R

TTG TCC TCA GCT AGG CAA TG

F

GAC CCC AGT ATC TCC CCA GA

R

ATG ACT GGG AAT CCC CTG GA

F

GTG ACA CCT TAC AAA ACC CG

R

TCA AGA ACG TCG GGC AGA G

F

AGT CTC TCT CCG CTC CTC TCA AT

R

CAG CCG AGA GGA GGG TTT GAT

Il33

Il13

Il5

Areg

Duox1

Il1rl1 (ST2)

Muc5ac

CT
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CHAPTER 4: SUMMARY, DISCUSSION, AND FUTURE DIRECTIONS

Evidence demonstrating the redox regulation of tyrosine kinases has existed for some
time, although the application of this concept to cellular signaling in airway diseases is
relatively underexplored. This chapter will summarize the results of the present work
with respect to broader implications, while integrating our recent findings regarding IL33 signaling and Src activation during acute allergen challenge. Additionally, it will
address possible future applications and avenues stemming from these findings. Finally,
an overall conclusion for this dissertation will be provided.

4.1. Summary
Our work discussed in Chapter 2 highlights a direct and specific mechanism of
Src oxidation leading to increased kinase activation. Through quantitative mass
spectrometry using heavy and light dimedone tags, coupled with in vitro assays utilizing
recombinant kinase and cell-based studies focused around Src C to A constructs, we have
identified roles for the C185 and C277 residues in Src activation and activity modulation.
In both cases, we found that these Cys residues were oxidized at relatively higher levels
compared to the other seven Cys in recombinant Src treated with H2O2, translating to
lower levels of H2O2-induced kinase activity when these Cys residues were mutated to
Ala. Similarly, Src protein expressed in airway epithelial cells carrying these same
mutations showed lower levels of activating Src phosphorylation, as well as lower levels
of sulfenylation, when compared to WT Src following ATP stimulation. Furthermore,
using molecular dynamics, we observed significant conformational change following Cys
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sulfenylation, specifically wherein sulfenylation of C185 causes both a disruption of SH2
domain-mediated interactions with pTyr 527 and increased solvent accessibility, while
sulfenylation of C277 causes major unfolding of the Src activation loop and exposure of
the activating Tyr 416 residue. Overall, this data suggests a role for Cys oxidation in Src
activation and activity enhancement, potentially though a concerted mechanism involving
both C185 and C277.
Chapter 3 demonstrates that Src is critically involved in IL-33 secretion through a
pathway that seemingly also involves the transactivation of EGFR, proceeding
downstream of DUOX1 activation, consistent with previous studies (Sham et al., 2013).
We have shown that the protein involved is specifically the Src kinase through the
utilization of Src+/- mice, as well as Src silencing in isolated epithelial cells. This IL-33
secretion appears to be predominantly epithelial given the general expression of IL-33 in
barrier tissues, as well as our findings utilizing isolated tracheal epithelial cells from
mice. Intriguingly, we have also observed that blockade or silencing of ST2 can suppress
IL-33 secretion in response to acute allergen challenge, suggesting a feedback or
“autoamplification” pathway. Similarly, we have seen that IL-33 itself can induce the
activation of DUOX1, Src, and EGFR. While these proteins were previously thought to
be exclusively upstream of IL-33 secretion, our current findings demonstrate their
involvement in the secretion of downstream type 2 cytokines as well. Utilizing a
consecutive four-day IL-33 challenge model in mice, we have observed that both
DUOX1 and Src contribute to IL-33 secretion and downstream type 2 responses in a
more prolonged exposure model. However, we observed minimal impact of DUOX1 or
Src on the expression of these different cytokines, suggesting a predominantly secretion211

based mechanism downstream of IL-33. Finally, we see a significant impact of IL-33
challenge on the development of airway hyperresponsiveness parameters, however, only
DUOX1 appears to significantly contribute to the worsening lung function with IL-33, as
Src+/- showed unchanged or higher responses compared to WT. Overall, the work
presented in Chapter 3 identifies a role for Src in acute airway epithelial allergen
responses in addition to identifying new roles for Src and DUOX1 in acute IL-33-induced
signaling and autoamplification.

4.2 Redox regulation of Src signaling
The work presented here expands upon previous evidence for the modulation of
Src activation by oxidation through the direct identification of involved Cys residues,
suggesting a mechanistic explanation for Src activity enhancement, and offering new
insight into downstream airway epithelial responses in which Src oxidation is relevant.
However, there is still much to be explored regarding the redox activation of Src with
respect to both Src signaling and regulation. Specifically, this work focuses primarily on
a somewhat narrow and linear pathway of Src oxidation downstream of DUOX1
activation. However, the reality of this pathway is that, within a cell, these events do not
exist in a vacuum.
While an increase in oxidant production can directly lead to increases in Src
activation, it is also important to consider the indirect oxidant-mediated regulation of Src.
Classically, oxidant-mediated regulation involves the inactivation of protein tyrosine
phosphatases (PTPs) by active site Cys oxidation, which are negative regulators of
protein tyrosine kinase (PTK) activity (Salmeen et al., 2003; Tonks, 2006). This process
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is particularly interesting with respect to Src, where phosphorylation is a critical
modification for both activation and inactivation, depending on whether the Y416 or
Y527 residues are respectively phosphorylated. For example, we have previously
observed that protein tyrosine phosphatase 1B (PTP1B) can be oxidized during DUOX1
activation within airway epithelial cells alongside Src activation, which would suggest
that it is simultaneously inactivated (Heppner et al., 2016). Similarly, this increase in PTP
inactivation is classically known to be involved in overall increased PTK activity due to
prolonged phosphorylation (Tonks, 2005). However, there is also significant evidence
that PTP1B (Bjorge et al., 2000; Roskoski, 2005), as well as other PTPs (Roskoski,
2005), are capable of positively regulating Src activity through Y527 dephosphorylation
as well, a process that would be inhibited by oxidation. Therefore, the involvement of
these enzymes may be more nuanced and context-dependent despite oxidation overall
favoring increased Src activation.
Similarly the main negative regulator of Src, C-terminal Src kinase (CSK), is also
a target of redox regulation. It has been observed that oxidation of CSK leads to
intramolecular disulfide formation within its SH2 domain and reduced kinase activity,
which could theoretically have the potential to lead to increased/prolonged Src activation
within cells (Mills et al., 2007). While this CSK modification has not yet been observed
in a cellular context, the possibility must still be considered given the well-established
link between oxidation and PTKs.
Another point of regulation to consider is the redox regulation of EGFR. While
this dissertation focuses on the role of EGFR with respect to transactivation by Src, it is
important to note that the classical view of Src signaling involves downstream activation
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following activation of EGFR and other RTKs (Bromann et al., 2004). EGFR activation
and activity are similarly regulated by oxidation (Paulsen et al., 2011; Truong et al.,
2016), and could therefore regulate Src activation, in turn potentially inducing further
downstream oxidant production involving NOX2 (Heppner et al., 2016) or DUOX1
(Sirokmány et al., 2016), and similarly inducing further growth factor liberation by Src
(Sham et al., 2013).
Finally, oxidation of individual Src monomers, or the oxidative activation of other
SFKs like Fyn (Yoo et al., 2012), could potentially further regulate Src. Src is known to
be activated by trans-autophosphorylation (Roskoski, 2005), therefore a redox-activated
Src molecule could theoretically induce further intermolecular Src/SFK activation due to
its higher activity level, leading to a higher cellular pool of activated Src/SFKs. In total,
these various methods of oxidant-mediated Src regulation point towards a complex
network of potential interactions that must be considered during observed kinase
activation, warranting further exploration.
Accordingly, while regulation of Src by oxidation is important to consider, there
is still the question of how Src oxidation alters downstream signaling and substrate
recognition. While redox regulation of Src activity is known to be involved in many
different contexts, there is a relatively low amount of information regarding potential
redox-dependent changes to Src signaling networks through conformational changes or
localization alteration. Further, limited observations have shown that Src is capable of
forming disulfide bonds with proteins that are integral to its regulation and signaling,
such as other Src molecules and C-terminal Src kinase (CSK) (Kemble et al., 2009), as
well as its known substrate cortactin (Evans et al., 2012), through the Cys residues
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highlighted in this work (C277 and C185 respectively). However, there are a lack of
studies addressing this question with more sophisticated and/or unbiased methodology.
Utilizing phosphoproteomic screens with C to A mutant Src cell lines, as well as
advances in kinase substrate microarray technology with recombinant C to A Src mutants
(Newman et al., 2013), we can rigorously evaluate the downstream impact of Src
oxidation on substrate phosphorylation, which can be subsequently evaluated with more
direct approaches. Additionally, Src activation is known to modulate downstream activity
of various transcription factors (e.g. STATs (Silva, 2004)), possibly altering gene
expression through oxidant-mediated alteration of activity or target binding. Therefore, it
would be similarly beneficial to probe the impact of Src redox regulation utilizing
RNAseq techniques. Finally, proteomic methods evaluating disulfide bonding following
Src activation could provide insight into disulfide-mediated partner interactions. As
outlined in Appendix A1, we have performed some initial studies probing Src disulfide
formation, and have identified the presence of possible intermolecular disulfides,
however we have not currently identified any binding partners and therefore need to
adopt more rigorous approaches. Overall, there is a clear need to further profile the
downstream processes and outcomes related to Src oxidation to determine the exact
consequences of upstream redox regulation.
One caveat of this work, however, is the current lack of empirical evidence for the
C277 and C185 sulfenylation-mediated conformational changes that we observed, as they
are based on molecular dynamics simulations and not physically acquired experimental
analyses. To this end, further steps need to be taken to address the potential for induction
of a more open Src confirmation by oxidation. One such method would be through
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hydrogen-deuterium exchange (HDX) mass spectrometry, or mass spectrometry utilizing
proton exchange with deuterated water (Marcsisin et al., 2010). This technique takes
advantage of proton exchange between proteins and the solvent to effectively label any
solvent exposed area with an isotopically heavy proton (deuterium), which can then be
detected by mass spectrometry. This would then allow for the identification of buried or
solvent inaccessible regions, which stay unlabeled (or, “light”) upon analysis. HDX mass
spectrometry would allow for the identification of conformational changes in response to
oxidation by determining which “light” regions in a recombinant Src construct become
“heavy” following deuterium incorporation upon oxidant treatment. In this way it would
then be possible to empirically determine conformational changes in Src following
oxidation, which would allow for the verification of our molecular dynamics results and
mechanism. Similarly, as mentioned in Chapter 2, there is still the lingering question
regarding the oxidation status of the seven Cys residues not explored in the present work.
We have observed that these Cys were oxidized as well but chose to focus our attention
on more robust examples, despite other studies identifying the oxidation of these residues
as significant sites for Src activity modulation (Giannoni et al., 2005; Zhang et al., 2015).
Cumulatively, these avenues suggest a number of key areas to explore with respect to
current findings in order to truly understand the impact of oxidation on Src activity and
activation.

4.3 Src activation in epithelial IL-33 signaling and feedback responses
Acute airway epithelial signaling is a critical process, regulating airway repair
following exposure to damaging particulates or microbial insults. However, repeated
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activation of these responses can often lead to disrepair due to heightened cellular
migration and excessive scarring/deposition of collagens, as is seen in both pulmonary
fibrosis and remodeling in asthma following repeated injury (Holgate, 2011). We, and
others, have shown that acute airway challenge leads to the active secretion of various
innate cytokines, most notably IL-33 (Hristova et al., 2016; Kouzaki et al., 2011). Recent
studies have demonstrated that EGFR-mediated signaling is critical in IL-33 secretion,
and that this signaling is associated with activation of DUOX1 (Habibovic et al., 2016;
Hristova et al., 2016), which we have now shown similarly involves the activation of Src.
Src is known to be involved in various aspects of epithelial repair and innate injury
signaling in airway epithelial barrier integrity (Hardyman et al., 2013) and cellular
migration (Gorissen et al., 2013; Sham et al., 2013). While we observed significant
suppression of HDM- and IL-33-induced responses using Src+/- mice, we were unable to
utilize Src-/- mice due to the reported deformities and low survival rates (Soriano et al.,
1991). Future studies could strengthen these results by bypassing the developmental
issues that are linked to Src deficiency with conditional knockouts, such as the floxed Src
mice previously utilized in a breast cancer model (Marcotte et al., 2012). Additionally,
these conditional knockouts can be targeted to the epithelium by utilizing specific
epithelial promoters, such as Scgb1a1 for Cre recombinase expression (Li et al., 2008),
which would target the knockout to the airway epithelial cells. In this way, we could then
specifically probe the effect of Src knockout in airway epithelial cells in vivo rather than
utilizing global knockout, which could alter many unknown pathways and potentially
induce compensatory expression of other SFKs. We have also observed that Src
oxidation appears to play a critical role in IL-33 secretion, however we do not know if
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this is relevant to an in vivo setting. To this end, there is a clear need to apply recent
advances in CRISPR-mediated gene editing (Inui et al., 2014) to Src mouse lines in
which Cys residues critical for Src regulation are mutated to Ala residues. Through this
type of manipulation, it would be possible to specifically probe the contribution of
oxidation to the in vivo function of Src in homeostatic regulation and responses to short
term insults/injuries.
An intriguing aspect of this work is the concept of IL-33-induced IL-33
secretion, an unexpected finding that arose from what were intended to be control
experiments. To date, this is a relatively new phenomenon with respect to IL-33 signaling
and secretion, with some prior evidence hinting towards the possibility of IL-33 inducing
its own secretion (Altman et al., 2019; Christianson et al., 2015). In fact, recently a study
was published demonstrating that IL-33 administration for four days induces not only IL33 expression and secretion, but also the expression of its receptor ST2 (Magat et al.,
2020). Interestingly, this autoamplification was accompanied by a rapid induction of
common phenotypes associated with asthma, such as higher levels of airway
hyperresponsiveness and tissue inflammation. However, our findings are particularly
novel due to their acute nature and the predominantly secretion-based mechanism that we
have observed, rather than a transcriptionally regulated mechanism, via DUOX1 and Src.
Interestingly, while we similarly observed an impact of these two proteins on cytokine
secretion, only DUOX1 appeared to have an impact on lung function, which was
consistent with previous findings (Habibovic et al., 2016). Src heterozygotes, despite
showing suppressed IL-33 and the type 2 cytokines secretion, seemed to show unchanged
or higher levels of airway hyperresponsiveness, despite Src’s theorized roles in airway
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disease (Katsumoto et al., 2013; Krymskaya et al., 2005; Randhawa et al., 2012), coupled
with an apparent suppression of Src expression with IL-33 instillation. This could
possibly point towards a protective IL-33-mediated response, or an underlying feature of
chronic IL-33 secretion. Moving forward, the exact impact of IL-33 signaling on Src
expression, and the contribution of Src to IL-33 in more chronic exposures, must be
addressed.
One outstanding question with respect to our studies is the impact of oxidation on
IL-33 itself. While IL-33 is secreted in a redox-dependent manner and is capable of
inducing the production of various oxidants, we have not yet explored whether IL-33 is,
in fact, oxidized following the activation of pathways involving significant extracellular
production of H2O2 (e.g. DUOX1 activation). As mentioned previously (Section 1.6.1.3.),
IL-33 can be rapidly inactivated following oxidation of multiple critical Cys residues,
leading to the formation of intramolecular disulfide bonds that serve to inactivate IL-33
function (Cohen et al., 2015). Given this information, as well as the rapid decline in
measured IL-33 that we observe in our culture and BALF sample at later timepoints, it is
not unreasonable to assume that much of what contributes to this observed decrease
involves IL-33 oxidation by excess DUOX1-generated oxidants. In this way, it could be
entirely possible that DUOX1-mediated oxidant production is not only a critical aspect of
IL-33 secretion, but also an intrinsic regulatory mechanism that evolved to take
advantage of simultaneous pathway activation, effectively serving as a safeguard
alongside the soluble ST2 decoy receptor if signaling is overactive. Interestingly, this is
not the only case of cytokine oxidation, as studies with recombinant IL-18, another the
IL-1 family member, demonstrated that it may be inactivated by disulfide-mediated
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oligomer formation, but this has not been validated in cells (Yamamoto et al., 2004). It
has also been demonstrated that IL-1β, but not IL-1α, is a target of S-glutathionylation,
which positively regulates activity and may prevent inactivation by oxidation, however
IL-33 was not evaluated and might also be similarly regulated (Zhang et al., 2017).
Additionally, this process is similar to the proposed function of extracellular oxidation of
the alarmin HMGB1, in which apoptotic cells producing significant ROS can oxidize and
inactivate released HMGB1, leading to a suppression of immune responses and
promotion of immune tolerance (Kazama et al., 2008). With this information in mind,
further work must be done to understand how oxidation, and specifically DUOX1mediated oxidation, controls IL-33 signaling and potential feedback responses.
While these studies demonstrate the importance of DUOX1 and Src signaling to
IL-33 activation, there is still the underlying question of how this process proceeds
mechanistically. While we have conducted some preliminary studies investigating the
activation mechanism and have identified that ATP and Ca2+ signaling are involved (
Figure 3.8) , we have not yet determined to what extent. Further approaches are needed to
probe the importance of Ca2+ signaling in IL-33-mediated DUOX1 activation, such as
inhibition of known Ca2+-induced signaling pathways through calcium chelation and
measuring IL-33 responses and H2O2 production. Similarly, using fluorescent probes to
determine Ca2+ mobilization in cells where ST2 signaling is blocked following IL-33
treatment could help directly unravel the induction of a Ca2+ response. We currently have
evidence that the TRPV channels are critical for the IL-33-induced secretion of IL-13,
consistent with recent findings highlighting the importance of these receptors in HDMmediated challenge (Schiffers et al., 2020), but we have not yet determined which
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channel is involved (Figure 3.8E). Additionally, we have not yet determined whether
these changes to Ca2+ mobilization are truly critical for downstream secretion of type 2
cytokines, or if it is simply happening parallel to the important events. However, given
the canonical activation of DUOX1 by Ca2+ signaling via binding to its EF-hand domains
(Donko et al., 2005), it would be fairly unprecedented for there to be activation of
DUOX1 independent of Ca2+. Additionally, it is also possible that DUOX1 may directly
interact with ST2 in an intermolecular signaling complex, based on recent reports of
EGFR and ST2 directly interacting in T cells (Minutti et al., 2017), and our previous
observations that DUOX1 and Src directly interact during signaling (Sham et al., 2013),
effectively grouping these enzymes together for oxidation and activation. However, there
is currently no evidence for this association and it therefore needs to be explored with
more

direct,

immunoprecipitation-

or

proximity

ligation-mediated

approaches.

Interestingly, it has been reported that NOX2 activation during IL-1β signaling in
endosomes may involve a complex with IL1-R1 via Rac-1 (Li et al., 2006), which may
point towards the possibility of a DUOX1/ST2 complex despite the differential activation
requirements between DUOX1 and NOX2. Similarly, it has been observed that NOX2
can interact with MYD88 and TRAF6 via Src during TLR4 activation which, despite not
being a cytokine receptor, similarly interacts with the same intracellular components as
the IL-1 receptors (Cho et al., 2016). In general, DUOX1 is thought to be upstream of
cytokine induction and regulation as demonstrated in this work focused on the
epithelium, or following Ca2+-mediated DUOX1 activation during T cell receptor
signaling (Kwon et al., 2010). However, it has been observed that cytokines are capable
of controlling NOX activity as well through various means. For example, this can
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proceed through cytokine-induced expression of NOXes, such as IL-4/IL-13 induction of
DUOX1 expression and IFN-γ induction of DUOX2 (Harper et al., 2005). It has also
been observed that cytokines may be directly involved in activation as well. For example,
IL-4, a cytokine known to induce DUOX1 expression, activates NOX1 and NOX5,
leading to PTP1B oxidation, a process also shown to be inducible with IL-13 (Sharma et
al., 2008). Similarly NOX1 can be induced by various inflammatory cytokines such as
TNF-α, which can be involved in necrotic cell death (Kim et al., 2007) or ROS
generation in vascular endothelial cells via PKCζ (Frey et al., 2002). Finally, a recently
published correspondence suggested that IL-33-induced ROS production in mouse
airways (and specifically, ILC2s) involves NOX2 activation, which suggests that IL-33
may be able to induce the activation of multiple NOX enzymes (Zheng et al., 2020).
Taken together, these findings warrant further exploration into the exact activation
mechanism of DUOX1 by IL-33.

4.4 Clinical and disease implications
Advances in our understanding of protein redox regulation, such as the findings of
this study, provide new avenues for therapeutic strategies. For example, a well-known
redox-sensitive Cys with relevance in cancer treatment is C797 in the epidermal growth
factor receptor (EGFR) (Paulsen et al., 2011). This Cys residue has played a crucial role
in the development of covalent EGFR inhibitors as the target of drugs like Osimertinib
and Afatinib, which were developed to bypass the T790M mutations that arose in EGFR
as a means of drug resistance (Cross et al., 2014; Li et al., 2008). While this Cys is the
main target of this inhibitor, it is also a known site for redox activation of the kinase,
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where oxidation leads to increased kinase activity (Paulsen et al., 2011; Truong et al.,
2016). Therefore, it is plausible that an unchecked redox environment could critically
impact the efficacy of a Cys-targeted inhibitor like Osimertinib (Schwartz et al., 2014;
Truong et al., 2016).
However, this is not the only important aspect of redox regulation that could
potentially alter therapeutic protein inhibition. An emerging field of study involves the
development of redox sensitive inhibitors or targeting redox-sensitive Cysteines
themselves (Gupta et al., 2017) as somewhat of a counter to (or improvement upon) the
use of antioxidant therapeutics, which have proven to have mixed effectiveness and
limited to no clinical use (Ghezzi et al., 2017). Indeed, it may be more advantageous to
determine the redox sensitive Cys residues in a protein, in addition to their level of
conservation within a protein’s specific family, prior to inhibitor generation. This would
allow for an initial idea of possible redox interference and a minimization of off-target
effects, as many inhibitors tend to target similar regions in proteins where critical amino
acids are conserved such as a kinase active site (Wu et al., 2016). For example, in the
case of Src, we have seen that the C185 and C277 residues are important in redox
activation Src and kinase activity modulation, which have independently been validated
as oxidation sites in a recent organism-wide oxidized proteome screen (Xiao et al., 2020).
Interestingly, unlike other reported redox active Cys residues in Src, these two Cys
residues have a fairlynlow level of conservation within the family (C185 is only
conserved in Src and C277 is only conserved in Src and Yes) (Table 2.1). Given the
importance of C185 and C277 for activation, this could be a critical feature of the protein
to consider for efficacious targeting when designing inhibitors and therapeutics, despite
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the common dogma stating that high levels of non-structural conservation indicate
important functional roles and/or redox sensitivity (Marino et al., 2010). In fact, recent
efforts to target C277 with an alkylating “warhead” do not take possible blockade of this
inhibition by oxidants into account (Du et al., 2020), and could therefore be impeded by
oxidation. With this low conservation, it could be entirely possible to design inhibitors
targeted to these Cys residues that can specifically target oxidized Src, or any other
protein with similarly unique oxidizable Cys residues. These strategies may then bypass
the issue of off-target effects that are commonly seen in protein inhibitors, which are
especially prevalent in kinase inhibitors targeted to ATP binding sites such as AZD0530
(See Chapter 3) (Green et al., 2009).
Another intriguing aspect of this work is the conformational alteration in Src
induced by simply sulfenylating C277, leading to the opening of the Src activation loop
to potentially increase phosphorylation of the activating tyrosine 416. To date, this is the
first instance of this being shown within Src, despite the recognition of C277 as a
potential activating oxidation site in previous studies (Zhang et al., 2015). Src activation
in this manner would likely be most prevalent in situations where the redox balance is
known to be significantly altered, such as a tumor microenvironment (Liou et al., 2010)
or various lung diseases (van der Vliet et al., 2018). This could then facilitate the
oxidation of Src and therefore its activation, which would potentially lead to downstream
shedding of growth factors (Sham et al., 2013), effectively causing a possible a feedback
loop by which Src can activate proteins known to be upstream of its activation such as
EGFR (Roskoski, 2015).
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Similarly, while Src has been theorized to contribute to asthma and airway
inflammation (Hardyman et al., 2013; Krymskaya et al., 2005; Randhawa et al., 2012),
the strategies detailed in our work overwhelmingly address an acute signaling model.
Therefore, it would be beneficial to conduct studies in which Src inhibitors are
administered to mice following a chronic challenge with allergens (e.g. HDM). Chronic
allergen challenge is an established model for inducing allergic inflammation and
asthma-like phenotypes in mice (Habibovic et al., 2016) and would therefore mimic
treating established asthma by targeting Src signaling. However, a potential caveat is that
our repeated IL-33 challenge studies, which showed increased features of airway
hyperresponsiveness (Figure 3.9G), did not show a potential role for Src as a treatment
solution, as heterozygous Src knockouts showed unchanged or worse responses to
methacholine challenge. Therefore, as previously mentioned, it would be beneficial to
utilize full knockouts and/or more targeted strategies alongside this chronic model to
determine whether this was in fact an issue that arose from the use of the heterozygous
knockouts. Similarly, a targeted conditional knockout, such as a floxed Src mouse with
Cre recombinase expression targeted to the airway epithelium via the Scgb1a1 promoter,
would allow for analogous chronic studies with more specific gene/protein deletion.
Similarly, there is still the question of how these findings are relevant to the
varied states in airway disease. For example, asthma can exist as multiple endotypes that
may differentially rely on these pathways, therefore these findings are not necessarily
broadly applicable to disease (Kuruvilla et al., 2019). Our observed DUOX1-mediated
IL-33 feedback pathway is much more likely to contribute to Th2 “high” asthma
endotypes such as what is seen in allergic asthma, where responses are weighted towards
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Type 2 cytokine secretion and eosinophilia, due to the critical role that IL-33 plays in
inducing type 2 responses and the involvement of DUOX1 in allergic asthmatics
(Habibovic et al., 2016; Hristova et al., 2016). Accordingly, it would likely be less
involved in Th2 “low,” an endotype weighted more towards Th1 and Th17 responses like
IFN-γ and IL-17 secretion, as well as airway neutrophilia (Kuruvilla et al., 2019).
However, this distinction is complicated due to evidence showing that IL-33 is capable of
inducing Th17 cell-mediated responses (Cho et al., 2012) as well as enhancing various
Th1 responses (Smithgall et al., 2008). Similarly, IL-33 is well known to contribute to
severe asthmas, which may develop through, or heavily involve, similar feedback
responses. Interestingly, with respect to steroid resistant asthma, IL-33 signaling is in fact
unchanged with steroid treatment in fungal asthmas (Castanhinha et al., 2015) and can
still induce responses such as airway remodeling following chronic HDM challenge
despite low Th2 cytokine contribution and reduced AHR with steroid treatment (Saglani
et al., 2013). Therefore, this pathway could be relevant in cases where asthma is resistant
to corticosteroid administration. Similarly, IL-33 has been shown to be involved in the
development of COPD, predominantly through disease exacerbation via increased
proinflammatory responses (Kearley et al., 2015). However, it is generally thought that
IL-33 needs to be upregulated by chemical insults such as cigarette smoke (Kearley et al.,
2015) or ROS (Aizawa et al., 2018) prior to release by another mediator such as viral
infection. Based on this model, it could be that IL-33 may in fact induce its own secretion
in these situations following an initial release, leading to exacerbated COPD responses,
similarly involving DUOX1 and Src. With respect to pulmonary fibrosis, IL-33 is known
to be expressed at higher levels in the lungs of fibrosis patients, in addition to acting as a
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mediator involved in worsened responses to bleomycin induced lung injury (Luzina et al.,
2013; Luzina et al., 2012). Given the importance of Th2-like phenotypes and secretion of
mediators such as IL-13 in the development of fibrosis (Gross et al., 2001; Wilson et al.,
2009), as well as the known epithelial feedback with respect to IL-13 and IL-33
responses in asthma, these IL-33 feedback mechanisms may play a critical role in the
development and exacerbation of pulmonary fibrosis. Overall, there are many
applications for this IL-33 feedback pathway, as well as the potential upstream roles of
DUOX1 and Src.
Finally, while this work spans isolated cell systems and utilizes in vivo models of
allergen challenge and IL-33 signaling, there is still much to be done with respect to
translating these results to human models, which is a critical leap in any biomedicallyadjacent field. This can prove to be significantly challenging given the inherent
differences between mice and humans, despite genetic similarities. A critical difference is
the localization of IL-33 secretion within the airways. It has been shown that IL-33 can
be secreted from different epithelial cells, depending on the organism. In humans, it is
predominantly thought to originate from tracheal epithelial cells , while in mice it is
thought to be secreted from alveolar epithelial cells (Liew et al., 2016). While we utilized
mouse tracheal epithelial cells in our studies, it is important to note that these cells, while
still functionally relevant, are not differentiated and are in submerged 2-dimensional
culture. Moving forward, it would be beneficial to not only the continuation of this work,
but to the field as a whole, to conduct these experiments with differentiated primary
epithelial cells from both mice and humans to gain a better understanding of how and
where these molecules secrete in a more heterogeneous and polarized system, expanding
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on previous studies with primary cells (Habibovic et al., 2016; Hristova et al., 2016).
Additionally, it would be beneficial to isolate alveolar epithelial cells from mice for direct
comparison to tracheal epithelial cells, allowing for what may be a more accurate and
direct analysis of the cytokine signaling pathways involved.

4.3 Conclusions
Redox signaling is a critical aspect of biological signaling and proper cellular
function, despite its past reputation as a harmful “cellular stress”. While there is still
much to learn, with respect to our understanding of redox processes, these features cannot
be ignored in the larger context of disease-relevant signaling. Our findings highlight a
distinct need for further exploration of these processes given the unique nature of many
oxidizable protein Cys residues. Redox processes are not exclusive to simply epithelial
repair and acute signaling, as Src and many other redox-active proteins are ubiquitously
expressed throughout many cell types and tissues. To this end, especially in cases where
we know redox signaling is critically involved in overactive and uncontrollable
inflammatory signaling, there is a pressing need to understand how these processes
function so that we may address outstanding concerns in protein inhibition and disease
treatment at a deeper level of specificity than current inhibition strategies.
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APPENDIX 1: INTERMOLECULAR DISULFIDE FORMATION AND TARGET
BINDING OF SRC KINASE

A1.1 Methods
Reagents – All reagents were purchased from Thermo Fisher Scientific (Waltham, MA)
or Sigma-Aldrich (St. Louis, MO) unless otherwise noted. All reagents were used at the
appropriate quality grade for cull culture, or the highest purity available.

Cell Culture and Treatments – H292 human mucoepidermoid carcinoma cells (ATCC)
were plated in 24 well plates and maintained in RPMI-1640 (Gibco) supplemented with
5% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Invitrogen) at 37°C and
5% CO2. Upon reaching confluence, cells were serum starved overnight, followed by
another medium change into serum-free RPMI-1640 for 1 hour. Cells were then
stimulated with either 10 mM H2O2 or 100 µM ATP for 10 min prior to lysis for 30 min
on ice with western solubilization buffer (50 mM HEPES, 250 mM NaCl, 1.5 mM
MgCl2, 1% Triton-X100, 10% glycerol, 1 mM ethyleneglycol-bis-(β-aminoethylether)N,N,N 9 ,N 9 -tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 2 mM Na3VO4 , 10
mg/mL aprotinin, and 10 mg/mL leupeptin; pH 7.4) and brief sonication.

siRNA Silencing - Silencing of gene expression in H292 cells was carried out when cells
were 60-70% confluent using DharmaFECT reagents (Dharmacon), according to
manufacturer protocol. Briefly, after 20 minute incubation of 100 nM siRNA and
Dharmafect reagent in serum-free media, reagent was added to cells previously changed
to serum-free media 72h prior to experimentation. After 24h, media was removed and
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replaced with full growth media for 24h, followed by starvation media 24h prior to
treatment.

PEG-Maleimide Analysis – Recombinant Src was generated as previously reported
(Chapter 2) (Heppner et al., 2018). 10 µg Src was incubated with 0 mM or 10 mM H2O2
in kinase assay buffer (100 mM Tris-HCl, 20 mM MgCl2, 2 mM EGTA, 0.02% Brij-35,
1.0 mM DTT at pH 7.4) for 1 hour prior to the addition of 10 mM PEG-maleimide (5000,
Sigma-Aldrich) in kinase assay buffer. Samples were then incubated at 37°C for 1-2h on
a thermal mixer set to 1400 RPM. Samples were then acetone precipitated to remove
excess PEG-Maleimide and the resultant pellet was resuspended in kinase assay buffer.
Samples were then mixed with 6X laemmli buffer and boiled, prior to SDS-PAGE and
western blot.

Differential Cys Alkylation and LC-MS/MS prep – 20 µg Src was incubated with or
without 0.5 mM H2O2 in kinase assay buffer for 1 hour. Samples were then desalted with
Amicon Ultra 0.5 mL filters 3x prior to addition of 1% SDS and sample boiling for 5
min. Samples were then treated with 1 mM N-ethylmaleimide (NEM) for 45 min, prior to
a second round of desalting. Finally, samples were mixed with 6X laemmli buffer and
boiled prior to SDS-PAGE and Coomassie blue staining. Src bands were then excised
and washed with water for 15 min prior to destaining with a 50 mM ammonium
bicarbonate and 50% acetonitrile solution. Following coomasssie stain removal, gel
pieces were washed with water and dehydrated with 100% acetonitrile, which was fully
removed utilizing a speed vac (Labconco). Gel pieces were then reduced with 10 mM
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DTT in 100 mM ammonium bicarbonate for 1 hour at 56 °C. 55 mM iodoacetamide in
100 mM ammonium bicarbonate was subsequently added for 45 min at RT and away
from light to alkylate all free Cys present. Gel pieces were then washed with 100 mM
ammonium bicarbonate and dehydrated with 100% acetonitrile twice, followed by a final
drying step in a speed vac. Gel pieces were re-swelled with a 12 ng/µL porcine trypsin
solution (Promega) to achieve a trypsin:protein ratio of 1:20-1:100. Samples were
incubated at 4°C for 30 min prior to overnight incubation at 37°C. Peptides were
extracted and collected by sequential treatment with 5% formic acid in water, 5% formic
aid in 50% acetonitrile, and finally 100% acetonitrile. The resulting solution was dried in
a speed vac and kept at -20°C until use, at which time peptides were reconstituted in a
2.5% acetonitrile/2.5% formic acid/95% water solution for LC-MS/MS analysis.

Dimethyl Labeling of Peptides –

Dimethyl labeling was performed as previously

described (Smith et al., 2015). Briefly, speed vac dried peptides were reconstituted in
10% formaldehyde containing 500 mM sodium cyanoborohydride (light)/sodium
cyanoborodeuteride (heavy) (Cambridge Isotope Laboratories) with 10% formaldehyde
(light)/d2-formadehyde (heavy) (Cambridge Isotope Laboratories). Peptides were
incubated at RT for 1 hour and labeling was repeated once prior to acidification with 7%
trifluoroacetic acid. Samples were then desalted using C18 ZipTips (Millipore), dried by
speed vac, and reconstituted in 2.5% acetonitrile/2.5% formic acid/95% water solution
for LC-MS/MS analysis.
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LC-MS/MS analyses – LC-MS/MS analyses were performed in collaboration with the
University of Vermont VGN Proteomics core as previously described in more detail
(Chapter 2) (Heppner et al., 2018). Briefly: Non-isotope labeled differential alkylation
samples were analyzed on a linear ion trap (LTQ) mass spectrometer coupled to a
Surveyor MS Pump Plus (Thermo Fisher Scientific, MA). Dimethyl labeled differential
alkylation samples were analyzed by capillary LC–MS/MS on a Q-Exactive mass
spectrometer coupled to an EASY-nLC (Thermo Fisher Scientific, Waltham, MA, USA).
Samples were run through

C18 columns with a gradient of: LTQ 3-35%

acetonitrile/0.1% formic acid for 45 min, 35-100% acetonitrile/0.1% formic acid for 1
min, 100% acetonitrile/0.1% Formic acid for 9.5 min and QE: 2.5-35% acetonitrile/1%
formic acid for 150 min, 35-100% acetonitrile/0.1% formic acid for 1 min, and 100%
acetonitrile/0.1% formic acid for 8 min.
Product ion spectra were searched as previously described (Chapter 2) (Heppner
et al., 2018). Briefly, Data was searched using the SEQUEST search engine and
Proteome Discoverer 1.4 (Thermo Fisher). Searches utilized a forward and reverse
Uniprot Homo Sapiens Database. Search parameters included: (1) full trypsin enzymatic
activity, (2), maximum missed cleavages = 2, (3) min. peptides length = 6, (4) Mass
tolerance: LTQ: 2 Da for precursor ions and 0.8 Da for fragment ions, Q-Exactive: 20
ppm for precursor ions and 0.02 Da for fragment ions (5) Dynamic modifications on
cysteine (NEM / +125.4005, Oxidation / +15.9949 Da, Dioxidation / +31.990 Da,
Trioxidation / +47.985 Da, Carbamidomethylation / +57.0215 Da, light Dimethyl adduct
(Dimethyl) / +28.0313 Da, Heavy Dimethyl Adduct (Dimet)/ +34.0689 Da) and (6) 4
maximum dynamic modifications allowed per peptide. False positive rates were limited
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to less than 1% in the data sets by including Percolator node in the workflow.
Quantitative analysis of peptides and Heavy:Light ratios were calculated by Proteome
Discoverer.

A1.2 Introduction
Redox regulation of target binding is a critical aspect of redox signaling, generally
applying to proteins in one of two ways. First, it is thought that oxidation of protein Cys
residues can induce conformational changes that non-covalently modulate substrate or
partner binding (Holmstrom et al., 2014). One of the most well-known examples of
redox-modulated partner binding is the Nrf2/Keap1 interaction, in which Keap1 noncovalently binds the transcription factor Nrf2 and promotes Nrf2 degradation until high
cellular ROS levels oxidize Keap1 Cys residues, inducing conformational change which
then causes the release of Nrf2 for nuclear translocation and gene expression (Ahmed et
al., 2017). Other examples of similar target binding modifications are the activation of
NF-κB via upstream oxidation of dynein light chain LC8 and its dissociation from IκBα
(Jung et al., 2008), as well as oxidation of receptor ligands leading to changes in their
receptor affinity, such as the oxidation of IL-33 (Cohen et al., 2015).
Secondly, redox regulation of target binding may also apply to proteins through
the formation of intermolecular disulfide bonds. These bonds generally form following
thiol-disulfide exchange between a protein or small molecule containing a free Cys
residue and a protein/small molecule containing a disulfide bond; or, they can form
through the interaction of a free Cys residue with a Cys that has another reversible
oxidative modification (Cremers et al., 2013; Dustin et al., 2019). The formation of these
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disulfides is most commonly seen with respect to antioxidant proteins such as
thioredoxins (Holmgren, 1985), which reduce oxidized proteins by forming
intermolecular disulfide bonds with target Cys residues. These disulfides are then
resolved by thiol-disulfide exchange with an internal resolving Cys or external Cys,
followed by enzymatic reduction by antioxidant proteins (e.g. thioredoxin reductase). It
has similarly been demonstrated that peroxiredoxin 2 can participate in intermolecular
disulfide bonding with STAT3 as a means of relaying oxidative equivalents, leading to
inhibition of downstream transcription factor activity (Sobotta et al., 2015). A third
example are the FOXO transcription factors, which are also known to participate in
disulfide bonding with transportin molecules during ROS generation (Putker et al., 2013),
leading to nuclear accumulation, or p300 acetyltransferase (Dansen et al., 2009), leading
to FOXO4 acetylation.
Additionally, recent evidence suggests that the Src kinase, a protein tyrosine
kinase known to be oxidant sensitive, may similarly be regulated by intermolecular
disulfide bonds leading to altered substrate recognition. The nonreceptor tyrosine kinase
Src has nine cysteines in total, located in either its SH2 Domain (C185, C238, and C245)
or its kinase domain (C277, C400, C483, C487, C496, and C498) (Dustin et al., 2019;
Heppner et al., 2018). None of these cysteines are known to be involved in structural
disulfides, and thus could potentially be involved in its redox regulation (Xu et al., 1999;
Xu et al., 1997). Multiple sources claim that Src may be activated by direct oxidation
involving multiple Cys residues (reviewed in (Dustin et al., 2019)), however few studies
have directly looked at oxidative modifications in Src, utilizing functional studies with
Src C to A/S mutants instead of direct probing methods (e.g. dimedone trapping (Nelson
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et al., 2010)). Our previous studies demonstrate DUOX1-dependent oxidation of Src is
coupled to activation in airway epithelial cells (Hristova et al., 2016; Sham et al., 2013),
and recent work from our group showed that there is a direct contribution of Cys
sulfenylation at both C185 and C277 to Src activation through a combination of
molecular dynamics simulations and cellular/recombinant protein studies, where we
observed disulfide formation in recombinant Src (Heppner et al., 2018) (Chapter 2). It has
also been demonstrated that inhibition of Src may occur through an intermolecular
disulfide dimer involving C277, potentially with both Src and/or Src's inhibitor Cterminal Src kinase (CSK) (Kemble et al., 2009). Interestingly, Src has also been
observed to form intermolecular disulfides with its substrate protein corcatin, involving
Src C185 and Cortactin C112/246 residues, in a mechanism required for cortactin
phosphorylation during cancer cell invadopodia formation (Evans et al., 2012). Aside
from these few examples, however, evidence for intermolecular disulfides in Src
mediating downstream target binding is limited. Additionally, it is still not known if these
disulfides are relevant to further instances of Src target binding. This appendix will detail
some of the efforts and techniques utilized to explore this question through recombinant
protein and cell-based studies.

A1.3 Results
Recombinant Src can be oxidized at multiple Cys residues.
We first set out to determine the levels of free Cys available following oxidation in
recombinant Src. Previous studies demonstrated that recombinant Src treated with H2O2
contained multiple simultaneously oxidized Src Cys residues (Chapter 2) (Heppner et al.,
2018). However, due to nature of LC-MS/MS analyzing tryptic peptides instead of whole
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protein samples, we wanted to further explore the question of how many Src Cys residues
could be simultaneously oxidized in an intact protein. To obtain a qualitative view of
overall Cys oxidation, we utilized a thiol reactive PEG-tagged maleimide following
initial oxidation of recombinant Src with H2O2 (Figure A1.1 A). Maleimide is a common
thiol-reactive functional group used in the alkylation of free thiol residues for various
applications, and the PEG tail linked to it induces an electrophoretic shift of roughly
5,000 Da per Cys modified (Burgoyne et al., 2013). When PEG-maleimide was added to
untreated Src, we observed a significant electrophoretic shift from 62 kDa (monomeric,
unmodified Src) to a single band of roughly 250 kDa likely indicating a fully PEGylated,
and therefore fully reduced, protein. Molecular weights are likely higher than expected
due to multiple PEG chains impeding migration through shape changes and/or
aggregation. When PEG-maleimide was added to recombinant Src treated with 10 mM
H2O2, we observed the formation of multiple higher molecular weight bands between 62
kDa and 130 kDa, indicating a varied level of Cys availability following treatment with
H2O2, suggesting the presence of multiple oxidized Cys residues.

Src forms intermolecular disulfide bonds in vitro
Following our observations that recombinant Src could be oxidized at multiple Cys
residues (Figure A1.1, Table 2.3), we next wanted to determine whether Src oxidation in
a cellular context could form intermolecular disulfide bonds. We have previously shown
that recombinant Src can form inter/intramolecular disulfide bonds when treated with
H2O2, and that these disulfides are dependent on both C185 and C277, two Cys residues
observed to be involved in Src disulfide bonding (Figure 2.3) (Heppner et al., 2018). We
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first treated H292 airway epithelial cells with increasing doses of H2O2 for 10 min and
analyzed both total and phosphorylated protein under reducing and non-reducing
conditions. We observed that under non-reducing conditions, there is a dose-dependent
increase in a Y416 phosphorylated species at 250 kDa that is not present when samples
were reduced with DTT, as well as multiple other bands at lower molecular weights,
predominantly in response to 10 mM H2O2 (Figure A1.2 A). We similarly observed an
increase in corresponding bands at similar molecular weights in membranes probed for
total Src protein, however, these only appeared with 10 mM H2O2 (Figure A1.2 B).
We next wanted to test the specificity of this apparent phosphorylated disulfide
bond, as commercial pY416 antibodies do not discriminate between different Src family
members. Therefore, we treated H292 cells with 10 mM H2O2 while silencing either Src
or the SFK family member Fyn. We similarly observed the presence of DTT reducible
high molecular weight species when we probed for pY416 and total Src, with minimal
changes in total Fyn molecular weight (Figure A1.3). Additionally, we observed that
these high molecular weight species largely disappeared when cells were treated with
siSrc, while cells treated with siFyn showed no discernable changes in response to
silencing (Figure A1.3).
Finally, we aimed to more specifically determine the presence of intermolecular
Src disulfide bonds due to the variable nature and low yield in reducing/non-reducing
western blots. To achieve this goal, we utilized a specialized technique called diagonal
gel electrophoresis. Analogous to classical 2-D gel electrophoresis, which first separates
proteins by isoelectric point in one dimension and then molecular weight in the second
dimension, diagonal gel electrophoresis is a 2-D gel technique that separates proteins
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based on disulfide bonding status (Samelson, 2001). As illustrated in Figure A1.4A, a
non-reducing gel is performed and the lanes are excised, soaked in a reducing agent
containing buffer, and then overlaid onto a second polyacrylamide gel. These proteins are
then run through the gel to achieve a second, reducing dimension. In general, most
proteins will run in a diagonal line due to the lack of a formed disulfide, resulting in
proteins running according to the same apparent molecular weight in both directions.
However, proteins forming an intermolecular disulfide will run at a higher molecular
weight in the first dimension, showing up at a point underneath the disulfide in the
second dimension. Intramolecular disulfide containing proteins are thought to run faster
due to a more compact and globular structure, and therefore appearing to above the
diagonal. Utilizing this technique, we analyzed lysates from H292 cells treated with
either 10 mM H2O2 or 100 μM ATP, the latter being a known stimulus for DUOX1
activity that induces Src oxidation (Heppner et al., 2016; Sham et al., 2013). Following
diagonal gel electrophoresis, we probed for total Src protein and observed a that Src was
predominantly localized to the area corresponding to roughly 62-65 kDa in both
dimensions when cells were unstimulated (Figure A1.4 B). However, when cells were
stimulated with 10 mM H2O2, we observed increased signal corresponding to Src in the
reducing dimension at 62-65 kDa and roughly 250-130 kDa in the non-reducing
dimension, indicating the formation of intermolecular disulfides (Figure A1.4 B).
Similarly, when we treated cells with ATP, we observed a significant signal between
250-72 kDa in the non-reducing dimension, suggesting significant intermolecular
disulfide formation (Figure A1.4 B). Overall, these results suggest that that cellular Src
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can form intermolecular disulfide bonds in response to both exogenous extracellular
oxidants, as well as triggers that induce cellular H2O2 generation.

Quantitative analysis of Src disulfide formation by LC-MS/MS
Our next goal was to specifically determine the extent of disulfide bonding within
Src by utilizing LC-MS/MS. Specifically, we chose to assess which Cys residues were
involved in disulfides by utilizing a technique known as differential alkylation, where a
protein is initially alkylated with one alkylating agent (in this case, N-ethylmaleimide,
NEM), treated with a reducing agent to break disulfide bonds, and then treated with a
different alkylating agent to label the newly free thiol residues (in this case,
iodoacetamide, IAM) with or without 0.5 mM H2O2 (Figure A1.5A) (Wojdyla et al.,
2015). In this way, it was possible to determine which Cys residues were in a DTTreducible oxidized state, suggesting either a disulfide bond or sulfenylation. We then
trypsin digested the differentially alkylated Src and utilized LC-MS/MS to assess the
difference in IAM (listed as carbamidomethyl) incorporation within H2O2-treated Src vs
our control. However, we observed no significant differences in IAM incorporation
between our control (Table A1.1) and H2O2-treated (Table A1.2) proteins when analyzed
by LC-MS/MS, with Cys residues showing both IAM and NEM incorporation regardless
of the presence of H2O2. We next reasoned that these alterations may not be captured due
to our non-quantitative LC-MS/MS analysis. Therefore, we utilized dimethyl labeling of
peptide amine groups with both isotopically heavy deuterated formaldehyde/sodium
cyanoborodeuteride

and

isotopically

light

regular

formaldehyde/sodium

cyanoborohydride in an effort to measure the relative levels of these differentially
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alkylated peptides (Figure A1.5B). Utilizing this technique, we treated our differentially
alkylated peptides with dimethyl heavy (0.5 mM H2O2, “dimet” in Table A1.3) and light
(0 mM H2O2 “dimethyl” in Table A1.3) labels prior to quantitative LC-MS/MS. In
general, we saw little change that would suggest an increase in oxidant-induced
alterations to IAM incorporation in heavy:light ratios between the labeled samples.
However, with respect to the tail peptide Cys residues C483-C498, as well as C238, there
appeared to be a positive level of heavy:light incorporation of IAM on all Cys residues.
Unfortunately, this ratio did not appear to also be higher for peptides carrying the
“dimethyl” modification, indicating a light label, than it did for the “dimet” modification,
indicating a heavy label (Table A1.3). Tentatively, however, we can say that there may be
some level of disulfide formation, inter- or intramolecularly as evidenced by Figures
A1.1-A1.4, as well as Figure 2.3, that may warrant further exploration.

A1.4 Discussion
Redox regulation of target binding through disulfide bonding is an intriguing
concept with broad application to many redox regulated proteins, from antioxidant
proteins (Hanschmann et al., 2013), to redox relaying proteins (Sobotta et al., 2015), and
to proteins that utilize disulfide bonding to closely interact with substrates and/or binding
partners (Dansen et al., 2009). It has been previously suggested that disulfide bonds can
similarly regulate Src in multiple ways. Specifically, disulfides have been suggested as an
inhibitory mechanism (Kemble et al., 2009), as a means of holding the fully active
protein open after oxidation (Giannoni et al., 2005), and as a means of binding Src to its
substrates (Evans et al., 2012). However, the evidence for disulfide-mediated Src target
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binding has been fairly limited. Our current findings further indicate the presence of
multiple oxidized Cys residues within Src in response to H2O2. Current efforts to detect
Src disulfides on SDS-PAGE have indicated that there are multiple high molecular
weight, reducing agent-sensitive Src bands present under non-reducing conditions when
cells are treated with oxidants. This is consistent with previous observations indicating
H2O2-inducible inter-/intramolecular disulfides that were dependent on C185 and C277
(Figure 2.3) (Heppner et al., 2018). Interestingly, through the use of diagonal gel
electrophoresis, we observed that there appear to be multiple unidentified disulfide
partners of Src within a cellular context, given the level of protein present at the higher
molecular weights of the non-reducing dimension, and that these disulfides are inducible
by the functionally relevant stimulus ATP. To this end, however, we have currently not
extensively attempted to identify these proteins, as our efforts to date were unable to
detect sufficient amounts of proteins by LC-MS/MS.
Unfortunately, our efforts to identify the specific Cys residues involved in
disulfide bonding by LC-MS/MS have not been successful, as our attempt at differential
Cys labeling of Src did not produce any conclusive evidence for Src disulfides within the
recombinant kinase despite previous studies suggesting the involvement of C185 and
C277 (Chapter 2, Figure 2.3) (Heppner et al., 2018). This likely suggests specific issues
that may be impacting detection, such as potential non-quantitative labeling by maleimide
through either insufficient reaction time or issues with reaction conditions, such as
leftover alkylating reagents in subsequent steps or maleimide hydrolysis at basic pH
(Boyatzis et al., 2017). Similarly, this method could likely be greatly improved by
utilizing isotopically-labeled Cys alkylating reagents, rather than labeling peptides after
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differential alkylation, to minimize sample workup and handling. Ideal candidates for this
method would be the OxICAT reagents that utilize isotopically labeled IAM molecules
(Leichert et al., 2008), or the more modern isobaric Cys targeted iodoTMT reagents (Qu
et al., 2014).
Despite difficulties with respect to detecting disulfides utilizing LC-MS/MS, there
are still multiple avenues available for the future of these studies, which were initially
planned with the intent of identifying proteins binding to Src. Our diagonal gel
experiments indicated that there is an inducible and detectable signal in cells that is
highly suggestive of intermolecular Src disulfides, however our analyses were limited in
that we only detected Src. To this end, it would be important to utilize diagonal gels in
conjunction with immunoprecipitation or affinity purification, so that other proteins can
be assessed while we are certain they are interacting with Src specifically. Additionally,
this avenue would require a means of specifically pulling Src out of solution without
breaking disulfide bonds, enabling the excision of proteins from these gels for LCMS/MS identification, which is the original purpose behind diagonal gels (Samelson,
2001; Saraswat et al., 2019). It may be similarly beneficial to instead utilize more
straightforward approaches for this question, such as probing for known Src interacting
proteins on these gels following immunoprecipitation rather than just Src itself in a whole
cell lysate. Simplifying our proteomic workup through non-reducible tags (e.g.
streptavidin binding peptide tags), that can stand up to stringent washing while bound to
streptavidin beads and can be simply eluted by using reducing agents, could additionally
streamline this process. These proteins could then be purified and analyzed by LC-
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MS/MS to identify any known redox-active, or Cys-containing, proteins that may be Src
binding partners in response to stimuli known to activate Src oxidation.
In summary, we have observed that Src appears to be capable of forming disulfide
bonds within itself and/or with other Src molecules (Figure 2.3) in both oxidized
recombinant protein, as well as in H292 airway epithelial cells. However, our efforts to
specifically determine what Cys residues are involved and to what degree were not
successful. A re-visitation of these studies is warranted with more precise methodology
so that we may better approach the question of Src signaling modulation through
disulfide bonding.
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FIGURES

Figure A1.1 - H2O2 induces oxidation of multiple Cys residues in
recombinant Src. (A) Experimental setup. (B) Recombinant Src treated
with or without H2O2 and PEG-Maleimide were run on SDS-PAGE gels
and analyzed by probing for Src on western blot. Positions for
monomeric Src as well as suspected numbers of PEG-Maleimide adducts
are indicated.
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Figure A1.2 – Exogenous H2O2 induces cellular Src disulfide formation. H292 airway
epithelial cells were serum starved and treated with increasing amounts of H2O2 for 10
min prior to harvest and analysis by western blot for (A) pY416 Src and (B) total Src
under reducing (+1 mM DTT) and non-reducing (-DTT) conditions.
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Figure A1.3 – Potential cellular disulfide formation is specific to Src and not Fyn.
72h prior to experimentation, H292 airway epithelial cells were treated with Nonsilencing siRNA or siRNA specific for Src or Fyn. Cells were serum starved and treated
with increasing amounts of H2O2 for 10 min prior to harvest and analysis by western blot
for (A) pY416 Src and (B) total Src under reducing (+1 mM DTT) and non-reducing (DTT) conditions
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Figure A1.4 – ATP- and H2O2-stimulated Src forms intermolecular disulfide bonds
in cells. (A) Schematic detailing the theory behind diagonal gel electrophoresis. (B) H292
airway epithelial cells were serum starved and treated with 10 mM H2O2 or 100 μM ATP
for 10 min prior to harvest and analysis. Lysates were subjected to diagonal gel
electrophoresis prior to transfer to nitrocellulose membranes and probing for total Src
protein. Molecular weights of both dimensions are indicated.
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Figure A1.5 – Schematic representations of LC-MS/MS experiments. Schematics
detailing the experimental workflow for (A) differential alkylation experiments and (B)
dimethyl labeling of differential alkylation experiments.
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TABLES
Table A1.1 - MS results for recombinant Src treated with 0 mM H2O2 prior to
differential alkylation.
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Table A1.2 - MS results for recombinant Src treated with 0.5 mM H2O2 prior to
differential alkylation.
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Table A1.3 - Quantitative dimethyl labeling analysis of oxidized Src
following differential alkylation
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